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2
3 Abstract: Retinal drusen formation is not only a clinical hallmark for the development of 
4 age-related macular degeneration (AMD) but also for other disorders, such as 
5 Alzheimer’s disease and renal diseases. The initiation and growth of drusen is poorly 
6 understood. Attention has focused on lipids and minerals, but relatively little is known 
7 about the origin of drusen-associated proteins and how they are retained in the space 
8 between the basal lamina of the retinal pigment epithelium and the inner collagenous 
9 layer space (sub-RPE-BL space). While some authors suggested that drusen proteins are 
10 mainly derived from cellular debris from processed photoreceptor outer segments and 
11 the RPE, others suggest a choroidal cell or blood origin. 
12 Here, we reviewed and supplement the existing literature on the molecular composition 
13 of the retina/choroid complex, to gain a more complete understanding of the sources of 
14 proteins in drusen. These “drusenomics” studies showed that a considerable proportion 
15 of currently identified drusen proteins is uniquely originating from the blood.  A smaller, 
16 but still large fraction of drusen proteins comes from both blood and/or RPE.  Only a 
17 small proportion of drusen proteins is uniquely derived from the photoreceptors or 
18 choroid.  We next evaluated how drusen components may “meet, greet and stick” to each 
19 other and/or to structures like hydroxyapatite spherules to form macroscopic deposits 
20 in the sub-RPE-BL space. Finally, we discuss implications of our findings with respect to 
21 the previously proposed homology between drusenogenesis in AMD and plaque 
22 formation in atherosclerosis.
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477 1. Drusen.
78
79 Drusen are extracellular deposits of bio-materials underneath the retinal pigment 
80 epithelium (RPE) in the eye (Farkas et al., 1971b; Sarks, 1976). They are considered 
81 clinical hallmarks for a number of diseases, including age-related macular degeneration 
82 (AMD) (Hogan, 1965; Sarks, 1976; Hageman et al., 2001; Khan et al., 2016), Alzheimer 
83 disease (AD) (Csincsik et al., 2018) and dense deposit disease (DDD) (Duvall-Young et 
84 al., 1989; Mullins et al., 2000; Boon et al., 2009). AMD is the leading cause of severe 
85 visual impairment, affecting 4% of the population over 60 years old (de Jong, 2006). AD 
86 is the biggest cause of dementia, affecting millions of people in the western world. DDD 
87 is a relatively rare juvenile disease characterized by kidney malfunction (Ito et al., 2017; 
88 Wang et al., 2017; Cunningham and Kotagiri, 2018). Despite the potential relevance for 
89 diseases, little is known about the composition of drusen and how and why biomaterials 
90 accumulate these deposits.
91 Drusen are heterogeneous in terms of size, shape, color on retinal imaging, retinal 
92 location and molecular content (Sarks, 1976; Sarks et al., 1980; Sarks et al., 1999; Crabb 
93 et al., 2002; Khan et al., 2016). In the clinic, drusen can be identified as yellow spots on 
94 funduscopy and color fundus images or dome shaped objects of different sizes under the 
95 RPE on Optical Coherence Tomography (OCT)(Marshall et al., 1992; Bird et al., 1995; 
96 Loeffler and Lee, 1998; Khan et al., 2016). Histopathological examination of drusen 
97 showed that are located between the basal lamina of the RPE cells and the Inner 
98 collagenous layer of the Bruch’s membrane, a space that had been termed recently as 
99 sub-RPE-BL space (Balaratnasingam et al., 2016; Li et al., 2018). Clinical definition of 
100 drusen depends on size, color, auto fluorescence, and retinal location (Sarks, 1976; Bird 
101 et al., 1995) (Figure 1). Drusen may appear in the macula, peri-macular area or in the 
102 mid-and/or far periphery (Lengyel et al., 2015; Domalpally et al., 2017; Csincsik et al., 
103 2018). A particular druse can be termed as “hard”, when it’s appearance is small, round 
104 and well demarcated, with a size of <63 μm. “Intermediate” drusen have a size of 
105 approximately 63-125 μm, while “soft” drusen are >125 μm in size, and frequently have 
106 more ill-defined edges (Bird et al., 1995). A few (<5) small hard (sub-clinical) drusen in 
107 the macula does not raise alarm bells, but when numbers of hard drusen increase, or the 
108 size of drusen increases such that they become “intermediate” and/or- “soft” drusen, the 
109 likelihood to progression to AMD is increased significantly (Bird et al., 1995). Drusen 
5110 should be distinguished from reticular pseudodrusen (or subretinal drusenoid deposits) 
111 that occur between the RPE and photoreceptor (PR) in the subretinal space (Zweifel et 
112 al., 2010; Spaide et al., 2018). Relatively little is known about pseudo-drusen and as 
113 such, they are excluded from this review. Drusen are formed in the sub-RPE-BL space, 
114 between the basement membrane of the RPE and the inner collagenous layer of Bruch’s 
115 membrane (BrM). 
116 The RPE is a multifunctional single neuro-epithelial cell-layer that act as a metabolic 
117 interface between the choroid and the neurosensory retina (Strauss, 2005). The RPE 
118 cells are connected by intercellular tight junctions, together forming the outer blood-
119 retina barrier. On the apical side, the photoreceptor cells line the RPE. On the basal side 
120 the interposing BrM separates the basement membrane of the RPE from the choroidal 
121 micro-vasculature (choriocapillaris). The choroidal capillaries are fenestrated, and not 
122 surrounded by pericytes or smooth muscle cells. The BrM consists of three interleaved 
123 layersː the inner and outer collagenous layers with an elastic layer in between them 
124 (Booij et al., 2010a). Often, the basement membranes of the endothelium and the 
125 epithelium are classified as part of the BrM but we will refer here to the BrM structure 
126 as tri-laminar (rather than as penta-laminar). Embedded in the BrM are macromolecules 
127 such as proteins and proteoglycans to help remodeling the extra cellular matrix (with 
128 age)(Guo et al., 1999; Guymer et al., 1999; Del Priore et al., 2006; Beattie et al., 2010; 
129 Booij et al., 2010a; Hussain et al., 2011). The diffuse thickening of BrM is also a 
130 characteristic age-related feature (Hogan, 1965; Sarks et al., 1999). This is largely due to 
131 the entrapment of proteins and lipids within the ECM (Curcio et al., 2011; Curcio and 
132 Johnson, 2012). The diffuse build-up of extracellular bio-materials between the 
133 basement membrane of the RPE and the inner collagenous layer of the BrM is called 
134 basal linear deposits while the deposit formation between the basement membrane and 
135 the cell membrane of the RPE are called basal laminar deposits (Sarks, 1976; Sarks et al., 
136 1980; van der Schaft et al., 1993; Abdelsalam et al., 1999; Curcio and Millican, 1999; 
137 Spraul et al., 1999). Due to the lack of information of the composition of these deposits, 
138 these specific classifications are excluded from our analysis. The deposits in BrM result 
139 in a decline in the conductivity of the membrane creating in a diffusion barrier that 
140 further enhances the accumulation of biomaterials (Green and Enger, 1993; Moore et al., 
141 1995; Starita et al., 1997; Curcio and Millican, 1999; Curcio et al., 2011; Curcio, 2018b). 
6142 This phenomenon may be a general “passive” pathophysiological process that resembles 
143 plaque formation in disorders such as AD or atherosclerosis.
144 Even more detailed insights into sub-RPE-BL space deposits originated from molecular 
145 and histochemical studies on isolated drusen material. Recent investigations have 
146 shown that drusen contain lipids, trace elements, including zinc, iron and calcium, as 
147 well as a wide array of different proteins (Crabb et al., 2002; Curcio et al., 2011; 
148 Thompson et al., 2015; van Leeuwen et al., 2018). The distribution of these components 
149 is not uniform, neither within nor between drusen, further emphasizing the 
150 heterogeneous nature of the deposits (Thompson et al., 2015).
151 Oxidative modification of lipids and proteins may result in the cross-linking of these 
152 molecules and may contribute to deposit formation and drusenogenesis. Subsequently, 
153 local cellular damage at the very early onset of AMD, via the complement cascade attack 
154 on drusen compounds and the NLRP3 inflammasome (Edwards and Malek, 2007; Yuan 
155 et al., 2010; Doyle et al., 2012), can lead to retinal damage and more advanced AMD.
156 Relatively few studies addressed the origin of proteins in the initiation and progression 
157 of drusen (Mullins et al., 2000; Nordgaard et al., 2006; Cryan and O'Brien, 2008; Wang et 
158 al., 2010; Crabb, 2014). A number of studies (Johnson et al., 2011; Kunchithapautham et 
159 al., 2014) have yielded conflicting data as to where drusen proteins originate from, and 
160 whether the accumulation of this apparent depositioning of biomaterials in BrM is a 
161 passive or an active process. Several questions remain, which include: to what extent do 
162 proteins in drusen originate from photoreceptors, RPE, choroidal endothelium or even 
163 the circulating blood? How do drusen form and how are drusen components recruited 
164 and deposited in the sub-RPE-BL space? What is the extent of the (molecular) 
165 heterogeneity that exists within and between drusen? Here, we will review and combine 
166 data from the existing literature, and supplement these with our own (new and recently 
167 published) data from subretinal transcriptomic, proteomic and immunohistochemical 
168 staining experiments. To enable this, we have functionally annotated a compiled list of 
169 drusen proteins and compared these proteins with those identified in specific 
170 transcriptomic and proteomic datasets derived from cells and tissues of the various 
171 relevant compartments. These include both subretinal and choroidal tissues, as well as 
172 the plasma proteome. Collectively, these analyses increase our understanding of 
173 drusenogenesis, which may provide clues for the prevention of drusen formation and, 
174 ultimately, for the prevention of drusen associated disorders (Khan et al., 2016) 
7175 2. Functional annotation of drusen proteins.
176
177 One of the key aims of this study is to identify the most likely original sources of drusen 
178 proteins. More specifically, do drusen proteins only come from the neural tissues 
179 (photoreceptors and RPE) or is there also a choroidal or systemic component? In the 
180 next chapters, we try to answer this question through a literature search and by using a 
181 variety of qualitative and quantitative transcriptomics and proteomics meta-analyses of 
182 the relevant genes and proteins involved. 
183 We did not distinguish between various drusen types, sizes and/or drusen locations, 
184 since little –omics data are available for each drusen subtype. Essentially, we followed 
185 the (sub-clinical) drusen type description used by Crabb and coworkers (Crabb et al., 
186 2002) who defined drusen to appear as opaque, 0 to 250 μm spherical to irregular 
187 deposits that remained attached to BrM after removing the RPE from human donor 
188 globes, both in the macular and the retinal periphery.
189 Based on relevant studies in the literature (Mullins et al., 2000; Crabb et al., 2002; Wang 
190 et al., 2010), we curated a list of 89 drusen proteins (Table 1). This was achieved by 
191 combining the published datasets and removing incomplete, duplicate or ambiguous 
192 entries. Several entries did not correspond to a single full-length cDNA annotated in the 
193 knowledge database Ingenuity (www.ingenuity.com) and were left out. Since the 
194 complement gene pathway is likely the best and most extensively studied pathway 
195 (compared to other pathways) we only added a few complement proteins to the list, to 
196 avoid bias toward one pathway and the “winner’s curse”. In addition, we also searched 
197 the literature for confirmatory immunohistochemistry (IHC) studies and manually 
198 added proteins from such smaller-scale studies. We realize this list may not be complete. 
199 For example, individual entries like the locally produced vitronectin (Hageman et al., 
200 1999; Wasmuth et al., 2009) present in drusen is missing in Table 1 and an entry like 
201 elastin may be present as contamination of the BrM rather than a “specific” drusen 
202 protein. The problem with selecting these proteins lies with the heterogeneity of drusen 
203 (one protein may be present in one drusen but not in the other), lack of uniform criteria 
204 “what is drusen-specific (?)”, lack of uniformity in healthy or diseased stage of examined 
205 samples and overall, how much evidence is needed to assign proteins to drusen (see also 
206 discussion section). Nonetheless, we believe that, for the purposes of this study, our 
8207 selection of 89 proteins, largely based on the proteomic study of Crabb and colleagues 
208 (Crabb et al., 2002) provides us with a sufficient representative drusen protein dataset 
209 for the purpose of this study.
210 We used the 89 drusen protein data set first to investigate the molecular aggregation 
211 and the functional annotation of drusen proteins. A similar study was previously carried 
212 out by Crabb and coworkers (Crabb et al., 2002; Crabb, 2014). However, here we used a 
213 slightly different list of drusen proteins and subjected this to additional, advanced 
214 bioinformatics analysis. Consequently, we ran an Ingenuity knowledge database core 
215 analysis using our list of drusen components (Table 1) which yielded biological motifs, 
216 canonical pathways and molecular structural or functional networks. A summary of the 
217 results of this analysis is shown in Table 2.
218 2.1. Biological or disease motifs and canonical pathways.
219 The functional annotation of the 89 drusen proteins (Table 2), revealed that these 
220 proteins (motifs or aggregates) can be associated with a number of functional or disease 
221 entities, such as “hereditary disorders”, “ophthalmic disease”, “organismal injury or 
222 abnormalities” and “metabolic disease and developmental disorders”. Although these 
223 annotation categories are broad and not very specific, they do point to a wide range of 
224 potential sources of drusen components from both local and systemic origin.
225 Ingenuity analysis also yielded a number of canonical pathways. A canonical pathway is 
226 the simplest linear representation of an established chain of biochemically related 
227 molecules in a given system or cellular environment. The software recognizes enriched 
228 canonical pathways specific for “acute phase response signaling”, the “retinoid- and 
229 farnesoid X receptors (LXR/RXR and FXR/RXR) response”, “atherosclerosis signaling” 
230 and “IL-12 signaling in macrophages” in the drusen dataset.
231 “The acute phase response” is a fast-systemic inflammatory response triggered by 
232 infection, tissue injury and/or immunological disease (Serhan et al., 2015). The response 
233 is mediated by the hypothalamus and several acute phase plasma proteins. These 
234 proteins have a broad-working spectrum: they kill micro-organisms and modulate 
235 complement activation, enzyme activity and the immune response. How and why these 
236 proteins potentially end up in drusen is not clear (Johnson et al., 2000). Although not 
237 undisputed, Despriet and coworkers found independently, that AMD is associated with 
9238 acute phase plasma protein levels and with genetic variation in C-reactive protein (CRP), 
239 one of the principal acute phase proteins (Despriet et al., 2006). Chirco and Potempa  
240 showed that CRP protein acts as a mediator of complement activation and inflammatory 
241 signaling in AMD (Chirco and Potempa, 2018). It is generally assumed that acute phase 
242 proteins are present in the blood; suggesting that some drusen proteins can originate 
243 from this pathway and have a systemic origin. While choroidal CRP apparently correlate 
244 to serum levels (Chirco et al., 2018), it cannot be said with certainty that these proteins 
245 are not (transiently and/or locally) produced by the choroid as well in cases of (nearby) 
246 low-grade inflammation.
247 “The retinoid X receptors (RXRs)” are nuclear retinoid receptors that regulate, via the 
248 ligand LXR, lipid and cholesterol metabolism as well as inflammation (Hiebl et al., 2018). 
249 Cholesterol metabolism is essential for many retinal functions (Pikuleva and Curcio, 
250 2014), while ocular (para-) inflammation is crucial for maintaining retinal homeostasis 
251 (Xu et al., 2009). In the eye, retinoid X receptor activation contributes to retinal 
252 photoreceptor differentiation, survival, and disease (Forrest and Swaroop, 2012), and 
253 more specifically, for docosahexaenoic acid-mediated protection of photoreceptors 
254 (German et al., 2013). The presence of this protein signature in drusen points toward a 
255 local cellular origin of this protein. LXR can form heterodimers with “the farnesoid X 
256 receptor (FXR)” which is also a nuclear receptor, and is an important regulator of a 
257 variety of bile acid, glucose and lipid-related metabolic pathways, including the removal 
258 of cholesterol (Tu et al., 2000; Hiebl et al., 2018). FXR protein was detected in a variety 
259 of tissues, including heart, ovary, thymus and eye. Both LXR and FXR may be involved in 
260 cholesterol homeostasis in RPE and retina (Zheng et al., 2015). The presence of these 
261 receptor proteins in drusen points toward a local cellular origin. 
262 “Atherosclerosis signaling”: Atherosclerosis is a low grade chronic inflammatory 
263 disorder characterized by local plaque deposition in the vessel wall, formed by a local 
264 accumulation of modified plasma lipoproteins and macrophage activation. The major 
265 cause of coronary events is rupture and thrombosis. Interestingly, clinical, 
266 epidemiological, pathobiological and molecular evidence suggest that an overlap exists 
267 between drusen in AMD and plaque formation in atherosclerosis. Indeed, like AMD, 
268 atherosclerosis is now considered as a low-grade chronic inflammatory process 
269 resulting from interaction (in) between plasma lipoproteins and the vascular wall 
270 (Mullins et al., 2000). In AMD, not only plasma lipoproteins, but also local lipoproteins 
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271 are involved. In section 8 of this manuscript, we describe the potential molecular and 
272 pathobiological overlap between drusen/AMD and vascular plaques in detail. Taken 
273 together, the homology between drusen and atherosclerotic plaques points toward a 
274 systemic origin of some drusen proteins.
275 “IL-12 Signaling and Production in Macrophages”: The production of the cytokine IL-12 
276 by activated (incoming) macrophages in damaged or diseased retinal tissue, is well 
277 known (Zamiri et al., 2006; Chen et al., 2013). However, IL-12 exerts an autocrine effect 
278 since macrophages and dendritic cells also respond to IL-12 by producing interferons 
279 that stimulates T-helper cell differentiation. The RPE is apparently able to suppress 
280 inflammation by modulating IL-12 production (Zamiri et al., 2006). Cao and coworkers 
281 showed that cultured RPE cell in vitro secrete several cytokines, including IL-12, under 
282 conditions of oxidative stress and replicative senescence (Cao et al., 2013). Therefore, 
283 the molecules identified in this category (IL-12 signaling) can originate from both the 
284 circulation as well as from the local cellular environment.
285 2.2. Molecular networks.
286 Molecular networks in Ingenuity are built up from a myriad of relevant literature 
287 connections and they are formed on the basis of most likely physical or functional 
288 interactions between (input) genes and/or proteins. For example, see molecular 
289 network 1 in Figure 2a. Based on millions of experimentally verified and curated data 
290 points, these networks represent the most likely functional associations between 
291 components of the “biological soup” in the context of the input molecules. Structural, 
292 functional and mixed molecular networks exist. Structural networks contain primarily 
293 networks of structurally and physically interacting entries. Functional networks are 
294 dominated by functional relationship between participating molecules. A third, “mixed” 
295 network, contains both structural and functional associations. The molecular network 
296 analysis of drusen proteins yielded 4 significant networks, with 6 distinct functional 
297 clusters. Note that the networks are not a priori built through their possible relationship 
298 with drusen or AMD per se.
299 2.2.1. Network 1.1, 1.2 and 1.3: Complement, collagens and crystallins.
300 The most significant network formed in the data-driven Ingenuity drusen analysis, is 
301 presented in Figure 2a. This network consists of three functionally more or less specific 
302 molecular clusters: the complement protein cluster, the collagen protein cluster and the 
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303 crystallin heat shock protein cluster (Table 3). The presence of complement proteins in 
304 drusen (and the choriocapillaris) was previously shown in older and AMD affected eyes 
305 through immunohistochemistry, long before the genetic involvement of CFH and other 
306 complement factors in drusen formation and AMD became genetically apparent 
307 (Johnson et al., 2000; Hageman et al., 2001; Edwards et al., 2005; Hageman et al., 2005; 
308 Haines et al., 2005; Klein et al., 2005). Analyzing the drusen proteome, we confirmed the 
309 involvement of the terminal complement protein complex by identifying the 
310 complement factors C7, C8A, C8B, C8G, and the membrane attack complex (MAC) in 
311 drusen. Of note, the MAC was initially identified in drusen from unspecified retinal 
312 locations, but was later shown not to be present in macular drusen (Johnson et al., 2000; 
313 Mullins et al., 2014). The MAC is the final downstream event of the complement cascade. 
314 It results from the binding of C5b to blood plasma complement proteins C6, C7, C8, and 
315 C9, forming transmembrane pores that leads to cell lysis and death. In the same cluster, 
316 we found the Prolyl endopeptidase-like protein (PRELP), a small leucine-rich 
317 proteoglycan (SLRP) (Hultgardh-Nilsson et al., 2015), which among others, is involved in 
318 the inhibition of complement activation (Warwick et al., 2014). The main complement 
319 cascade regulator CFH is another member of the complement cascade that is present in 
320 the drusen proteome. Genetic variation in CFH may regulate complement activation on 
321 RPE cells (Radu et al., 2014). Of note, is that a certain degree of low-grade complement 
322 activation and para-inflammation is always present in healthy aging eyes, to maintain 
323 local health (Xu et al., 2009). In a recent review, Warwick et al. concluded that 
324 complement deposition in the retina could be of local and/or systemic origin (Warwick 
325 et al., 2014). The majority of complement genes are expressed in the liver, resulting in 
326 an abundance of complement proteins in the blood. However, the RPE expresses several 
327 key complement genes which may modulate the complement attack on RPE and drusen 
328 (Chen et al., 2007; Kim et al., 2009; Pao et al., 2018). Interestingly, locally produced CFH 
329 is, at least in cultured RPE cells, secreted apically, and not basally (Kim et al., 2009; Pao 
330 et al., 2018). Consequently, the potential regulating role of locally produced CFH in vivo, 
331 and other complement factors, potentially involved in the complement attack on drusen, 
332 needs to be further investigated. A diversity of collagen proteins, such as COLA1, A2, 
333 6A1, 6A2 and 8A1 were previously consistently identified in basal laminar deposits and 
334 basal linear deposits, and, occasionally, in drusen (Newsome et al., 1987; Booij et al., 
335 2010a; Curcio and Johnson, 2012). Newsome and coworkers (1987) noted that the 
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336 involvement of extracellular matrix components in drusen is variable but these findings 
337 have not been confirmed in other studies. These molecules may primarily present as a 
338 remnant from the (ab)normal turnover of BrM components (Newsome et al., 1987). 
339 Alternatively, they may be secreted by the RPE in response to challenges presented by 
340 drusen or by the conditions that lead to drusen formation. Interestingly, collagen IV is 
341 not present in our curated drusen dataset, despite the fact that collagen IV 
342 accumulations are found in autosomal dominant radiant drusen in Doyne Honeycomb 
343 Retinal Dystrophy caused by 
344 EFEMP1(EGF-containing fibulin extracellular matrix protein 1) mutations (Sohn et al., 
345 2015). In fact, in the absence of detailed electron microscopic examination it is not clear 
346 whether these are drusen or basal laminal deposits.
347 The presence of crystallin proteins in drusen had been shown by Crabb and co-workers 
348 (Crabb et al., 2002) and functionally studied by Nakata et al. (Nakata et al., 2005). These 
349 authors found that BrM, drusen and part of the choroidal connective tissue, when 
350 affected by AMD, showed higher immunoreactivity for α- and β-crystallins than healthy 
351 control tissues. Retinal crystallins are also up-regulated in a variety of other retinal 
352 pathologies, including diabetic retinopathy, ischemia, mechanical injury and uveitis. The 
353 α-crystallin family plays a crucial role in neuroprotection and inflammation (Fort and 
354 Lampi, 2011), while the β- and γ-crystallins are small proteins with a possible ganglion 
355 cell protective role in glaucoma (Anders et al., 2017) and a role in retinal tissue 
356 remodeling and repair (Thanos et al., 2014). Consequently, the presence of these 
357 proteins in drusen points to a local cellular origin.
358 2.2.2. Network 2.4 development, genetics of ophthalmic disorders.
359 The fourth cluster in our drusen protein analysis is actually similar to the entire network 
360 2 which is functionally annotated as “network of genetic and developmental disorders”. 
361 The components of this cluster are functionally presented in detail in Figure 2b; Table 3. 
362 This network contains annexin A2 (ANXA2), a relatively small calcium and 
363 phospholipid-binding protein involved in multiple intra-cellular transport functions. The 
364 RPE secretion data set, called RPE-IVS (Table 3; STable 1) reveals that this protein is 
365 indeed secreted basally by the RPE (Pao et al., 2018). The protein was initially assigned 
366 to drusen (Crabb et al., 2002). However, the same authors showed, using IHC in a 
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367 number of human donor eyes, that ANXA2 is not associated with the interior of drusen, 
368 but with the basal lamina of the RPE close to the drusen surface. 
369 2.2.3. Network 3.5: Immunological response.
370 The fifth functional cluster in our drusen protein analysis represents network three: 
371 “Injury and inflammatory response; dermatological disease” (Figure 2c). The 
372 components are given in Table 3. This network contains, among others, annexin A1 
373 (ANXA1). ANXA1 antibodies intensely stained whole drusen, but also the BrM and 
374 choroid (Rayborn et al., 2006). Given its positive staining in entire drusen, we consider it 
375 here as a drusen protein. Apolipoprotein E (APOE) is also present in this group. APOE is 
376 classically thought of as a cholesterol carrier. Risk alleles of the APOE gene were 
377 associated with a variety of diseases including AMD, AD and atherosclerosis (Klaver et 
378 al., 1998; Ashford, 2004; Song et al., 2004; Tikellis et al., 2007). Its presence in laminar 
379 deposits and drusen was initially established by Klaver and colleagues (Klaver et al., 
380 1998) and later confirmed by Anderson and Malek (Anderson et al., 2001; Malek et al., 
381 2003). Interestingly, in an RPE cell culture model that mimics drusen formation, Pao 
382 (2018) and coworkers found that APOE is secreted basally by these cells. Subsequent 
383 exposure of these cultures to human serum led to heterogeneous sub-RPE-BL space 
384 deposits, some of which were rich in serum-derived proteins such as vimentin, clusterin 
385 and amyloid P (Pao et al., 2018). In addition to ANXA1 and APOE, the serum amyloid 
386 proteins S100A7, S100A8 and S100A9 are part of this functional cluster and the drusen 
387 proteome. S100 proteins are a family of small calcium-binding proteins, produced in the 
388 nucleus and cytoplasm of a wide variety of cells (Gross et al., 2014; Narumi et al., 2015; 
389 Cunden et al., 2017).
390 2.2.4. Network 4.6 Cell-to-cell signaling and systemic involvement, lipid metabolism.  
391 The sixth cluster “cell-to cell signaling and systemic involvements” (Figure 2d; Table 3) 
392 points to proteins which come from an extracellular environment. For example, The 
393 APOA1, APOA4 and SAA1 lipoproteins and S, and the protein-groups related to the LDL, 
394 HDL, VLDL metabolism (that have been added by Ingenuity to construct a meaningful 
395 network) are most likely derived from the blood, and not from the retina. However, 
396 cautious interpretation of these general data is warranted, since the RPE is also capable 
397 of secreting a number of lipoproteins, such as APOB (Li et al., 2005b). The mechanisms 
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398 of biogenesis of lipid-laden soft drusen has been recently reviewed elsewhere (Curcio, 
399 2018a, b) as has the role of lipids in AMD  (van Leeuwen et al., 2018).
400 In at least two blood proteomics datasets (Table 3) the ORM1 (acute phase plasma 
401 protein of unknown function; www.genecards.org) and the SERPINA1 (serine protease 
402 inhibitor; www.genecards.org) proteins occur, which point also at a systemic origin of 
403 these drusen proteins.  Furthermore, in this cluster we see the drusen protein clusterin 
404 (CLU), which is expressed in many cell types, including photoreceptors or RPE, and is 
405 also present in blood (Garcia-Aranda et al., 2018). The presence of annexin 6 (ANXA6) in 
406 drusen (and BrM) was previously confirmed using immunohistochemistry (Rayborn et 
407 al., 2006). Finally, we observe also the presence of the (systemic) HRG protein, which is 
408 extensively discussed in section 7 of this manuscript.
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409 3. Drusenomics, part I: Where do drusen proteins come from: the literature.
410 Multiple epidemiological, genetic, biochemical and pathophysiological studies in the 
411 literature address the origin of drusen. While many studies address the origins of metal 
412 ions or lipids in drusen, here we focus on the likely source of proteins. Drusen proteins 
413 could originate from either the neural side of drusen (Photoreceptors, RPE), the 
414 systemic side (BrM, choroid complex, blood) BrM, or both (Penfold et al., 2001; Curcio 
415 and Johnson, 2012).
416 3.1. The neural side of drusen.
417 Theories on drusen accumulation from the neural side vary: proteins may either come 
418 from dying PR and RPE cells, or from (basal) secretion of proteins generated by the 
419 normal functions of the RPE (Crabb et al., 2002; Kinnunen et al., 2012). Respectively, 
420 cellular debris or secreted proteins may get trapped in BrM or drusen. Evidence for 
421 these origins was gathered from histopathological investigation, retinal imaging, and 
422 proteomics studies.
423 3.1.1. Histopathological and retinal imaging observations.
424 Drusen formation goes hand in hand with hypo- or hyperpigmentation (Curcio et al., 
425 1998) of the RPE, especially in the early stages of AMD. Indeed, retinal cells overlying 
426 drusen exhibit numerous irregular structural and molecular abnormalities which are 
427 confined to areas directly internal to drusen (Farkas et al., 1971b; Hogan, 1972; Burns 
428 and Feeney-Burns, 1980; The Eye Disease Case-Control Study, 1992; Johnson et al., 
429 2003). Deflection and shortening of rod inner and outer segments of rod photoreceptors 
430 have been postulated to contribute to sub-RPE deposit formation (Farkas et al., 1971a). 
431 Drusen have been also associated with more indirect changes, such as alterations in the 
432 synaptic terminals of photoreceptor cells and an increase in vimentin and glial fibrillary 
433 acidic (GFAP) protein within Müller cells (Johnson et al., 2003). Other retinal cells, such 
434 as bipolar, horizontal, amacrine and ganglion cells are most likely unaffected by 
435 drusenogenesis (Johnson et al., 2003). 
436 Using immunohistochemical, molecular biological and biochemical approaches, 
437 Hageman and coworkers found that RPE cell loss is correlated with increasing drusen 
438 density (Hageman et al., 2001). More recent OCT studies, focusing on the integrity of the 
439 RPE layer directly internal to drusen showed that 41.3% of all drusen coincided with an 
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440 intact overlying RPE, and that in 28.1% of cases, the RPE was irregular but continuous 
441 (Schlanitz et al., 2018). In 30.6% of cases, the RPE layer adjacent to drusen was 
442 discontinuous. Larger drusen were associated with higher probability of RPE loss 
443 (Schlanitz et al., 2018). Taken together, these results suggest that RPE or PR cell death is 
444 associated with drusenogenesis. However, it is not clear whether the observed cellular 
445 damage is a cause or consequence of sub-RPE deposit formation. 
446 The presence of cytoplasmic (Burns and Feeney-Burns, 1980), fibrous and 
447 membranous/lipoid material (Fine, 1981; Young, 1987; Green and Enger, 1993; Loeffler 
448 and Lee, 1998; Curcio and Millican, 1999) in drusen suggest that deposits are formed 
449 after cellular degeneration. According to Coats, small colloid bodies derived from 
450 degenerated RPE cells, develop into larger drusen due to uptake of biomolecules 
451 through a defective BrM (Coats, 1905) and clinical support was provided for the 
452 existence of these bodies (Pauleikhoff et al., 1990). Later, necrotic RPE cells were 
453 presumed to be incorporated into existing drusen (Young, 1987). However, these 
454 findings also did not distinguish between cause or consequence of deposit formation. To 
455 complicate matters further, there are a number of reports in the literature describing 
456 drusen regression; in an experimental study after laser photocoagulation and in clinical 
457 studies using fluorescein angiograms (FAs) fundus photography (Bressler et al., 1995) 
458 and OCT (Yehoshua et al., 2011). A similar observation were done in rhesus monkeys 
459 (Duvall and Tso, 1985) in APOE mice with thickened BrM as well as AMD patients 
460 (Jobling et al., 2015). This intriguing phenomenon may be linked to transiently 
461 increasing the RPE-mediated release of active MMP enzymes that alter the turnover of 
462 BrM  (Zhang et al., 2012). 
463 3.1.2 Proteomic level observations.
464 Proteomics studies into drusenogenesis can be divided into studies on (archived) 
465 human post-mortem eyes, in vitro RPE culture, and proteomic studies on retinas of 
466 animal models. A variety of techniques, such as 2D gels and LC-MS/MS analysis have 
467 been used. To date, up to over 500 healthy and AMD-affected post-mortem human eye 
468 tissue specimens (numerous contributions of Sarks, Hageman, Mullins, Lutty, Bergen, 
469 Lengyel, and Curcio) have been examined by light, confocal, or electron microscopy, in 
470 conjunction with proteomics and with antibodies to specific drusen-associated proteins 
471 (Curcio et al., 2017). These studies emphasize the heterogeneity of drusen, a concept 
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472 initially developed by Sarks and coworkers (Sarks et al., 1980; Sarks et al., 1994; Sarks et 
473 al., 1999) and strongly suggest that chronic local inflammation at the level of BrM is an 
474 important contributor to drusenogenesis.
475 In vitro, the transcriptome and proteome of RPE cells, such as cultured primary retinal 
476 cells (fetal or from postmortem human donor eyes) (Alge et al., 2003; Oshikawa et al., 
477 2011; Pao et al., 2018) has been determined. Stable isotope labeling of amino acids 
478 showed that these cells secrete a variety of extracellular matrix proteins, complement 
479 factors, and protease inhibitors, that have also been reported to be major constituents of 
480 drusen (An et al., 2006). In addition, abnormal protein secretion by human primary RPE 
481 cultures derived from AMD patients has been observed compared to age-matched 
482 controls (An et al., 2006). However, the fact that major components of drusen can be 
483 reproduced by RPE cells without the need for PR outer segments, supports a crucial role 
484 of RPE in drusen formation (Pilgrim et al., 2017). At the same time, it suggests that PRs 
485 may contribute but are not essential for drusenogenesis. Off note, it is important to 
486 emphasize that cells in culture were treated with heat-inactivated serum, and that the 
487 contribution of components from this material to drusenogenesis, as “dietary” 
488 contribution, is highly likely (Bretillon et al., 2008; Pikuleva and Curcio, 2014; Pilgrim et 
489 al., 2017).
490 Wang and coworkers found that, after simultaneous mass spectrometry analysis of both 
491 archived drusen and RPE material, similar protein profiles, but with higher intensities 
492 and greater variability in the drusen. Within the limits of unavoidable sample 
493 contamination, these data suggest that other than RPE alone, additional local cells or 
494 tissues contribute to formation of debris in the sub-RPE-BL space (Wang et al., 2010). 
495 3.2. The systemic side of drusen.
496 Drusenogenesis theories have focused on the role of lipids and immune-mediated 
497 effects. Lipoproteins, neutral lipids (Curcio et al., 2011), complement-activating 
498 molecules and other immune mediators as well as monocyte-derived cellular processes 
499 have been identified within drusen (Hageman et al., 2001; Penfold et al., 2001; Anderson 
500 et al., 2010; Molins et al., 2018), which indicates the biogenesis or propagation of drusen 
501 from the systemic side. 
502 3.2.1. Bruch’s membrane.
18
503 The main functions of BrM are structural, to support the RPE, and to regulate the 
504 transport of fluid, ions and biomolecules from the choroid to the RPE, and vice versa 
505 (Curcio and Johnson, 2012). BrM thickening and decline of hydraulic conductivity have 
506 been observed during aging (Hussain et al., 2010; Cankova et al., 2011).  Studies suggest 
507 diffuse thickening of the inner aspect of BrM is associated with retinal pigment epithelial 
508 hypopigmentation, focal atrophy, and soft (large) drusen formation (Bressler et al., 
509 1994). A variety of extracellular matrix components have been detected in diffuse 
510 thickenings of BrM (Fernandez-Godino et al., 2016). Immunohistochemical reactivity of 
511 BrM showed age-related accumulation of type I collagen and localized changes 
512 associated with some drusen (Newsome et al., 1987; Curcio and Johnson, 2012). The 
513 tissue inhibitor of metalloproteinases-3 (TIMP-3) protein, a major component of the 
514 drusen proteome, showed high immune-reactivity in human drusen and in BrM (Fariss 
515 et al., 1997). The continuous turnover of BrM during life could provide a continuous 
516 local supply of BrM proteins. Some of the remnants may be cleared to the blood but 
517 some of them might end up in drusen. Please note, that most studies on the aspects of 
518 BrM thickening have been performed by light microscopy on paraffin sections. In future 
519 studies, it will require TEM or high resolution light microscopy to confirm the majority 
520 of these findings, and to distinguish, for example, between “BrM thickening” and basal 
521 laminar deposits.
522 3.2.2. Choroidal capillaries.
523 The choriocapillaris is located directly underneath the RPE and BrM. It is composed of a 
524 unique vascular network which provides nutrients and fluid for the RPE and the retina 
525 (Bernstein and Hollenberg, 1965). The abundance of fenestrations on the RPE aspect of 
526 the choriocapillaris endothelium makes this vascular bed much leakier than non-
527 fenestrated vessels (Bernstein and Hollenberg, 1965). A compromised interface can 
528 result in various abnormalities such as choroidal neovascularization (CNV) and AMD 
529 (Lutty et al., 2010).
530 With age and in AMD, the choroid thins. The choriocapillaris loses density and covers an 
531 increasingly smaller portion of BrM. At the same time, increased drusen deposition 
532 occurs, as witnessed by histopathological evidence (Ramrattan et al., 1994; Ida et al., 
533 2004). OCT Angiography (OCTA) showed atrophy of choriocapillaris underneath and 
534 beyond the region of photoreceptors and RPE loss (Wakatsuki et al., 2015; Moreira-Neto 
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535 et al., 2018), in agreement with previous and parallel histopathological studies (McLeod 
536 et al., 2009; Biesemeier et al., 2014). In human macular sections, histopathological 
537 evaluation of the sub-RPE-BL deposits together with potential vascular changes, showed 
538 that vascular density was inversely correlated with sub-RPE-BL deposit density 
539 (Biesemeier et al., 2014). Curcio and coworkers observed that modest endothelial cell 
540 loss in the  choriocapillaris also occurred directly adjacent to basal linear deposits and 
541 subretinal drusenoid deposits (Curcio et al., 2013). Sub-RPE-BL deposits showed a 
542 positive correlation with the number of ghost vessels in the choroid, suggesting that 
543 vascular endothelial cell loss could contribute to deposit formation (Mullins et al., 2011). 
544 It has also been shown that the presence of complement components and specifically, 
545 MAC, in the choroid increases with aging, and increases even more in AMD-affected eyes 
546 (Mullins et al., 2014; Chirco et al., 2016). In fact, C5b-9 complement complexes are 
547 present in hard drusen, BrM, and extend to the choriocapillaris in some cases (Johnson 
548 et al., 2000; Anderson et al., 2002). C5b-9 complexes were not observed in soft drusen 
549 (Mullins et al., 2014).
550 On whole-mount hydrated preparations of the choroid and BrM, (hard) drusen were 
551 located to the intercapillary pillars of the choroid, suggesting a close relationship 
552 between drusen formation and the capillary bed (Lengyel et al., 2004). This was 
553 observed in earlier studies, but not systematically examined (Friedman et al., 1963). It 
554 was suggested that drusen are a manifestation of (a) disturbed transport mechanism(s) 
555 of substances across the capillary wall or BrM (Penfold et al., 2001). Whether this 
556 indicates that drusen deposition is the result of slower clearance at the intercapillary 
557 pillars or a manifestation of a disturbed transport mechanism of substances across the 
558 capillary wall, or both, needs additional investigation.  Of note, further pathological 
559 compromise of the vascular bed and BrM leads eventually to the development of 
560 subretinal neovascularization and wet AMD.
561 3.2.3. Contribution of blood proteins.
562 Penfold and coworkers suggested that breakdown of the normal choroidal vascular 
563 function allows the movement of plasma proteins to the sub-RPE-BL space and this 
564 leakiness is one of the cause of initiating the progression to AMD (Penfold et al., 2001). 
565 Another study involved the analysis of age-related changes in various proteins and lipids 
566 in the BrM using multiplexed Raman spectroscopy and found age dependent change in 
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567 heme signals (Beattie et al., 2010). However, there are no detailed and definitive studies 
568 how these plasma molecules end up in the sub-RPE-BL space.  Involvement of 
569 fenestrations, breakdown of tight junctions, active vesicle transport (caveola) and 
570 receptor-mediated endocytosis (for macromolecules) have been suggested. 
571 Fenestrations are found predominantly on the endothelial vessel wall closest to the RPE 
572 (Bernstein and Hollenberg, 1965; Pino, 1985; Mancini et al., 1986). Rodent studies 
573 suggested that the number of fenestrae initially increases with age; but in advanced age 
574 and in AMD the number of fenestrae decreases (Burns and Hartz, 1992; McLeod et al., 
575 2009). Transport through fenestrae is likely to be tightly regulated but it is not yet fully 
576 characterized (Pino and Essner, 1981; Essner and Gordon, 1983). Tight junctions of the 
577 choroidal capillaries show a tendency to become leaky with age, and lack transport 
578 regulation which may facilitate movement of plasma proteins from the choroid towards 
579 to the RPE (Nakanishi et al., 2016) (Aiello et al., 1998). Finally, vesicle- or receptor-
580 mediated transport of proteins also exist in the choroid. (Smith et al., 1989). Taken 
581 together, transport of proteins at the choroid/BrM interface is complex and warrants 
582 further investigation.
583
584 It has long been speculated that both blood plasma and incomplete digestion of 
585 photoreceptor outer segments contribute to the buildup of drusen material (Farkas et 
586 al., 1971a). It has also been suggested that drusen formation in the retina may be similar 
587 to plaque formation in arterial walls (Curcio et al., 2001), which, again, suggests that the 
588 contribution of blood proteins may be more important than previously thought (see 
589 section 8 on “drusen and plaques”). However, there is a paucity of information as to 
590 what extent proteins from the blood really contribute to drusen formation. It is thus 
591 plausible that some molecules exit the choroidal vessels into the extracellular space 
592 adjacent to the RPE, especially as the barriers in place to prevent such an event from 
593 happening, become compromised with age.
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594 4. Selection of transcriptomic and proteomic datasets to determine the origin of drusen 
595 proteins
596 4.1. Exclusion criteria and considerations. 
597 One of the main goals of this study was to compare subretinal cellular transcriptomics 
598 and proteomics as well as the blood proteome with proteins that are present in drusen. 
599 To achieve this, we made use of a subset of studies from the literature as well as our own 
600 data. Apart from the drusen protein studies, which date back to 2002, we only 
601 considered here mRNA and protein studies published over the last 8 years; we did not 
602 include retinal microRNA studies, non-coding RNA, metabolomics, imprinting studies 
603 and data from (differences in) single-cell expression studies, simply because there are 
604 relatively few confirmed and validated studies for the various types of retinal tissues 
605 available yet.
606 Multiple excellent transcriptomics and proteomics studies have been published on 
607 different layers of the retina/RPE/choroid complex, these are reviewed by a number of 
608 authors recently (Skeie and Mahajan, 2014; Tian et al., 2015; Zhang et al., 2015a). 
609 However, the studies currently available differ in many aspects, including study design, 
610 retinal area and retinal cell type examined, sample source selection, sample handling, 
611 sample numbers investigated, probe labeling methodology, microarray- or RNA 
612 sequencing- methodology as well as the platform, quality and type of bioinformatics 
613 programs used for analysis. It is not our goal here to describe and compare all the retinal 
614 transcriptomic or proteomic data in the literature. Nonetheless, if one wants to compare 
615 different sources (subretinal transcriptomics and proteomics, blood proteomics) and/or 
616 outcomes (drusen proteins), similarity of the components and parameters of the 
617 comparison(s) is obviously, highly desirable (Ahmad et al., 2018). 
618 In the relevant transcriptomics literature, at least three phases can be observed: studies 
619 before and after the introduction of the MIAME (Minimum Information About a 
620 Microarray Experiment) quality guidelines studies (Brazma et al., 2001); studies before 
621 and after the introduction of whole genome microarrays (at least 22000 genes (22 K or 
622 more)) and studies before and after the introduction of RNA-Seq and GTex criteria. Over 
623 time, a similar technological development has taken place in the proteomics field: from 
624 2-D gels to high pressure liquid chromatography columns coupled and high throughput 
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625 mass-spectrometry-based studies (Geyer et al., 2016). In principle, the quality of large-
626 scale transcriptomics and proteomics studies has continued to improve, and better and 
627 more complete datasets may become available in time that may change some of the 
628 interpretations described here.
629 There are several obvious differences between transcriptomics and proteomics studies. 
630 In principle, transcriptomics techniques are highly sensitive and highly quantitative, but 
631 as such, highly susceptible to RNA contamination or degradation. In addition, 
632 transcriptome changes may not equate with changes on coded proteins and as such are 
633 further away from biological function. 
634 Proteomics studies, however, are usually less sensitive and quantitation can only be 
635 achieved under certain circumstances, but proteomes per se are closer to function. 
636 During disease progression, transcriptomics and proteomics profiles of a tissue can 
637 change rapidly depending on disease stage. Also, a single tissue under study can be 
638 affected by two or more consecutive disease stages at the same time. For example, in 
639 AMD, new hard drusen continue to appear in the sub-RPE-BL space, while other drusen 
640 in the same tissue already become confluent, and perhaps part of the same retina is 
641 already prone to neovascularization. Consequently, for a disease like AMD, where the 
642 RPE is subject to consecutive, insidious and overlapping disease stages, it is very difficult 
643 to sift out useful and consistent healthy and disease stage specific expression profiles for 
644 this cell layer. 
645 Obviously, transcriptomics and proteomics studies cannot be translated one-to-one, due 
646 to, for example, differences in RNA and protein synthesis and turnover rates. The sound 
647 interpretation of both transcriptomics and proteomics is highly dependent on the use of 
648 advanced bioinformatics and knowledge databases, which combine millions of data-
649 points from human, mouse, and rat studies. Nonetheless, it is the investigator, with 
650 knowledge of disease pathology, molecular biology and bioinformatics alike, who can 
651 make the difference.
652 There are two goals with most transcriptomics (or proteomics) studies: One type of 
653 study aims to find a complete molecular blueprint of the cells or tissues of interest; these 
654 studies usually yield an enriched expression data set for the cell of interest. This type of 
655 study usually includes both genes specifically expressed in the cell type of interest, but 
656 also genes expressed in similar cell types. For example, the RPE is probably defined by a 
657 few hundred RPE-specifically expressed genes, a few thousand neural cell-type 
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658 expressed genes, many expressed housekeeping genes for basic functions, as well as 
659 many genes which are on “standby”. The genes that are on “standby” have a very low 
660 (leaky) expression if the cell in is a state of homeostasis. However, if the environment 
661 changes, these very low expressed genes can rapidly be expressed to adapt the cell to a 
662 changing environment. For example, the RPE shares most likely the RNA expression of a 
663 large portion of its transcriptome: neural cell type genes, the household genes, and low-
664 level expressed genes, with the other (neural) cell types in the retina (own 
665 observations). Finally, there are many specific non-expressed genes in a certain cell-
666 type. An example of expression studies which aim to find a molecular blueprint of the 
667 cell is the uncurated RPE expression dataset, RPE-ET (Table 3), which contains 10% of 
668 the biologically highest expressed genes in the RPE (Booij et al., 2009).
669 The other type of study aims to find only a maximum of genes specifically expressed in 
670 only the cells or tissue of interest. These few hundred genes, in the context of the more 
671 generally expressed genes, give the cells of interest their specific cell type-associated 
672 functionalities. An example is the dataset, RPE-ST (Bennis et al., 2015), which contains 
673 170 RPE-specific expressed genes derived from previous RPE expression studies (Booij 
674 et al., 2009; Booij et al., 2010b; Strunnikova et al., 2010) (STable 2). 
675 4.2. Description of expression datasets used for drusenomics.
676 Apart from the 89 drusen protein data set, we used in this review 11 additional 
677 subretinal and blood data-sets derived from previous transcriptomics and proteomics 
678 studies; this is summarized in Table 3. We found that these transcriptomics and 
679 proteomics databases complement each other and, together, give a more complete 
680 overview of relevant expressed genes/proteins per tissue investigated. A common 
681 feature of all high throughput studies is that they generate, by default, a small 
682 percentage of misidentifications. This is due to cellular or molecular contaminations, or 
683 mis-representation due to experimental sample handling. Therefore, individual gene 
684 findings usually need to be confirmed by at least a second technique which focuses on 
685 the analysis of single genes or proteins. 
686 We used pure, enriched and curated cellular expression datasets. Pure datasets are 
687 those without possible contaminations of other cell types while enriched datasets are 
688 those datasets that have a certain degree of contamination of adjacent cell types. Finally, 
689 curated datasets are those which are manually enriched either by bioinformatics or by 
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690 literature search to remove inevitable contaminations or irrelevant data as much as 
691 possible. The curation strategies employed are presented in Figure 3. 
692 Most of the (non-curated) data were used for qualitative studies, have been published 
693 and analyzed elsewhere, and are mentioned below for reference. For the quantitative 
694 studies, we used curated datasets. The photoreceptors and choroidal transcriptome 
695 datasets, cPR-ET and cChor/ET (Booij et al., 2010b) (GEO database accession number 
696 GSE20191) have not been fully published before and therefore, their description will 
697 receive a little more attention here.
698
699 First of all, we used (1) a combined data set for drusen proteins, curated by hand as 
700 described above (Table 1). Furthermore, we used (2) a photoreceptor outer segment 
701 proteomics dataset published by Kiel and coworkers (Kiel et al., 2011), which contains 
702 proteins reflecting a multiscale signaling network associated with rhodopsin, the major 
703 protein component of rod photoreceptor outer segments. It was constructed by 
704 combining relevant proteomics datasets, structural and functional literature mining and 
705 bioinformatics approaches (Table 3; STable3). Most likely, this database listing contains 
706 some contamination from adjacent cell types, the RPE and choroid. Therefore, a curated 
707 list was used for the quantitative studies: we subtracted the most highly expressed 
708 sequences of the choroid (top 10% chor Booij; Chor-ET; and the uniquely expressed 
709 sequences of the RPE (RPE-ST, Bennis)) from this database listing. The acronym used for 
710 this dataset in this manuscript is PRos-EP (Photoreceptor outer segment-enriched 
711 proteomics). The annotation of the curated version (c) of this dataset is cPRos-EP.
712 (3) The RPE-specific database with 170 entries was constructed by bioinformatic 
713 curating and combining other (highly) enriched RPE gene expression databases (Booij et 
714 al., 2010b; Strunnikova et al., 2010; Bennis et al., 2015). This database listing should be 
715 viewed as a minimal number of RPE-specific expressed genes based on previous –omics 
716 studies; the acronym used here is RPE-ST (Specific Transcriptomics) (Table 3; STable 2).
717 (4) The RPE secretome data from (Pao et al., 2018) that was published recently. RPE 
718 cells were grown in vitro to confluency while adding various amounts of zinc to the 
719 culture medium. Both the apically and basally secreted RPE proteomes were 
720 determined. Here, we use the basal secretome proteomics listing which contains 276 
721 entries. (Table 3; STable 1). Due to its nature, this dataset does not contain 
722 contamination from other cell types but may contain contaminants from the culture 
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723 medium. In addition, its in vitro basis may not be fully representative of the in vivo 
724 situation, particularly in the disease state. The acronym for this database in this study is 
725 RPE-IVS (in vitro secreted) (Table 3).
726 (5) The RPE/choroid proteomics dataset from Zhang and coworkers that contain 
727 proteins extracted from RPE/choroid tissues of eyes from five individuals, fractionated 
728 and separated using SDS-PAGE and analyzed using mass spectrometry (Zhang et al., 
729 2016). In the RPE/choroid the authors identified 2755 non-redundant proteins. This 
730 dataset is rather large in components and is likely to contain entries from multiple cell-
731 types (RPE, choroid, blood and possibly PR), and not only (RPE/choroid), given the 
732 inevitable contaminations of the PR sample with RPE and vice versa, and the 
733 contamination of the choroid with blood. The authors deposited their data to the 
734 ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
735 identifiers PXD001424 and PXD002194. The acronym for this database in this 
736 manuscript is RPE/chor-EP (RPE/choroid-enriched proteomics) Table 3.
737 (6) The blood proteome listing by Geyer and coworkers was produced by a new efficient 
738 plasma proteome profiling pipeline (Geyer et al., 2016). Using a modified mass 
739 spectrometry-based workflow they were able to identify and quantify at least 1000 
740 plasma proteins. Given the nature of the samples, it is unlikely to contain other retinal 
741 cells or proteins as contamination. The acronym for this database in this study is BL-SP1 
742 (Blood plasma-specific proteomics; no 1) (Table 3; STable 4) (Geyer et al., 2016).
743 (7) The blood proteome dataset by Farrah and coworkers contains a non-redundant set 
744 of 1929 protein sequences from human plasma detected by tandem MS (Farrah et al., 
745 2011). The full data are available via PeptideAtlas, a large, international database of 
746 publicly accessible peptides identified in tandem MS experiments in a multitude of 
747 organisms. This is also a “pure” database listing. The original dataset contains 
748 endogenous chemicals, which we removed for our analyses. The acronym for this 
749 database in this study is BL-SP2 (Blood plasma-specific proteomics, no 2); (Table 3). 
750 (8) The BL-PHP blood proteome dataset consists of 262 HAP binding proteins from AMD 
751 patients and controls, as recently described (Arya et al., 2018). Plasma samples were 
752 taken from 23 individuals aged 65-90 with late stage AMD, each displaying drusen and 
753 choroidal neovascularization in clinical images and attending the anti-VEGF injection 
754 clinic at Moorfields Eye Hospital, London (STable 5).
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755 (9) The atherosclerosis plaque proteomics dataset contains 3196 entries based on a 
756 comprehensive review of the literature in this field (Bleijerveld et al., 2013). The 
757 acronym used in this study is AS-EP (Atherosclerosis-enriched proteomics) (Table 3).
758 The (large) dataset is available as supplementary file to the authors’ publication.
759 (10-12) Transcriptomics datasets of the photoreceptor (acronym: PR-ET: 
760 Photoreceptor; enriched transcriptomics), the choroid (acronym: Chor-ET: Choroid-
761 enriched transcriptomics.) (Table 3), and RPE (acronym: RPE-ET: RPE-enriched 
762 transcriptomics) were produced using the same Agilent methodology and platform. For 
763 functional annotation and quantitative analyses, curated versions of these databases 
764 were constructed, named, respectively, cPR-ET (STable 6) and cChor-ET (STable 7). The 
765 (c)RPE(-ET) database has been extensively published elsewhere (Booij et al., 2009; Booij 
766 et al., 2010b).
767 4.3. Functional annotation photoreceptor (cPR-ET) and choroidal (cChor-ET) datasets.
768 The PR-ET and Chor-ET datasets contain, respectively, the averaged top 10% highest 
769 expressed genes in the photoreceptor and choroid. The isolation methods, study design 
770 and methodological issues for these datasets have been extensively discussed elsewhere 
771 (Booij et al., 2009; Booij et al., 2010b). These raw datasets were used for the qualitative 
772 studies in this manuscript. The experimental studies were performed in agreement with 
773 the declaration of Helsinki concerning the use of human material for research and 
774 followed both MIAME and GTex criteria (Brazma et al., 2001; Consortium, 2013).  
775 We curated both datasets PR-ET and Chor-ET according to scheme C in Figure 3. In 
776 order to obtain cell-specific datasets for photoreceptor and choroid, which are useful for 
777 both cell-specific functional annotation and for quantitative studies described elsewhere 
778 in this manuscript. Consequently, we removed from the PR-ET and Chor-ET datasets 
779 all expressed genes that overlap between them (either contaminations or truly shared 
780 gene expression). This resulted in two smaller curated datasets. Subsequently, we also 
781 removed all potentially present RPE-expressed unique sequences (RPE-ST dataset) to 
782 generate the cPR-ET and cChor-ET datasets. Thus, the resulting cPR-ET and cChor-ET 
783 datasets contain less, but highly cell-specific entries compared to PR-ET and Chor-ET. 
784 Hence, we ended up with a highly photoreceptor-enriched gene expression dataset 
785 consisting of 745 genes (STable 6) and a highly enriched expression dataset for the 
786 choroid of 848 entries (STable 7). 
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787 We ran an Ingenuity core analysis (www.ingenuity.com) on both cPR-ET and cChor-ET 
788 datasets. This type of analysis typically yields data-driven functional annotations (i.e. it 
789 produces biological motifs, canonical pathways and molecular networks enriched in the 
790 dataset). The results of the cPR-ET analysis are presented in Table 4; PDF summary. We 
791 found some very basic and very specific functional features related to established 
792 photoreceptor function. The basic annotations included “cancer”, “cellular function and 
793 maintenance” as well as “tissue morphology”. One could speculate that these relate to 
794 the unique shape of the photoreceptor cell, and its unique ability to renew its 
795 photoreceptor outer segments. More specific (highly ranked) annotations included 
796 “photo transduction cascade”, “visual system development and function” and 
797 “neurological disease”. These data-driven results clearly fit with reported specific 
798 photoreceptor functionalities from the literature (Diamond, 2017; Musser and Arendt, 
799 2017; Fain and Sampath, 2018).
800 The choroidal transcriptomics dataset cChor-ET was generated in a similar way to the 
801 photoreceptor cPR-ET dataset described above. Obviously, the choroid is not a single 
802 tissue, but consists of multiple cell types, including endothelial cells, fibroblast cells, 
803 melanocytes, macrophages, and resident lymphocytes. The choroid is unavoidably 
804 contaminated with blood cells and proteins. Nevertheless, after curation, we obtained 
805 848 genes with a highly enriched choroidal expression in the cChor-ET dataset (STable 
806 7). Following Ingenuity core analysis, the resulting functional picture of the choroid is, as 
807 expected, completely different from that of the photoreceptors (Table 5; PDF summary). 
808 We found that two of the top five biological motifs (“inflammatory response” and 
809 “inflammatory disease”) and three canonical pathways (“antigen presentation pathway”, 
810 “acute phase response signaling” and “complement system”) are all involved with the 
811 immune system. This confirms the crucial role of the choroid and blood in external 
812 immune surveillance of the eye (Dick, 2017). The second highlight of this analysis was 
813 the canonical pathway “atherosclerosis signaling” which again points to an important 
814 resemblance between healthy or disease processes going on at the BrM (choroidal-RPE 
815 interface) and the vessel walls (see also section 8). 
816 Finally, both the canonical pathways and the highest ranked networks identified in this 
817 cChor-ET analysis indicate tissue damage and injury. One possible explanation is that 
818 this damage refers to early molecular complement attack already present or setting in, 
819 which may be well before any morpholocial changes or damage may be visible. 
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820 Alternatively, although we used data from healthy post-mortem eyes, performed the 
821 studies according to MIAME and GTex guidelines, 3’ primer design which avoids 
822 potential problems due to 5’ directed degradation, as well as very stringent RNA quality 
823 controls, the tissue damage and injury might still be due to post-mortem damage. 
824 Detailed data relating to both cPR-ET and cChor-ET analyses are available on request.
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825 5. Drusenomics, part II: Qualitative analysis.
826 5.1. Comparative study design considerations.
827 From the previous sections, it has become clear that a systematic investigation into the 
828 origin of proteins in drusen is lacking in the literature. Authors suggest a variety of 
829 protein sources, frequently on the basis of single observations. Systematic investigation 
830 of this phenomenon is hampered by the heterogeneity of source samples, methodology, 
831 and analysis. Large scale transcriptomics or proteomics studies frequently end up with a 
832 rather abstract annotation analysis, allowing a certain error rate and lack of detail; small 
833 scale studies frequently lack sufficient technical, methodological or biological replicates. 
834 In a first attempt to investigate the origin of drusen-proteins systematically, we used the 
835 presence of functional protein clusters identified in drusen (described in section 2). 
836 Subsequently, we investigated whether expression of entities in these clusters also 
837 (partly) occurs in the various non-curated expression database sets selected for this 
838 study. An overview of this comparison is presented in Table 3. This comparison serves 
839 two purposes: Firstly, the presence or absence of clusters in subcellular databases or 
840 blood may give a qualitative indication of the origin of (the proteins in) the cluster and 
841 secondly, it gives an indication of the completeness, quality, and contamination in each 
842 of the databases listed.
843 We argued above (section 4.2.) in detail that all individual transcriptomic and 
844 proteomics database lists used here (and those in the literature) are incomplete and, as 
845 a rule, have a degree of RNA/protein/cellular contamination due to original mixed cell 
846 sampling. How do we compare incomplete, contaminated datasets? 
847 First of all, one should have some knowledge of the study-design and character of the 
848 dataset under study, to understand why certain entries do, or do not, appear. The 
849 characteristics of the databases used are described in section 4.2 above. As an example, 
850 in the study of RPE/Chor-EP expression dataset (Table 3) we systematically identified 
851 that a large number of functional cluster queries/entries are indeed present. However, 
852 this is most likely due to the fact that the RPE/Chor-EP study contains proteins from 
853 photoreceptor, RPE, choroid and blood. Thus, we decided to use this dataset as a positive 
854 control (i.e., a dataset where almost all genes relevant to the study are 
855 expressed/present). Similarly, we used either the unique sequences from the RPE-ST 
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856 dataset, or the consequent absence of an entry in a set of similar dataset listings, as a 
857 negative control.
858 In our qualitative comparison, the incompleteness and potential contaminations of the 
859 various non-curated datasets (Table 3) may be largely overcome by considering similar 
860 data from different studies at the same time. For example, a specific query may be 
861 present in all photoreceptor studies, and, at the same time be absent from all blood 
862 proteomics studies. 
863 5.2. Where do proteins in drusen come from? A qualitative comparison.
864 We will now turn to the interpretation of the highlights of the comparative study results 
865 presented in Table 3. In the first column (top to bottom) the functional gene clusters 
866 from the molecular networks of drusen (Figure 2a-2d) are presented together with their 
867 individual gene content (column 2) and functional annotation (column 3). On the top 
868 rows (fourth column onward), subretinal transcriptomics and proteomics as well as 
869 blood proteomics data(sets) from the literature are given. For full length names of the 
870 abbreviated gene/proteins, see Table 1.
871 5.2.1. Network 1.1: The complement gene cluster.
872 The first functional cluster (Table 3; Figure 2a), in our analysis consists of the 
873 complement end proteins: C7, C8 isoforms as part of the/and the Membrane Attack 
874 (MAC) protein group in general as well as the multifunctional PRELP protein. Mutations 
875 in PRELP cause myasthenic syndrome (Engel, 2018). Among other functions, PRELP is 
876 involved in regulation of the complement cascade (Engel, 2018). As expected, we 
877 observed that the (alternative pathway) complement gene transcripts/proteins are 
878 absent from all photoreceptor and/or RPE transcription and proteomics datasets (PRos-
879 EP, PR-ET, RPE-ET, RPE-ST, RPE-IVS). The only possible exception is the presence of 
880 these proteins in the RPE/chor-EP dataset (positive control), where they most likely 
881 originate from the choroid/blood component of the sample (please note again that the 
882 choroid sample is inevitably contaminated with blood). In contrast, in 2 out of 3 blood-
883 plasma datasets (BLP-SP1 and BLPHP) this cluster is present, except for PRELP. The 
884 latter entry is apparently uniquely present in the Chor-ET listing (and in the positive 
885 control RPE/Chor-EP) and is probably produced in the choroid. Interestingly, this leads 
886 us to suggest that the systemic driven complement attack from the blood is locally 
887 regulated by PRELP produced by choroidal cells (Happonen et al., 2012).
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889 5.2.2. Network 1.2: The collagen cluster.
890 The second functional cluster is that of the collagens and related molecules (Table 3; 
891 Figure 2a). Here, the picture directly becomes, perhaps understandably, more 
892 complicated. Collagen proteins are likely to be produced (RNA, protein) by the basal 
893 secretion of the RPE and apical secretion of choroidal cells, and become part of the a-
894 cellular BrM (Booij et al., 2010a) and, at least theoretically, by the apical RPE and by the 
895 PR for the interphotoreceptor matrix (IPM). Indeed, proteomics of apical RPE secretion 
896 in vitro (Fort and Lampi, 2011) and functional annotation of the in vivo human RPE and 
897 photoreceptor predicted secretomes (based on transcriptomics of the RPE and 
898 photoreceptor cells; Bergen, unpublished), suggest that several specific collagen 
899 proteins may (transiently) be present in the IPM, although their presence was never 
900 detected by immunohistochemistry (yet). 
901 During life, there is a constant turnover of ECM’s, resulting in a mix of newly synthesized 
902 and (partly) digested collagen fragments shuttling around the subretinal area. 
903 Interestingly, the unique RPE-ST database (170 entries) does not contain any collagen 
904 related entries, thereby confirming that, if the RPE produces collagen, none of these 
905 collagens are made exclusively by the RPE (but also by adjacent tissues like the choroid). 
906 Further to this, it is of interest to note that collagen (type 8A1) is produced or present in 
907 the PR-ET, RPE-ET, Chor-ET and the RPE/CHOR-ET datasets, which supports the 
908 hypothesis that the (two collagenous layers of the) BrM, at least in part, are built from 
909 both the RPE and choroid sides side (Booij et al., 2010a). The data in Table 3 further 
910 suggest that the BrM proteins COL1A2, COLA1 and COLA2 are produced or are present 
911 exclusively (or at least mainly) in the Chor/blood, and not in the PR and RPE datasets. 
912 COL6A1 is secreted basally by the RPE in vitro (Pao et al., 2018) (Table 3), and is part of 
913 the BrM (Booij et al., 2010a). Consequently, the protein may end up in the drusen 
914 dataset either as a contamination, or as a remnant of the turnover of BrM components.  
915 The proteins THBS4 and TNC occur only in one of the blood proteomics datasets (BL-
916 SP1). The presence of other entities (RBP3, EFEMP1, PLG, GPNMB, SEMA3B, TBHS4) 
917 from this cluster in multiple PR/RPE and Chor/blood listings suggest that these 
918 genes/proteins can be derived from different sources. 
919 5.2.3. Network 1.3: The crystallin cluster.
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920 The third cluster of drusen proteins to be discussed are the crystallins (Crabb et al., 
921 2002; Nakata et al., 2005) (Figure 2a), frequently referred to as heat-shock proteins, 
922 which act as chaperones to prevent or reduce protein degradation in stressed or aging 
923 cells. Although they may have a more structural role, it is possible that the expression of 
924 crystallins is increased only in those studies in which cells or tissues have been exposed 
925 to a relatively large amount of stress. This would mean that further systematic and 
926 methodological analysis of consistent (differences in) expression does not make sense. It 
927 is remarkable however, that the CRYBB2 protein is present in the PRos-PT, RPE-IVS, and 
928 the RPE/Chor-EP studies and in drusen. Consequently, this protein may originate from 
929 the PR outer segments, processed, transported and secreted by the RPE and then 
930 accumulates in drusen. To our knowledge, this is the only photoreceptor protein known 
931 to possibly make it through phagocytosis and lysosomal processing in the RPE and end 
932 up in drusen (Feeney-Burns et al., 1988; Hoppe et al., 2001).
933 5.2.4. Network 2.4: Genetic and developmental ophthalmic disorders.
934 The fourth functional gene cluster (Network 2, Figure 2b) can be considered as a 
935 pathobiological cluster of developmental and ocular disease. The comparative analysis 
936 (Table 3) shows that ATP5F1B, ACTB and annexin2 (ANXA2), are present in a number of 
937 PR/RPE and Chor/blood expression datasets. These entries may thus be expressed in 
938 multiple cell types or blood. ANXA2 is included here “within brackets”, since it was 
939 initially assigned to drusen using proteomics, but later the same authors stained for 
940 ANXA2 in human donor eyes and concluded it was not present in drusen (Crabb et al., 
941 2002; Nakata et al., 2005). The CRYAB, ENO2 and SPTAN1 proteins cannot be clearly 
942 assigned, but appear to be of a local cellular origin (PR, RPE, or Chor) and not from the 
943 blood. The subcellular/systemic assignment of the FN1 and MYH9 entries are not clear. 
944 The BFSBP1 and BFSP2 proteins neither occur in the subretinal datasets, the blood 
945 proteomics lists, nor the positive control (RPE/Chor-EP; Table 3). According to the 
946 literature, both are structural proteins that specifically form filaments in the 
947 cytoskeleton of lens-cells (www.ingenuity.com). We therefore conclude that these are 
948 very weakly expressed genes which express proteins that build up slowly and/or with a 
949 long half-life. The only other explanation that could be offered is that they are 
950 contaminations within the drusen dataset. 
951 5.2.5. Network 3.5: Injury, inflammation and dermatological disease.
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952 The fifth functional drusen cluster (Network 3; Figure 2c) is related to interacting genes 
953 and proteins involved in injury, inflammation and dermatological disease. A substantial 
954 number of entries of this group seem to have both a cellular as well as a systemic 
955 presence or origin since they are present in at least two database listings from PR/RPE 
956 and Chor/blood category. These include ANXA1, ANXA5, CKB, GAPDH, PRDX1 and 
957 S100A8. 
958 The SERPINA3 and ALDH1A1 proteins appear only in at least two of the RPE-Chor-EP, 
959 Chor-ET, BL-SP1, BL-SP2 and the BL-PHP datasets, but not in the PR/RPE dataset. Thus, 
960 both proteins appear to come from the systemic side of drusen. FRZB (SFRP3) 
961 (www.genecard.org) is present in 3 PR/RPE listings (Table 3), including the RPE-specific 
962 listing (RPE-ST), and in only one choroid-enriched list (Chor-ET). We tentatively assign 
963 this drusen protein primarily to the RPE, and as a contamination in the (PR and/or) Chor 
964 database listings. S100A7 is only once present in the PRos-EP proteomics dataset. 
965 Assignment of S100A9, TYRP1, LAMB2, APOE, and FrzB or LUM to a single source cannot 
966 be done on the basis of this comparison.
967 5.2.6. Network 4.6: Cell to cell signaling; systemic involvement. 
968 As can be expected from the functional annotation “cell to cell signaling; systemic 
969 involvement”, almost all of the entries of this category of drusen proteins, appear in the 
970 Chor/blood datasets (Table 3). The exceptions are clusterin (CLU), ANXA6 and HRG. 
971 From the literature, we know that CLU is a ubiquitously expressed gene that is 
972 expressed in all cell types (Wilson and Zoubeidi, 2017). It is therefore not surprising that 
973 it features in both the PR/RPE as well as the Chor/blood listings. The final assignment of 
974 ANXA6 and HRG, on the basis of this comparison is not clear. The role of the systemically 
975 derived HRG drusen protein is discussed in detail below (section 7). Of particular 
976 interest is the expression of CFH, given its central regulatory role in the complement 
977 attack on (chemically modified) drusen components. There is compelling evidence in the 
978 literature that CFH is present in the blood, the neural retina and that it is also expressed 
979 by the RPE (Li et al., 2014; Mullins et al., 2014; Whitmore et al., 2014; Chirco et al., 2016; 
980 Chirco and Potempa, 2018; Toomey et al., 2018). The presence of CFH protein in the 
981 blood corresponds with the data and proteomics listings of blood in Table 3. What is not 
982 entirely clear is why CFH does not pop up in the RPE listings. This can perhaps be 
983 explained as follows: The enriched RPE-ET transcriptomics list contains only the highest 
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984 10% expressed genes in the RPE. Apparently, CFH is somewhat lower expressed and so 
985 does not belong to this group (Warwick et al., 2014). Also, the RPE-ST specific listing 
986 only contains 170 entries uniquely expressed by the RPE; whilst CFH is produced in 
987 other cells or blood as well. Finally, CFH does not occur in the RPE-IVS basal secretion 
988 proteomics listing, which is not entirely unexpected as recent evidence suggests that 
989 CFH is secreted apically, not basically by the RPE (Kim et al., 2009; Pao et al., 2018).
990 5.2.7: Conclusion.
991 On the basis of our qualitative comparison, we suggest that a number of (functional 
992 clusters of) drusen proteins come from the blood, while others come from a subretinal 
993 cellular compartment. These results are in line with the findings in the literature. 
994 However, it is not clear yet how many of the drusen proteins come from each particular 
995 compartment. The latter may be estimated by a more quantitative analysis, which is the 
996 subject of the next section. 
997
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998 6. Drusenomics, part III: A quantitative approach
999
1000 6.1. Quantitative analysis and curation of datasets.
1001 In this chapter, we quantitatively compare drusen proteins with transcripts and proteins 
1002 from adjacent retinal compartments (photoreceptor, RPE, choroid) and blood. As 
1003 described in section 2 above, the drusen protein list was compiled manually according 
1004 to the curation strategy presented in Figure 3, scheme A. Similar to the qualitative 
1005 studies, the quantitative analysis of the origin of drusen proteins is also hampered by 
1006 two problems: (a) most large scale cellular transcriptomics and proteomics datasets 
1007 contain some contamination (both RNA and/or protein) from adjacent cells or tissues, 
1008 and (b) most of the datasets are incomplete due to differences in the study design and 
1009 methodology used in contributing studies. In other words, we need to use a quantitative 
1010 comparison strategy that maximizes the signal (number of entries to be compared) and 
1011 minimizes the noise (number of contaminations in datasets). We overcame the 
1012 incompleteness of various datasets by pooling the entries from various similar (cell-type 
1013 specific) studies, to get a more complete numerical picture (Figure 3, scheme 3A).
1014 With regard to possible contaminations, we used two types of datasets. The first 
1015 category includes datasets that, by definition or by previous curation in the literature, 
1016 contain cell-specific expressed entries only, such as the RPE-ST, RPE-IVS, BL-SP1 and the 
1017 BL-SP2 datasets (section 4.2 and/or Table 3). . The curation of datasets PR-ET and Chor-
1018 ET into cPR-ET (STable 6) and cChor-ET (STable 7) was already described above 
1019 (section 4.2). The other category datasets used (PRos-EP, PR-ET, Chor-ET) were newly 
1020 curated, as presented in Figure 3 and 4, in such a way that they, after curation, also only 
1021 contained cell-type specific entries
1022 The PRos-EP dataset was curated according to the curation strategy presented in Figure 
1023 3, scheme 3C: We removed from the PRos-EP dataset (in principle containing 
1024 photoreceptor outer segment expressed genes only) all choroidal highly expressed 
1025 genes (from Chor-ET) as well as potentially present uniquely RPE expressed entries 
1026 (from RPE-ST) resulting in the curated cPRos-EP dataset (STable 6). The removed 
1027 choroidal and RPE entries were (potentially) present in the PRos-EP dataset due to truly 
1028 overlapping gene expression between these different cell types and/or due to 
1029 contaminations in the original cell sample. Of note, cPRos-EP does still contain entries 
1030 from both photoreceptor and RPE since contamination between these two is inevitable.
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1031 Together, the database listings cPRos-EP, cPR-ET, RPE-ST and RPE-IVS form the neural 
1032 side of drusen database listings (Figure 4). Similarly, the cChor-ET, the BL-SP1 and the 
1033 BL-SP2 constitute the systemic side of proteins found in the drusen dataset. In summary, 
1034 we ended up with three large datasets suitable for further robust analysis: The drusen 
1035 protein dataset, the “neural source of drusen” database, and the ’systemic source” of 
1036 drusen dataset (Figure 4). 
1037 Next, we compared the entries present in the “neural source listing” and in “the systemic 
1038 source listing” with the proteins present in drusen. The result of this analysis is 
1039 summarized in the Venn-diagram in Figure 5. The comparison revealed that 10 proteins 
1040 appeared to be uniquely derived from the neural side (Table 6) and 37 proteins are 
1041 derived from the systemic drusen side (STable 8). In addition, there were 23 proteins 
1042 that come (potentially) from both the neural and systemic side (STable 9). For 19 drusen 
1043 proteins (out of the 89), the origin remained unclear as they were neither present in the 
1044 “neural source” nor in the “systemic source” expression datasets (STable 10).
1045 6.1.1. Ten out of 89 drusen proteins originate uniquely from the PR/RPE.
1046 Our analysis yielded 10 drusen proteins that originate from the PR or RPE (Figure 5; 
1047 Table 6). They are both uniquely present in the drusen proteomics dataset and the 
1048 neural source of drusen database listing. We traced these proteins back to their original 
1049 source(s), and we observed that three of them (FRZB, RDH5 and RGR) originally came 
1050 from the unique entries in the RPE-ST dataset, five came from the RPE-IVS dataset 
1051 (CRYBA1, CRYBA4, CRYBB2, ENO2 and TUBB3), and the remainder from the cPRos; cPR-
1052 ET datasets. Taken together, 8 out of the 89 drusen proteins originated uniquely from 
1053 the RPE, while 2 came from the curated PR/RPE database listings (cPROS; CPR-ET) 
1054 (Table 3). Finally, we also reviewed the psychochemical properties and molecular 
1055 weight (Mw) of these 10 proteins (Table 6). We do not know the HAP binding properties 
1056 of these proteins, but they do not occur in the BH-PLP HAP-binders’ dataset (STable 5). 
1057 In conclusion,, we did not observe any common signatures of these proteins that would 
1058 explain why they in particular are trapped in the sub-RPE-BL space (whilst other 
1059 proteins are not).
1060 6.1.2. Twenty-three of 89 drusen proteins originate from both neural and systemic 
1061 sources. 
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1062 From our analysis, 23 drusen proteins were present in both the “neural source” as the 
1063 “systemic source” datasets (Figure 5; STable 9). From these, only 1 protein (S100A9) 
1064 falls in the curated PR/RPE category (Figure 4). Additional groups of two and twenty 
1065 proteins come from the unique RPE RPE-ST and the RPE-IVS datasets, respectively. At 
1066 the same time, all 23 of these proteins are also present in the blood. Remarkably, in this 
1067 shared category the majority of proteins are either secreted basally by the RPE or 
1068 present in a soluble form in the blood plasma. We hypothesize that the proteins in this 
1069 category enter the sub-RPE-BL from both sides, where they “meet, greet and stick”, i.e. 
1070 form aggregates that cannot be cleared and therefore contribute to drusenogenesis. 
1071 Functional and pathobiological annotation of (combinations of) these proteins can be 
1072 found in STable 9a.
1073 6.1.3. Thirty-seven out of 89 drusen proteins originate from the choroid/blood.
1074 We found that 37 out of 89 drusen proteins uniquely originate from choroid or blood 
1075 datasets (STable 8). From these, 31 proteins came from the plasma-proteomics datasets 
1076 (BL1-SP1 and BL-SP2). The remaining six entries (ANXA6, FLBN5, HLA-DRA, MFAP4, 
1077 PRELP, SEMA3B) are present in cChor-ET database listing and thus originate from either 
1078 the choroid or blood. Functional and pathobiological annotation of (combinations of) 
1079 these proteins can be found in STable 8a. 
1080 In summary, we again observed a large proportion of drusen proteins are most likely 
1081 originating from the blood. If we take this unique category (31 proteins from plasma) 
1082 and the shared contribution of plasma (23 proteins) from the previous paragraph into 
1083 account, we can conclude that as many as 54 out of 89 drusen proteins (>60 %) are (co-) 
1084 derived from blood plasma. 
1085 6.2. Nineteen drusen proteins out of 89 were not assigned.
1086 We can, in the end, still not determine the possible origin of 19 out of 89 drusen proteins 
1087 (STable 10) Why is this not possible? Do these proteins have a number of characteristics 
1088 in common that prevents us to determine their origin? To attempt to answer these 
1089 questions we need to take a closer look at these remaining drusen proteins. The 
1090 functional annotation of these proteins is presented in STable 10a and they can be 
1091 divided in five groups: (1) a gamma-crystallin group; (2) a histone cluster group; (3) 
1092 (remnants from) BrM turnover group (4) a beaded filament group; (5) a rest group 
1093 containing a variety of proteins that do not belong to a specific functional group. 
38
1094 In group one, we observed several gamma-crystallin-isoforms in drusen, which have not 
1095 been assigned to a specific source (as yet). Crystallins are commonly found in the lens 
1096 but are also present in soluble form in the retina (Jones et al., 1999) and probably act as 
1097 chaperone proteins after (oxidative) stress. Indeed, in the mouse retina, crystallin 
1098 expression has a binary nature in which either they are highly upregulated, or their 
1099 expression is extremely low (Templeton et al., 2013). Gamma-crystallins may have a 
1100 neuroprotective role (Thanos et al., 2014). At least one specific type of crystalline 
1101 (alphaB type) is known to be secreted by the RPE through micro-vesicle release (Kannan 
1102 et al., 2016). In conclusion, the source assignment of gamma-crystallin isoforms in 
1103 drusen, in our comparison, may be hampered by this binary expression. More 
1104 specifically, it will simply be absent from a number of subretinal expression datasets 
1105 and, as such, too little evidence exists to make a definite assignment.
1106 Next, we found a group consisting of HIST1H1E, HIST1H2BJ, HIST1H2BL and 
1107 HIST2H2BE. Histones are highly basic proteins that have an essential role in the 
1108 maintenance of nuclear DNA structure and gene transcription. HIST1H1E is a 219-amino 
1109 acid protein that binds to the linker DNA stretch between nucleosomes, while HIST2, 
1110 together with HIST3 and HIST 4, are part of the nucleosome core (Tessarz and 
1111 Kouzarides, 2014). Damaged or dying cells (potentially RPE or endothelial cells of the 
1112 choroid) can release cellular as well as nuclear fragments that may contain histones. 
1113 Alternatively, high concentrations of serum histones have been detected in several 
1114 human diseases (Yang et al., 2015). These extracellular histones may get trapped in BrM 
1115 and drusen. Interestingly, extracellular histones trigger activation of multiple signaling 
1116 pathways related to cell death, growth and inflammation and may play a role in auto-
1117 immunity, aging and disease (Allam et al., 2014; Kalbitz et al., 2015; Zhang et al., 2015b). 
1118 Why these specific histone proteins (and not others) are trapped in drusen and cannot 
1119 be assigned to a source remains to be elucidated.
1120 The third drusen protein group with an as yet unassigned source contains elastin (ELN), 
1121 collagen 8A1 (COL8A1), biglycan (BGN) and tissue inhibitor of metalloproteinase 3 
1122 (TIMP-3) proteins. These proteins may come from an as yet little considered drusen 
1123 protein source: the BrM and its (turnover) components (Booij et al., 2010a; Curcio and 
1124 Johnson, 2012). TIMP-3 is expressed in the RPE (Ruiz et al., 1996) and is crucial for the 
1125 maintenance of BrM. Mutations in TIMPO-3 caused Sorsby Fundus dystrophy, a 
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1126 monogenic disease that resembles the phenotype of AMD  (Weber et al., 1994).  Indeed, 
1127 as described previously, BrM is dynamic in nature, not only in a physiological sense, but 
1128 its composition and properties vary with age. Proteins involved in BrM and its turnover 
1129 may be absent from (some of) our subretinal transcriptomics and proteomics datasets, if 
1130 the relative expression levels of such entries are low. The middle layer of the BrM 
1131 consists of elastin so it is conceivable that the RPE and/or choroidal cells make this 
1132 protein. Within the BrM, elastin turnover might be relatively low, thus little “new” 
1133 elastin is needed. While elastin protein fragments (tropo-elastin) might be present in 
1134 some drusen as a remnant from BrM-turnover, there is little evidence in the literature 
1135 that they accumulate in drusen.
1136 Fourth, two members of the beaded filament structural protein family, BFSP1 and 
1137 BFSP2, remain unassigned. Similar to crystallins, these proteins were initially 
1138 discovered as lens fiber proteins. To our knowledge, it is not clear whether they also 
1139 play a role in retina/RPE or maybe even the BrM. How these proteins end up in drusen 
1140 and their origin remains unclear. 
1141 The fifth, yet unassigned group contains a number of, apparently, unrelated proteins, 
1142 including retinol binding protein 3 (RBP3), tyrosinase protein-like 1 (TYRP1), spectrin 
1143 alpha, non-erythrocytic 1 (SPTAN1), disco interacting protein homologue (DIP2C), 
1144 forkhead-associated phosphor peptide (FHAD1), and scavenger receptor class B 
1145 member 2 (SCARB2). 
1146 The RBP3 gene is transcribed in the PR and its protein is located in the 
1147 interphotoreceptor matrix (IPM). It binds to retinoids which are shuttled from the PR to 
1148 the RPE, and vice versa (Gonzalez-Fernandez et al., 1993). The TYRP1 gene belongs to 
1149 the tyrosinase family transcribed in the RPE and encodes an enzyme in the melanin 
1150 biosynthetic pathway (Lai et al., 2018). Mutations in this gene are one of the causes of 
1151 albinism (Kamaraj and Purohit, 2014; Kruijt et al., 2018). Both RBP3 and TYRP1 genes 
1152 may be absent from our datasets given their relatively low, transient or binary 
1153 expression in the relevant tissues.
1154 Finally, FHAD1 is a small protein that recognizes phosphorylated epitopes on a wide 
1155 range of proteins as part of an evolutionarily ancient mechanism enabling assembly of 
1156 protein complexes (Durocher and Jackson, 2002). The expression of FHAD1 is very low 
1157 in many tissues including the retina but is high in the testis and lungs. Since the 
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1158 expression is very low, the transcript and protein production or presence may go 
1159 undetected in the subretinal and blood transcriptomics and proteomics studies we used 
1160 in this study. However, once the FHAD1 protein has accumulated, as apparently in 
1161 drusen, it may be (more) detectable there. DIPC2 is a ubiquitously expressed protein 
1162 that shares homology with a Drosophila protein that interacts with the transcription 
1163 factor disco (www.ncbi.nlm.nih.gov). It is possible that the expression of this type of 
1164 protein is transient or binary; and it may go undetected in our retinal compartment and 
1165 blood transcriptomics and proteomics studies for that reason. 
1166 Finally, the last two proteins, SPTAN1 and SCARB2 may have related functionalities. The 
1167 SPTAN1 protein is a part of the cytoskeletal spectrin protein family that is involved in 
1168 stabilizing membranes of both cell and organelles (Tohyama et al., 2015). It is highly 
1169 expressed in the brain, and still expressed to a significant level in multiple other tissues. 
1170 SCARB2 is a ubiquitously expressed gene that encodes a lysosomal type III plasma 
1171 membrane glycoprotein (Gonzalez et al., 2014). Given the involvement of this type of 
1172 proteins in the lysosomal digestion of cellular material, it is tempting to speculate that 
1173 these proteins come from (transiently present in high numbers) lysosomal membrane 
1174 fragments basally secreted by the RPE. 
1175 6.3. Blood proteins are an important source of drusen proteins.
1176 If we summarize the combined data from our literature search and our qualitative and 
1177 quantitative analyses, we conclude that blood proteins are an important protein source 
1178 for drusen development. Further studies are needed to confirm and enhance our data, 
1179 especially on the single-protein level. Given the apparent contribution of blood to the 
1180 formation of drusen, the next chapters will discuss the role of hydroxyapatite as a 
1181 retainer of blood proteins during drusen formation, and the similarities that exist 
1182 between drusen and atherosclerotic plaques, which occur exclusively in the vasculature.
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1183 7. Drusen and hydroxyapatite
1184 Our analyses provide strong evidence that proteins in drusen come from multiple 
1185 sources. The next logical step was to consider how proteins arrive and how they are 
1186 retained in the sub-RPE-BL space. One possibility is that proteins may bind to 
1187 constituents of the BrM (Tabas et al., 2007). Another is the formation of large oligomers 
1188 in the sub-RPE-BL space in the presence of the high concentration of trace metals 
1189 (Lengyel et al., 2007; Nan et al., 2013; Flinn et al., 2014). In addition, it was recently 
1190 hypothesized that proteins might be retained in the sub-RPE-BL space due to their 
1191 binding to hydroxyapatite spherules recently identified in human drusen (Thompson et 
1192 al., 2015) (Figure 6). Since this hypothesis is relatively new, it is described in more detail 
1193 below.
1194 Using confocal microscopy and hydroxyapatite (HAP)-specific fluorescent dyes, small 
1195 hollow spherical structures ranging from 0.5 µm to 20 µm in diameter were identified 
1196 within sub-RPE-BL deposits in retinal tissue sections of human cadaveric eyes 
1197 (Thompson et al., 2015). The HAP spherules were present in all deposits examined 
1198 (Thompson et al., 2015). Protein constituents of drusen, such as amyloid-beta, 
1199 vitronectin and complement factor H, were localized to the surface of the HAP spherules, 
1200 either individually or in combination (Thompson et al., 2015). Although not all 
1201 investigated drusen proteins appeared to bind to the surface of HAP (Thompson et al., 
1202 2015), this finding proved that the retention of proteins can, at least partly, occur 
1203 through this protein-HAP interaction. These results also suggested that the binding of 
1204 proteins to HAP spherules is a wide ranging, though selective, process and thus 
1205 understanding which proteins can bind to HAP might be important. The plasma protein-
1206 binding capacity and selectivity of HAP was recently examined using a quantitative 
1207 proteomic approach called Sequential Window Acquisition of all theoretical fragment-
1208 ion spectra-Mass Spectrometry (SWATH-MS) (Arya et al., 2018). Using this approach, 
1209 242 proteins with the propensity to binding HAP were identified and quantified (Table 
1210 3; STable 5) (Arya et al., 2018). Taking advantage of the quantitative nature of the 
1211 analysis the binding of samples from participants with wild type and the AMD associated 
1212 high risk CFH variant, T1277C were compared. Quantitative differences in the 
1213 abundance of at least 34 proteins were identified, suggesting that the genetic 
1214 background is likely to affect the protein composition of drusen “simply” due to the 
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1215 availability of proteins in the blood. This approach also highlighted that there are 
1216 proteins, whose presence and potential role in sub-RPE deposit formation and in AMD 
1217 had not previously been explored. One such example is the pregnancy zone protein 
1218 (Arya et al., 2018), a plasma protein whose levels are known to increase in pregnancy 
1219 and some disease states such as AD (Nijholt et al., 2015).
1220 It appears therefore that while drusen deposition is a hallmark of AMD, HAP deposition 
1221 is a hallmark of drusen formation. The study by Thompson and coworkers was not the 
1222 first to identify calcified components of drusen (Thompson et al., 2015). Spherical 
1223 particles of similar size were previously identified within drusen and BLinD (Green and 
1224 Key, 1977), and electron microscopy (Ulshafer et al., 1987; van der Schaft et al., 1992; 
1225 van der Schaft et al., 1993; Thompson et al., 2015). Particles size observed in these 
1226 studies ranged from 0.5 µm to 10 µm in diameter and contained calcium and phosphate 
1227 as determined by elemental analysis (Ulshafer et al., 1987). More recent studies using 
1228 von Kossa staining, a silver enhancement technique that identifies phosphates salts also 
1229 indicated that calcium phosphates were present within deposits in the sub-RPE-BL 
1230 space (Suzuki et al., 2015). 
1231 The precipitation of calcium phosphate from an aqueous solution is a complex process 
1232 (Kani et al., 1983; Tas, 2000; Jang et al., 2014). At neutral pH, HAP is considered the most 
1233 thermodynamically stable form of calcium phosphate. In fact, it is possible that HAP is 
1234 stable enough that once the lipid or protein components of the drusen regress (Sallo et 
1235 al., 2009; Toy et al., 2013; Novais et al., 2015), HAP still remains and continues to 
1236 interact with its environment. This may suggest that HAP interactions, not only with the 
1237 BrM and the RPE but also with the remanence of photoreceptor cells or other parts of 
1238 the neurosensory retina (Bird et al., 2014) may require further investigation. 
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1240 Figure 7 summarizes the model of HAP associated deposit initiation. Under normal 
1241 circumstances, there is a physiological exchange of material between the RPE and the 
1242 choroidal circulation (Fig.7A and A’), and this includes the exchange of lipid particles 
1243 (Curcio et al., 2011). With age and disease lipid particles start accumulating in the sub-
1244 RPE space including the BrM (Fig.7B and B’) (Curcio et al., 2011). In the presence of lipid 
1245 droplets and homeostatic changes in calcium and phosphate availability in the sub-RPE-
1246 BL space, HAP can precipitate on the surface of the lipid droplets (Fig.7C and C’).  Then, 
1247 on the surface of the HAP spherules drusen proteins can accumulate (Fig.7D and D’) via 
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1248 directly interacting with HAP (Arya et al., 2018). Based on fluorescence labeling of HAP 
1249 in human eyes, it is appeared that HAP spherules can exist without drusen (Fig.7C’), but 
1250 drusen have not been seen without HAP spherules (Fig.7D and D’) (when specifically 
1251 looked for) thus far (Thompson et al., 2015). Based on these observations it was 
1252 proposed that HAP deposition is a seeding point for drusen formation (Thompson et al., 
1253 2015).
1254 The next obvious question to ask is where the HAP spherules are originating from? 
1255 Could they be blood or RPE derived? Do they exist as spherules only in the sub-RPE-BL 
1256 space or is the material present in the surrounding tissues? Spherules have not been 
1257 detected in any of the cellular or intercellular spaces although the calcium phosphate 
1258 crystals had been showed in mitochondria (Carafoli, 2010). Therefore, it appears that 
1259 HAP spherules are deposited in the retina exclusively in the sub-RPE-BL space. In fact, it 
1260 had been shown that HAP deposition can occur in primary RPE cell models which 
1261 showed that HAP deposition can be initiated by the RPE alone, although contribution of 
1262 the culture medium cannot be ruled out (Pilgrim et al., 2017). Whether spherical 
1263 structures can develop in a cell culture system that are co-cultured with endothelial cells 
1264 and/or fed with photoreceptor outer segments will need to be investigated.
1265 HAP mineralization in the retina clearly differs from classical mineralization in bone, but 
1266 it may, or may not, share some key features with general soft tissue/elastin calcification 
1267 (Figure 8). Obviously, the retina lacks extracellular matrix forming osteoblasts. Also, no 
1268 relationship has been found between spherule mineralization and general HAP 
1269 deposition on elastin and/or collagen. However, systemic driven HAP deposition can 
1270 take place in the BrM, as reported before (Gorgels et al., 2012). Indeed, a systemic lack of 
1271 inorganic PPi in the blood (Jansen et al., 2013) may be involved in local HAP deposition 
1272 in BrM, facilitated by local conditions, such as oxidative stress (Mungrue et al., 2011).  
1273 Interestingly, investigation of the ultrastructure and composition of vascular micro-
1274 calcifications associated with uremia showed the presence of spherical particles in the 
1275 media of the kidney, with internal structures comparable to those observed in the 
1276 human eye (Schlieper et al., 2010). Similarly, the loose stroma of the choroid plexus of 
1277 the aging or Alzheimer’s disease brain contain psammoma bodies, which are entities 
1278 with distinct HAP cores and multiple concentric rings or swirls of collagen wrapped 
1279 around it (Alcolado et al., 1986). More recently, similarly structured spherules were also 
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1280 identified within patients with osteoporosis and in cardiovascular disease (Bertazzo et 
1281 al., 2013; Shah et al., 2017). Thus, comparable mineralization mechanisms in a variety of 
1282 non-osseous tissues appear to be associated with a number of different disease 
1283 conditions.
1284 Alternatively, transcriptomic data suggests that part of the elements of the physiological 
1285 mineralization process are (also) present in the RPE cells (Booij et al., 2009), or at the 
1286 RPE/choroid interface (Whitmore et al., 2014). This evidence suggests that the 
1287 molecular machinery required for general physiological mineralization (depicted in 
1288 Figure 8) could (also in part) be assembled in the outer retina. Given that the bulk of the 
1289 calcium is extracellular, while phosphate is mainly localized intracellularly, the 
1290 conditions that allow mineralization to happen could be present locally, in the sub-RPE-
1291 BL space. This concept is novel and has not been investigated previously but may lead to 
1292 HAP-based treatment strategies and/or new early detection mechanisms. 
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1293 8. Drusen and plaques: age-related macular degeneration and atherosclerosis
1294
1295 The finding that a substantial number of drusen proteins are blood-borne prompted us 
1296 to re-summarize a possible relationship between initiation and propagation of drusen 
1297 and atherosclerotic plaques. A possible link between these two diseases was previously 
1298 suggested based on (controversial) epidemiological evidence, the involvement of similar 
1299 lipoproteins in the formation of extracellular deposits in AMD and atherosclerosis and 
1300 structural commonalities between the vessel wall and Bruch’s membrane (Curcio et al., 
1301 2001; Sivaprasad et al., 2005).
1302 AMD is a disease starting with (multiple macular) drusen formation. Drusen consist of 
1303 (oxidatively-modified) lipids and proteins as well as minerals (Sarks et al., 1988; Green 
1304 and Enger, 1993; Curcio and Millican, 1999; Crabb, 2014; Flinn et al., 2014; Handa et al., 
1305 2017; Pilgrim et al., 2017; Spaide et al., 2018). Drusen constituents most likely invoke a 
1306 complement attack and sustain a continuous low-grade inflammation, which leads to 
1307 serious events such as RPE cell loss, neovascularization and ultimately, central vision 
1308 loss (Bird et al., 1995; de Jong, 2006). 
1309 Atherosclerosis is a disease associated with the build-up of plaques also composed of 
1310 (oxidatively-modified) lipids, proteins as well as minerals in the vessel wall of arteries 
1311 that, via complement attack and low-grade inflammation, can lead to serious events 
1312 including heart attack, stroke or aneurysm (Simmons et al., 2016). 
1313 There are a number of clear differences between AMD and atherosclerosis, such as 
1314 location of the deposition, the local metabolic physiology (Stefansson et al., 2011), 
1315 involvement of other (different) genes or molecules and obviously, aspects of the 
1316 pathological consequences of deposition build up (Hageman et al., 2001; Hopkins, 2013). 
1317 For example, other than in plaques in atherosclerosis, deposit (drusen) formation in 
1318 AMD most likely blocks the exchange of biomolecules between the retina and the 
1319 choroid. It is thought that this interferes with the “nourishment” of the sensory cells in 
1320 the retina causing them to die. Over time the cells cannot be replaced leading to a loss of 
1321 vision, typically within the macula, which progressively deteriorates over time 
1322 contributing to the AMD pathology (Bhutto and Lutty, 2012). 
1323 Nonetheless, a relatively large number of commonalities have been found between both 
1324 drusen and atherosclerotic plaque formation and their associated diseases. Available 
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1325 evidence comes from clinical, epidemiological, genetic, histological and pathobiological 
1326 investigations (see below).
1327 8.1. Clinical and epidemiological studies.
1328 Verhoeff and Grosmann were the first to suggest a relationship between vascular 
1329 disease and AMD (Verhoeff and Grossman, 1937). Except for a few reports (Gass, 1967; 
1330 Kornzweig, 1977), this observation was largely ignored for over forty years when 
1331 Maltzman and Hyman (Maltzman et al., 1979; Hyman et al., 1983) pioneered a plethora 
1332 of subsequent epidemiological studies on the subject (Vidaurri et al., 1984; Vingerling et 
1333 al., 1995; Snow and Seddon, 1999). Some studies between atherosclerosis (and similar 
1334 diseases) and AMD showed positive associations (The Eye Disease Case-Control Study, 
1335 1992; Klein et al., 1993), while others did not (Hyman et al., 1983). These controversial 
1336 results, especially in the early investigations, were partly due to differences in 
1337 description of the clinical phenotype, use of different end phenotypes, study design, 
1338 population size, lack of suitable replication populations, and insufficient knowledge of 
1339 possible confounders. Nonetheless, this issue has not been resolved up until today.
1340 A wide range of epidemiological studies have also suggested that there are certain risk 
1341 factors which are common to both AMD and atherosclerosis (-associated cardiovascular 
1342 disease). These most consistently include environmental factors, such as age and 
1343 tobacco smoking (Woodell and Rohrer, 2014). These studies indicate that, 
1344 mechanistically, oxidative stress and potentially lipid metabolism may play an important 
1345 role in both disorders (Serban and Dragan, 2014; Gehlbach et al., 2016; George et al., 
1346 2018; van Leeuwen et al., 2018; Wilson et al., 2018). 
1347 8.2. Histological and pathobiological similarities.
1348 Histological and pathobiological similarities between drusen and atherosclerotic 
1349 plaques and their associated diseases include similarities of lipid and mineral content 
1350 and structural similarities between the BrM and the vascular wall, endothelial cell 
1351 dysfunction, and proteoglycan turnover. Curcio and coworkers proposed, for the first 
1352 time, a relationship between drusen and atherosclerotic plaques since both contain 
1353 similar neutral lipids and both accumulate cholesterol esters (Curcio et al., 2001). This 
1354 finding was confirmed by others (Chung et al., 2005; Wang et al., 2010). These and 
1355 subsequent studies made clear that diseases related to this type of accumulations may 
1356 be mediated by genetic variation, oxidative stress and inflammation. The accumulation 
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1357 of lipids in drusen and atherosclerosis has recently been reviewed elsewhere in detail 
1358 (Pikuleva and Curcio, 2014; van Leeuwen et al., 2018; Xu et al., 2018).
1359 Sivaprasad and coworkers observed that the BrM and the vascular intima share a 
1360 number of common structural modalities, and age-related changes (Sivaprasad et al., 
1361 2005). Indeed, similar to the vessel wall, and given the presence of local fenestrated 
1362 choroidal capillaries, BrM acts a collagen and elastin rich physical barrier for the blood. 
1363 Both the BrM and vascular intima thicken through accumulation of extracellular lipids 
1364 and other debris and become less flexible with age (Chung et al., 2005; Curcio and 
1365 Johnson, 2012).
1366 Another important feature of the ECM of both the vessel wall and BrM are the presence 
1367 and turnover of a variety of proteoglycans. In BrM, the ratio between several 
1368 proteoglycan types, most notably heparan sulfate and chondroitin sulfate, changes 
1369 dramatically during aging and the development of AMD (Barzegar-befroei et al., 2012). 
1370 In atherosclerosis and AMD, (oxidatively) modified proteoglycans may bind and retain 
1371 specific apolipoproteins from the circulation in, respectively the artery wall (Williams 
1372 and Tabas, 1995; Tabas et al., 2007) and the BrM (Curcio et al., 2009; Al Gwairi et al., 
1373 2016) BrM. Indeed, proteoglycans may play an, as so far underestimated, role in 
1374 regulating the complement response and the development of both AMD and 
1375 atherosclerosis pathology (Tate et al., 1993; Toomey et al., 2018). Happonen and 
1376 coworkers (2012) recently showed that small proteoglycans, such as PRELP, are 
1377 regulators of the complement cascade (Happonen et al., 2012). Please note that 
1378 choroidal cells produce PRELP (as suggested in the current study) and that this protein 
1379 apparently accumulates in drusen. There are a few reports which have established the 
1380 different patterns of distribution of large (Clark et al., 2011) and small proteoglycans 
1381 (Keenan et al., 2012); the latter including biglycan, decorin, fibromodulin, lumican, 
1382 mimecan, opticin, and prolargin in post-mortem eye or vascular tissue. 
1383 Both atherosclerosis and AMD patients may suffer from endothelial cell dysfunction. 
1384 Accumulating evidence suggests that endothelial cell dysfunction may be the initiating 
1385 step in atherosclerosis (Miteva et al., 2018). In their AMD studies, Schaumberg and 
1386 coworkers provided epidemiological evidence that at least one marker for endothelial 
1387 dysfunction and inflammation, sICAM-1 is linked to drusen formation and 
1388 neovascularization (Schaumberg et al., 2007). Interestingly, higher levels of circulating 
1389 endothelial cells (CECs), a biomarker for a diversity of systemic complications, including 
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1390 vascular disorders, were found in AMD patients compared to controls (Machalinska et 
1391 al., 2011).
1392 While these studies focused on common risk factors and parallel development of drusen 
1393 and plaques, the possibility that atherosclerosis plays a direct role in the development of 
1394 AMD cannot be ruled out. Using FA, a slow filling of the choroidal capillaries over time 
1395 has been observed in AMD patients (Pauleikhoff et al., 1990). This may be due to (a 
1396 combination of) thickening of the BrM, a declining function of the RPE or by decreased 
1397 atherosclerosis-driven perfusion of these capillaries. Reduced capillary blood flow could 
1398 directly enhance the initiation of drusen or development of AMD.
1399 As with drusen, deposition of calcified mineral, that includes hydroxyapatite (Lee et al., 
1400 2012) is associated with the formation of atherosclerotic plaques (Doherty et al., 2003). 
1401 Such mineral is readily quantifiable using radiography and even serves as a marker for 
1402 atherosclerosis. It has been reported that the presence of mineral in cardiovascular soft 
1403 tissue can be used to predict mortality (Okuno et al., 2007; Kestenbaum et al., 2009), and 
1404 morbidity of cardiovascular disease in various forms (Arad et al., 2000; Keelan et al., 
1405 2001). The specific molecular mechanisms underlying mineral formation in such tissues 
1406 remains to be fully elucidated. However, both AMD and atherosclerosis are associated 
1407 with low grade inflammation in the respective affected tissues (Hansson et al., 2006; 
1408 Kauppinen et al., 2016), and it has been proposed that soft tissue mineralization may be 
1409 best conceptualized as a convergence of bone biology with inflammatory pathobiology 
1410 (Doherty et al., 2003).
1411 8.3. Genetics and molecular biology.
1412 Early candidate gene association studies found an association between genetic variation 
1413 in APOE in both AMD (Klaver et al., 1998; Toops et al., 2016) and atherosclerosis (Zhang 
1414 et al., 2018), thereby implicating lipid metabolism and transport in both disorders. 
1415 Genetic variations in apolipoproteins and complement factors showed strong 
1416 associations with AMD and CVD conditions. For example, polymorphisms in the CFH and 
1417 a number of other complement factor genes confer at-risk genotypes for AMD (Klein et 
1418 al., 2005), whilst similar associations between complement C5 and the complement 
1419 receptor 1 genes confer an increased risk of atherosclerosis (Hoke et al., 2012; de Vries 
1420 et al., 2017). Of note, although the same genes may be frequently associated with both 
1421 (or other) diseases, different alleles are frequently implicated in the associations found 
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1422 between these disorders. A well-known example is the APOE4 allele, that increases the 
1423 risk of Alzheimer’s disease, and perhaps atherosclerosis (Mahley, 2016),  but is 
1424 protective in age-related macular degeneration (Klaver et al., 1998).  Indeed, these 
1425 observations were confirmed and extended by large GWAS studies that implicated 
1426 regulation of lipid metabolism, extracellular matrix remodeling and the immune system 
1427 low-grade inflammation in both AMD and atherosclerosis (Fritsche et al., 2016; 
1428 Schunkert et al., 2018). A recent study by the International AMD consortium explored 
1429 the overlap between 34 AMD-associated loci with other complex diseases (Grassmann et 
1430 al., 2017). Surprisingly, the authors found that an increased risk of AMD correlates with 
1431 a reduced risk for cardiovascular disease. 
1432 A key similarity between atherosclerotic plaque and drusen formation are the molecular 
1433 components involved. Both types of deposit have a significant lipid component 
1434 (including cholesterol and neutral fats) and mineral content, as described above. It has 
1435 also been reported that drusen contains a number of proteins that are also common to 
1436 atherosclerotic deposits (Mullins et al., 2000; Klein et al., 2005; Booij et al., 2010a). To 
1437 gain information as to the degree of this overlap in proteins contributing to these 
1438 pathologies we compared a dataset of 3196 proteins known to be present in 
1439 atherosclerotic plaques from Bleijerveld and coworkers (Table 3) with our drusen data 
1440 set, as shown in Figure 9a (Bleijerveld et al., 2013). The resultant Venn-diagram 
1441 revealed that out the 89 drusen-associated proteins, 64 of these (72%) were also 
1442 present in atherosclerotic plaques. Indeed, 50 out of 60 drusen proteins derived from 
1443 blood are also present in atherosclerotic plaques (Figure 9b). Details of proteins found 
1444 to be common to both plaques and drusen can be found in STable 11 and STable 11a.
1445 Closer inspection of proteins common to both atherosclerotic plaques and drusen as 
1446 defined in this manuscript revealed a number of functional classes of protein in this 
1447 group including apolipoproteins (APOA1, A2 and E), complement factors (C7, C8A, C8B, 
1448 C8G and complement factor H), as well as lipid- and Ca2+-binding annexins (annexins-1, 
1449 2, 5 and 6). Obviously, our analysis may not be fully comprehensive, since it is limited to 
1450 the entries which are present in both database listings. Another limitation is that similar 
1451 proteins still may originate from different sources. For example, the previously 
1452 suggested presence of APOB as principal protein of LDL in both sub-RPE-BL deposits 
1453 and cardiovascular plaques (Curcio et al., 2001) is missing from the current overlap, 
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1454 since detailed investigation of the (presence and origin) of this lipoprotein (Li et al., 
1455 2005a) suggested that APOB isolated from BrM thickenings is (also) present in a 
1456 distinct, non-LDL lipid profile. Consequently, it was suggested that APOB in BrM 
1457 thickenings is made locally, while APOB in plaques is probably from systemic origin. 
1458 Cytoskeletal proteins (actinin α1, tubulin α1c and tubulin β3) as well as extracellular 
1459 matrix proteins such as collagens (type 1 α2, type 6 α1, type 6 α2 and type 8 α1), 
1460 tenascin C, microfibril-associated protein 4 and vimentin were found to be present in 
1461 both BlamD deposits and atherosclerotic plaques (Fernandez-Godino et al., 2016; 
1462 Pelisek et al., 2016). Analysis of proteins common to both plaques and drusen in 
1463 biological processes revealed significant contribution of this group of proteins to other 
1464 diseases and processes including various cancers, development of the vasculature, cell 
1465 movement and AD (tauopathy and amyloidosis; see STable 11a). The involvement of 
1466 these proteins in AD is particularly interesting as it is another disorder of which 
1467 extracellular deposits are a feature (Figure 9c). Furthermore, drusen reside on the 
1468 interface between the neural and cardiovascular system, so it may share properties of 
1469 both types of atherosclerosis and Alzheimer’s plaques (Booij et al., 2010a). 
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1470 9. Future directions and conclusions.
1471 Our review of the literature and the qualitative and quantitative meta-analysis of retinal 
1472 and blood transcriptomic and proteomic data all point in the same direction: proteins in 
1473 drusen originate from multiple sources. Based on the data we have available, the largest 
1474 number of protein contribution from a single source appears to be the blood. The 
1475 second-most prominent source of number of specific proteins in drusen is from the RPE, 
1476 while the contribution from the choroid and the photoreceptors appears to be relatively 
1477 modest. However, the varying number of proteins cannot be directly translated to 
1478 concentration. There is the possibility that a relatively small number of proteins 
1479 contribute the bulk of proteins in drusen.
1480 How proteins get recruited to and retained in the sub-RPE-BL space is still not fully 
1481 understood. In vivo and in vitro BrM conductance studies suggest that human proteins 
1482 of average size, such as proteins of 53 kDa (source: NCBI) , can readily diffuse through 
1483 healthy BrM, while macromolecular migration through BrM is slower and/or limited 
1484 (Curcio and Johnson, 2012). Moore and Clover found that proteins of 200 kDa could 
1485 readily cross young BrM (Moore and Clover, 2001). More recent work suggested that the 
1486 transport exclusion size limit in healthy young BrM can be as high as 180-500 kDa, well 
1487 over the size of macro molecules like HDL (Hussain et al., 2010; Cankova et al., 2011). In 
1488 our current study, we found that 9 out of 10 drusen proteins that are uniquely derived 
1489 from the RPE had a Mw of less than 50 kDa (Table 6). Moreover, we took a random 
1490 sample of 30 proteins from the RPE-IVS basal secretion dataset (Table 3), containing 
1491 proteins which are likely to encounter BrM in vivo, and determined their average Mw: 
1492 95 kDa). After taking three extremely large proteins out (APOB, AHNAK, and C4B; 
1493 proteins that we did not identify in drusen in this study) that average dropped to 60 kDa 
1494 (data not shown). Six of these 30 proteins are present in drusen (ALB, ANXA1, ANXA2, 
1495 APOA4, APOE, ATP5F1B) and have a MW <66.5 kDa. Although the overall transport 
1496 capability BrM decreases substantially in the AMD-affected and aging retina (Hussain et 
1497 al., 2010; Cankova et al., 2011; Curcio and Johnson, 2012; Lee et al., 2015), older BrM 
1498 was found to be still permeable to proteins in excess of 100 kDa (Moore and Clover, 
1499 2001). Taken together, entrapment of proteins in the sub-RPE-BL space is unlikely to be 
1500 due to size if single molecules. They might become entrapped by forming aggregates that 
1501 are no longer capable of leaving through BrM, as was suggested for CFH (Nan et al., 
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1502 2008; Nan et al., 2011; Nan et al., 2013). Therefore, drusen proteins, especially the ones 
1503 that come from multiple sources, “meet, greet and stick” to form sub-RPE-BL space 
1504 deposits. 
1505 There are several ways proteins can interact in BrM to form larger aggregates: they can 
1506 interact among themselves, with other lipids, proteins and/or mineral deposits, or stick 
1507 to the ECM of BrM itself. These interactions may be enhanced by chemical modification, 
1508 (Blaum et al., 2010) including oxidative damage and glycosylation of lipids, proteins and 
1509 carbohydrates (Crabb et al., 2002; Hollyfield et al., 2010) and they may be further 
1510 facilitated by the structure and dynamic nature of BrM (Booij et al., 2010a). Over time, 
1511 several changes in BrM occur, that may hinder protein clearance from the sub-RPE-BL 
1512 space. Remodeling of BrM ECM takes place, including proteoglycan changes and 
1513 turnover, elastin changes and eventually mineralization takes place. BrM becomes laden 
1514 with lipids to form a hydrophobic barrier (“lipid wall”) and accumulates other debris 
1515 (Curcio and Johnson, 2012). Consequently, the role of the structure and function of BrM 
1516 and the chemical state of the sub-RPE-BL space may be even more important in sub-
1517 RPE-BL space deposit formation than its exact protein composition.
1518
1519 An important source of entrapment of proteins in BrM may be the formation of HAP 
1520 surfaces in the sub-RPE-BL space (Thompson et al., 2015). In our current study, at least 
1521 30% of the 89 drusen proteins can bind to HAP. This percentage increases towards at 
1522 least 50% if only the blood borne proteins are counted (data not shown). Thus, HAP 
1523 readily binds a substantial number, but not all drusen proteins (Arya et al., 2018). 
1524 The finding that blood proteins are seemingly the most important contributors to 
1525 drusen formation provides a new target to prevent the initiation and propagation of sub-
1526 RPE-BL space deposits. Reducing the concentration of blood proteins that interact with 
1527 HAP may lead to a reduction of the source of drusen components and ultimately 
1528 postpone, or potentially even stop, the progression to AMD.
1529 Finally, it is also important to mention that the non-specific interaction of proteins with 
1530 HAP will also affect their ability to carry out their physiological function. For example, 
1531 once CFH binds to the HAP surface it may not be able to regulate the alternative 
1532 complement pathway. Therefore, this interaction with HAP could be a double whammy: 
1533 it increases the bulk of sub-RPE-BL space deposits and stops the local protein function. It 
1534 will be important to understand the role of the blood-derived proteins in the sub-RPE-
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1535 BL space, if any. The study and potential modification of these interactions is now 
1536 possible and could lead to intervention strategies through modified diet, 
1537 supplementation or through manipulation of retinal molecular or cellular processes.
1538 An important specific question in the context of this study that needs still to be resolved 
1539 is how plasma proteins find their way into the sub-RPE-BL space. Apart from the 
1540 mechanisms already described above (chemical modification of interacting 
1541 biomolecules, dynamic structure and functional changes BrM, and HAP-binding) it is 
1542 tempting to speculate that not only blood composition but also blood pressure plays a 
1543 role. Why blood pressure? It was previously shown that a relationship exists between 
1544 drusen location and choriocapillary pillars. Indeed, by investigating retina whole 
1545 mounts, initially Friedman, and subsequently, Lengyel and coworkers concluded that 
1546 drusen deposition is the result of a lower clearance at the choroidal intercapillary pillars 
1547 (Friedman et al., 1963; Lengyel et al., 2004). Thus, in other words, higher clearance of 
1548 sub-RPE-BL space debris corresponds with the vascular lumen, through which the blood 
1549 flows and directly encounters BrM. Much in line with the reflections of Penfold and 
1550 others (Penfold et al., 2001) , we hypothesize that the pulsating blood pushes debris 
1551 through endothelial fenestrations into BrM, through relatively open BrM pores; and at 
1552 the same time, clears debris which was already present in BrM. One could compare that, 
1553 by analogy, with the sea bringing and taking, wave after wave, debris to and from the 
1554 beach. Changes in blood composition, choroidal endothelial cell compromise and rising 
1555 blood pressure with age (Pinto, 2007)  may negatively change the dynamics of this 
1556 proposed “debris-exchange”.
1557 Our review further underlines the importance of comparative studies between drusen 
1558 deposition and atherosclerosis plaque formation. Clinical, (genetic) epidemiological 
1559 pathobiological and molecular similarities between these two disorders have been 
1560 highlighted previously (see section 8). Such similarities include that both are 
1561 extracellular lipid/protein/mineral-based depositions that invoke a low-grade immune 
1562 response leading to further disease. Several molecular similarities between drusen and 
1563 plaques have also been described. We currently add the observation that most drusen 
1564 (and plaque) components are blood-borne. Therefore, the genesis of drusen and plaques 
1565 may be similar, and should be subject of further multidisciplinary studies.
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1566 While studying the literature for this review, we have made a number of additional 
1567 observations that may guide future research directions: First, while the number of 
1568 retinal (cell-type-specific) transcriptomics studies are large and proteomics information 
1569 is emerging, there are very few proteomics studies on different types of (human) sub-
1570 RPE-BL space deposits (types). For example, additional proteomics studies of hard 
1571 versus soft drusen or macular versus peripheral drusen might improve our 
1572 understanding of deposition formation in the sub-RPE-BL space and their association 
1573 with different disorders or disease stages. Next, transcriptomics, proteomics, and 
1574 immunohistochemical studies have their own conceptual and technical advantages and 
1575 limitations. However, in the literature, the description of these strengths and 
1576 weaknesses are not always clear and standardization is lacking. International 
1577 agreements such as MIAME and MISFISHIE (minimum information specification for in 
1578 situ hybridization and immunohistochemistry experiments) guidelines (Deutsch et al., 
1579 2008) are a step in the right direction, but must be seen as initial steps for further 
1580 standardization. A few examples for illustration: How many confirmatory 
1581 transcriptomics or proteomics studies should be performed before a definite subcellular 
1582 assignment can be made? How do we define cellular specificity and cellular enrichment? 
1583 How many drusen types should be screened and how many different antibodies should 
1584 be used before proteins are clearly assigned as drusen proteins (or as sub-types). When 
1585 should we designate labeling drusen specific? Do we consider staining of the border of 
1586 hydroxyapatite or drusen important; or is only the staining of the whole inner mass of 
1587 drusen relevant? Given the heterogeneity of drusen: what is the exact location of the 
1588 drusen under study and its appearance? Indeed, in line with recent similar calls by 
1589 Curcio and co-workers (Curcio, 2018a, b) we call here for better considerations, 
1590 agreements and definitions of these issues.
1591 Last but not least, it will be interesting to understand whether drusen heterogeneity is a 
1592 direct feature of a disease or a reflection of the change in the (micro-) environment that 
1593 results in initiation and growth of the deposits. While drusen deposition clearly is a 
1594 hallmark of AMD and is associated with a number of other diseases (Khan et al., 2016), 
1595 its actual composition might reflect the disease state at the RPE/choroid interface more 
1596 than (cause) the disease. The identification of why and not necessarily what proteins 
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1597 and lipids are deposited in the sub-RPE-BL space might therefore an important question 
1598 to consider for future studies.
56
1599 References
1600
1601 1. Abdelsalam, A., Del Priore, L., Zarbin, M.A., 1999. Drusen in age-related macular degeneration: 
1602 pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 44, 1-
1603 29.
1604 2. Ahmad, M.T., Zhang, P., Dufresne, C., Ferrucci, L., Semba, R.D., 2018. The Human Eye Proteome 
1605 Project: Updates on an Emerging Proteome. Proteomics 18, e1700394.
1606 3. Aiello, L.P., Gardner, T.W., King, G.L., Blankenship, G., Cavallerano, J.D., Ferris, F.L., 3rd, Klein, R., 
1607 1998. Diabetic retinopathy. Diabetes Care 21, 143-156.
1608 4. Al Gwairi, O., Thach, L., Zheng, W., Osman, N., Little, P.J., 2016. Cellular and Molecular Pathology of 
1609 Age-Related Macular Degeneration: Potential Role for Proteoglycans. J Ophthalmol 2016, 2913612.
1610 5. Alcolado, J.C., Moore, I.E., Weller, R.O., 1986. Calcification in the human choroid plexus, 
1611 meningiomas and pineal gland. Neuropathol Appl Neurobiol 12, 235-250.
1612 6. Alge, C.S., Suppmann, S., Priglinger, S.G., Neubauer, A.S., May, C.A., Hauck, S., Welge-Lussen, U., 
1613 Ueffing, M., Kampik, A., 2003. Comparative proteome analysis of native differentiated and cultured 
1614 dedifferentiated human RPE cells. Investigative ophthalmology & visual science 44, 3629-3641.
1615 7. Allam, R., Kumar, S.V., Darisipudi, M.N., Anders, H.J., 2014. Extracellular histones in tissue injury 
1616 and inflammation. J Mol Med (Berl) 92, 465-472.
1617 8. An, E., Lu, X., Flippin, J., Devaney, J.M., Halligan, B., Hoffman, E.P., Strunnikova, N., Csaky, K., 
1618 Hathout, Y., 2006. Secreted proteome profiling in human RPE cell cultures derived from donors with 
1619 age related macular degeneration and age matched healthy donors. J Proteome Res 5, 2599-2610.
1620 9. Anders, F., Liu, A., Mann, C., Teister, J., Lauzi, J., Thanos, S., Grus, F.H., Pfeiffer, N., Prokosch, V., 
1621 2017. The Small Heat Shock Protein alpha-Crystallin B Shows Neuroprotective Properties in a 
1622 Glaucoma Animal Model. Int J Mol Sci 18.
1623 10. Anderson, D.H., Mullins, R.F., Hageman, G.S., Johnson, L.V., 2002. A role for local inflammation in 
1624 the formation of drusen in the aging eye. Am J Ophthalmol 134, 411-431.
1625 11. Anderson, D.H., Ozaki, S., Nealon, M., Neitz, J., Mullins, R.F., Hageman, G.S., Johnson, L.V., 2001. 
1626 Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: 
1627 implications for the process of drusen formation. Am J Ophthalmol 131, 767-781.
1628 12. Anderson, D.H., Radeke, M.J., Gallo, N.B., Chapin, E.A., Johnson, P.T., Curletti, C.R., Hancox, L.S., 
1629 Hu, J., Ebright, J.N., Malek, G., Hauser, M.A., Rickman, C.B., Bok, D., Hageman, G.S., Johnson, L.V., 
1630 2010. The pivotal role of the complement system in aging and age-related macular degeneration: 
1631 hypothesis re-visited. Prog Retin Eye Res 29, 95-112.
1632 13. Arad, Y., Spadaro, L.A., Goodman, K., Newstein, D., Guerci, A.D., 2000. Prediction of coronary 
1633 events with electron beam computed tomography. J Am Coll Cardiol 36, 1253-1260.
1634 14. Arya, S., Emri, E., Synowsky, S.A., Shirran, S.L., Barzegar-Befroei, N., Peto, T., Botting, C.H., 
1635 Lengyel, I., Stewart, A.J., 2018. Quantitative analysis of hydroxyapatite-binding plasma proteins in 
1636 genotyped individuals with late-stage age-related macular degeneration. Exp Eye Res 172, 21-29.
1637 15. Ashford, J.W., 2004. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol 
1638 Neurosci 23, 157-165.
1639 16. Balaratnasingam, C., Hoang, Q.V., Inoue, M., Curcio, C.A., Dolz-Marco, R., Yannuzzi, N.A., Dhrami-
1640 Gavazi, E., Yannuzzi, L.A., Freund, K.B., 2016. Clinical Characteristics, Choroidal Neovascularization, 
1641 and Predictors of Visual Outcomes in Acquired Vitelliform Lesions. Am J Ophthalmol 172, 28-38.
1642 17. Barzegar-befroei, N., Peto, T., Bergen, A.A., Lengyel, I., 2012. Understanding the Role of Bruch's 
1643 Membrane in Cnv. Retinal Physician 9, 20-25.
1644 18. Beattie, J.R., Pawlak, A.M., Boulton, M.E., Zhang, J., Monnier, V.M., McGarvey, J.J., Stitt, A.W., 
1645 2010. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. 
1646 FASEB journal : official publication of the Federation of American Societies for Experimental Biology 
1647 24, 4816-4824.
1648 19. Bennis, A., Gorgels, T.G., Ten Brink, J.B., van der Spek, P.J., Bossers, K., Heine, V.M., Bergen, A.A., 
1649 2015. Comparison of Mouse and Human Retinal Pigment Epithelium Gene Expression Profiles: 
1650 Potential Implications for Age-Related Macular Degeneration. PLoS One 10, e0141597.
57
1651 20. Bernstein, M.H., Hollenberg, M.J., 1965. Fine structure of the choriocappillaris and retinal 
1652 capillaries. Invest Ophthalmol 4, 1016-1025.
1653 21. Bertazzo, S., Gentleman, E., Cloyd, K.L., Chester, A.H., Yacoub, M.H., Stevens, M.M., 2013. Nano-
1654 analytical electron microscopy reveals fundamental insights into human cardiovascular tissue 
1655 calcification. Nat Mater 12, 576-583.
1656 22. Bhutto, I., Lutty, G., 2012. Understanding age-related macular degeneration (AMD): relationships 
1657 between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. 
1658 Mol Aspects Med 33, 295-317.
1659 23. Biesemeier, A., Taubitz, T., Julien, S., Yoeruek, E., Schraermeyer, U., 2014. Choriocapillaris 
1660 breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 35, 
1661 2562-2573.
1662 24. Bird, A.C., Bressler, N.M., Bressler, S.B., Chisholm, I.H., Coscas, G., Davis, M.D., de Jong, P.T., 
1663 Klaver, C.C., Klein, B.E., Klein, R., et al., 1995. An international classification and grading system for 
1664 age-related maculopathy and age-related macular degeneration. The International ARM 
1665 Epidemiological Study Group. Surv Ophthalmol 39, 367-374.
1666 25. Bird, A.C., Phillips, R.L., Hageman, G.S., 2014. Geographic atrophy: a histopathological 
1667 assessment. JAMA Ophthalmol 132, 338-345.
1668 26. Blaum, B.S., Deakin, J.A., Johansson, C.M., Herbert, A.P., Barlow, P.N., Lyon, M., Uhrin, D., 2010. 
1669 Lysine and arginine side chains in glycosaminoglycan-protein complexes investigated by NMR, cross-
1670 linking, and mass spectrometry: a case study of the factor H-heparin interaction. J Am Chem Soc 132, 
1671 6374-6381.
1672 27. Bleijerveld, O.B., Zhang, Y.N., Beldar, S., Hoefer, I.E., Sze, S.K., Pasterkamp, G., de Kleijn, D.P., 
1673 2013. Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis. 
1674 Proteomics Clin Appl 7, 490-503.
1675 28. Booij, J.C., Baas, D.C., Beisekeeva, J., Gorgels, T.G., Bergen, A.A., 2010a. The dynamic nature of 
1676 Bruch's membrane. Prog Retin Eye Res 29, 1-18.
1677 29. Booij, J.C., ten Brink, J.B., Swagemakers, S.M., Verkerk, A.J., Essing, A.H., van der Spek, P.J., 
1678 Bergen, A.A., 2010b. A new strategy to identify and annotate human RPE-specific gene expression. 
1679 PLoS One 5, e9341.
1680 30. Booij, J.C., van Soest, S., Swagemakers, S.M., Essing, A.H., Verkerk, A.J., van der Spek, P.J., 
1681 Gorgels, T.G., Bergen, A.A., 2009. Functional annotation of the human retinal pigment epithelium 
1682 transcriptome. BMC Genomics 10, 164.
1683 31. Boon, C.J., van de Kar, N.C., Klevering, B.J., Keunen, J.E., Cremers, F.P., Klaver, C.C., Hoyng, C.B., 
1684 Daha, M.R., den Hollander, A.I., 2009. The spectrum of phenotypes caused by variants in the CFH 
1685 gene. Mol Immunol 46, 1573-1594.
1686 32. Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., 
1687 Ansorge, W., Ball, C.A., Causton, H.C., Gaasterland, T., Glenisson, P., Holstege, F.C., Kim, I.F., 
1688 Markowitz, V., Matese, J.C., Parkinson, H., Robinson, A., Sarkans, U., Schulze-Kremer, S., Stewart, J., 
1689 Taylor, R., Vilo, J., Vingron, M., 2001. Minimum information about a microarray experiment (MIAME)-
1690 toward standards for microarray data. Nat Genet 29, 365-371.
1691 33. Bressler, N.M., Munoz, B., Maguire, M.G., Vitale, S.E., Schein, O.D., Taylor, H.R., West, S.K., 1995. 
1692 Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. 
1693 Waterman study. Arch Ophthalmol 113, 301-308.
1694 34. Bressler, N.M., Silva, J.C., Bressler, S.B., Fine, S.L., Green, W.R., 1994. Clinicopathologic correlation 
1695 of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 
1696 14, 130-142.
1697 35. Bretillon, L., Thuret, G., Gregoire, S., Acar, N., Joffre, C., Bron, A.M., Gain, P., Creuzot-Garcher, 
1698 C.P., 2008. Lipid and fatty acid profile of the retina, retinal pigment epithelium/choroid, and the 
1699 lacrimal gland, and associations with adipose tissue fatty acids in human subjects. Exp Eye Res 87, 
1700 521-528.
1701 36. Burns, M.S., Hartz, M.J., 1992. The retinal pigment epithelium induces fenestration of endothelial 
1702 cells in vivo. Curr Eye Res 11, 863-873.
58
1703 37. Burns, R.P., Feeney-Burns, L., 1980. Clinico-morphologic correlations of drusen of Bruch's 
1704 membrane. Trans Am Ophthalmol Soc 78, 206-225.
1705 38. Cankova, Z., Huang, J.D., Kruth, H.S., Johnson, M., 2011. Passage of low-density lipoproteins 
1706 through Bruch's membrane and choroid. Exp Eye Res 93, 947-955.
1707 39. Cao, S., Walker, G.B., Wang, X., Cui, J.Z., Matsubara, J.A., 2013. Altered cytokine profiles of human 
1708 retinal pigment epithelium: oxidant injury and replicative senescence. Mol Vis 19, 718-728.
1709 40. Carafoli, E., 2010. The fateful encounter of mitochondria with calcium: how did it happen? 
1710 Biochim Biophys Acta 1797, 595-606.
1711 41. Chen, M., Forrester, J.V., Xu, H., 2007. Synthesis of complement factor H by retinal pigment 
1712 epithelial cells is down-regulated by oxidized photoreceptor outer segments. Exp Eye Res 84, 635-
1713 645.
1714 42. Chen, M., Hombrebueno, J.R., Luo, C., Penalva, R., Zhao, J., Colhoun, L., Pandi, S.P., Forrester, J.V., 
1715 Xu, H., 2013. Age- and light-dependent development of localised retinal atrophy in CCL2(-/-
1716 )CX3CR1(GFP/GFP) mice. PLoS One 8, e61381.
1717 43. Chirco, K.R., Flamme-Wiese, M.J., Wiley, J.S., Potempa, L.A., Stone, E.M., Tucker, B.A., Mullins, 
1718 R.F., 2018. Evaluation of serum and ocular levels of membrane attack complex and C-reactive protein 
1719 in CFH-genotyped human donors. Eye (Lond).
1720 44. Chirco, K.R., Potempa, L.A., 2018. C-Reactive Protein As a Mediator of Complement Activation 
1721 and Inflammatory Signaling in Age-Related Macular Degeneration. Front Immunol 9, 539.
1722 45. Chirco, K.R., Tucker, B.A., Stone, E.M., Mullins, R.F., 2016. Selective accumulation of the 
1723 complement membrane attack complex in aging choriocapillaris. Exp Eye Res 146, 393-397.
1724 46. Chung, B.H., Franklin, F., Liang, P., Doran, S., Cho, B.H., Curcio, C.A., 2005. Phosphatidylcholine-
1725 rich acceptors, but not native HDL or its apolipoproteins, mobilize cholesterol from cholesterol-rich 
1726 insoluble components of human atherosclerotic plaques. Biochim Biophys Acta 1733, 76-89.
1727 47. Clark, S.J., Keenan, T.D., Fielder, H.L., Collinson, L.J., Holley, R.J., Merry, C.L., van Kuppevelt, T.H., 
1728 Day, A.J., Bishop, P.N., 2011. Mapping the differential distribution of glycosaminoglycans in the adult 
1729 human retina, choroid, and sclera. Investigative ophthalmology & visual science 52, 6511-6521.
1730 48. Coats, G., 1905. The structure of the membrane of Bruch, and its relation to the formation of 
1731 colloid excrescences. J. & A. Churchill.
1732 49. Consortium, c.G., 2013. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580-585.
1733 50. Coppen, E.M., van der Grond, J., Hart, E.P., Lakke, E., Roos, R.A.C., 2018. The visual cortex and 
1734 visual cognition in Huntington's disease: An overview of current literature. Behav Brain Res 351, 63-
1735 74.
1736 51. Crabb, J.W., 2014. The proteomics of drusen. Cold Spring Harb Perspect Med 4, a017194.
1737 52. Crabb, J.W., Miyagi, M., Gu, X., Shadrach, K., West, K.A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, 
1738 L., Rayborn, M.E., Salomon, R.G., Hollyfield, J.G., 2002. Drusen proteome analysis: an approach to the 
1739 etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 99, 14682-14687.
1740 53. Cryan, L.M., O'Brien, C., 2008. Proteomics as a research tool in clinical and experimental 
1741 ophthalmology. Proteomics Clin Appl 2, 762-775.
1742 54. Csincsik, L., MacGillivray, T.J., Flynn, E., Pellegrini, E., Papanastasiou, G., Barzegar-Befroei, N., 
1743 Csutak, A., Bird, A.C., Ritchie, C.W., Peto, T., Lengyel, I., 2018. Peripheral Retinal Imaging Biomarkers 
1744 for Alzheimer's Disease: A Pilot Study. Ophthalmic Res 59, 182-192.
1745 55. Cunden, L.S., Brophy, M.B., Rodriguez, G.E., Flaxman, H.A., Nolan, E.M., 2017. Biochemical and 
1746 Functional Evaluation of the Intramolecular Disulfide Bonds in the Zinc-Chelating Antimicrobial 
1747 Protein Human S100A7 (Psoriasin). Biochemistry 56, 5726-5738.
1748 56. Cunningham, A., Kotagiri, A., 2018. A long history of dense deposit disease. BMC Ophthalmol 18, 
1749 228.
1750 57. Curcio, C.A., 2018a. Antecedents of Soft Drusen, the Specific Deposits of Age-Related Macular 
1751 Degeneration, in the Biology of Human Macula. Investigative ophthalmology & visual science 59, 
1752 Amd182-amd194.
1753 58. Curcio, C.A., 2018b. Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via 
1754 the Oil Spill Strategies. Investigative ophthalmology & visual science 59, Amd160-amd181.
59
1755 59. Curcio, C.A., Johnson, M., 2012. Structure, function, and pathology of Bruch's membrane, in: S. J. 
1756 Ryan, A.P.S., C. P. Wilkinson, D. R. Hinton, S. Sadda, P. Wiedemann (Ed.), Retina, Londen. Elsevier, pp. 
1757 465-481.
1758 60. Curcio, C.A., Johnson, M., Huang, J.D., Rudolf, M., 2009. Aging, age-related macular degeneration, 
1759 and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res 28, 
1760 393-422.
1761 61. Curcio, C.A., Johnson, M., Rudolf, M., Huang, J.D., 2011. The oil spill in ageing Bruch membrane. 
1762 The British journal of ophthalmology 95, 1638-1645.
1763 62. Curcio, C.A., Medeiros, N.E., Millican, C.L., 1998. The Alabama Age-Related Macular Degeneration 
1764 Grading System for donor eyes. Investigative ophthalmology & visual science 39, 1085-1096.
1765 63. Curcio, C.A., Messinger, J.D., Sloan, K.R., McGwin, G., Medeiros, N.E., Spaide, R.F., 2013. 
1766 Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, 
1767 prevalence, topography, and biogenesis model. Retina 33, 265-276.
1768 64. Curcio, C.A., Millican, C.L., 1999. Basal linear deposit and large drusen are specific for early age-
1769 related maculopathy. Arch Ophthalmol 117, 329-339.
1770 65. Curcio, C.A., Millican, C.L., Bailey, T., Kruth, H.S., 2001. Accumulation of cholesterol with age in 
1771 human Bruch's membrane. Investigative ophthalmology & visual science 42, 265-274.
1772 66. Curcio, C.A., Zanzottera, E.C., Ach, T., Balaratnasingam, C., Freund, K.B., 2017. Activated Retinal 
1773 Pigment Epithelium, an Optical Coherence Tomography Biomarker for Progression in Age-Related 
1774 Macular Degeneration. Investigative ophthalmology & visual science 58, Bio211-bio226.
1775 67. de Jong, P.T., 2006. Age-related macular degeneration. N Engl J Med 355, 1474-1485.
1776 68. De, S., Rabin, D.M., Salero, E., Lederman, P.L., Temple, S., Stern, J.H., 2007. Human retinal 
1777 pigment epithelium cell changes and expression of alphaB-crystallin: a biomarker for retinal pigment 
1778 epithelium cell change in age-related macular degeneration. Arch Ophthalmol 125, 641-645.
1779 69. de Vries, M.A., Trompet, S., Mooijaart, S.P., Smit, R.A., Bohringer, S., Castro Cabezas, M., Jukema, 
1780 J.W., 2017. Complement receptor 1 gene polymorphisms are associated with cardiovascular risk. 
1781 Atherosclerosis 257, 16-21.
1782 70. Del Priore, L.V., Tezel, T.H., Kaplan, H.J., 2006. Maculoplasty for age-related macular 
1783 degeneration: reengineering Bruch's membrane and the human macula. Prog Retin Eye Res 25, 539-
1784 562.
1785 71. Despriet, D.D., Klaver, C.C., Witteman, J.C., Bergen, A.A., Kardys, I., de Maat, M.P., Boekhoorn, 
1786 S.S., Vingerling, J.R., Hofman, A., Oostra, B.A., Uitterlinden, A.G., Stijnen, T., van Duijn, C.M., de Jong, 
1787 P.T., 2006. Complement factor H polymorphism, complement activators, and risk of age-related 
1788 macular degeneration. Jama 296, 301-309.
1789 72. Deutsch, E.W., Ball, C.A., Berman, J.J., Bova, G.S., Brazma, A., Bumgarner, R.E., Campbell, D., 
1790 Causton, H.C., Christiansen, J.H., Daian, F., Dauga, D., Davidson, D.R., Gimenez, G., Goo, Y.A., 
1791 Grimmond, S., Henrich, T., Herrmann, B.G., Johnson, M.H., Korb, M., Mills, J.C., Oudes, A.J., 
1792 Parkinson, H.E., Pascal, L.E., Pollet, N., Quackenbush, J., Ramialison, M., Ringwald, M., Salgado, D., 
1793 Sansone, S.A., Sherlock, G., Stoeckert, C.J., Jr., Swedlow, J., Taylor, R.C., Walashek, L., Warford, A., 
1794 Wilkinson, D.G., Zhou, Y., Zon, L.I., Liu, A.Y., True, L.D., 2008. Minimum information specification for 
1795 in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol 26, 305-
1796 312.
1797 73. Diamond, J.S., 2017. Inhibitory Interneurons in the Retina: Types, Circuitry, and Function. Annu 
1798 Rev Vis Sci 3, 1-24.
1799 74. Dick, A.D., 2017. Doyne lecture 2016: intraocular health and the many faces of inflammation. Eye 
1800 (Lond) 31, 87-96.
1801 75. Doherty, T.M., Asotra, K., Fitzpatrick, L.A., Qiao, J.H., Wilkin, D.J., Detrano, R.C., Dunstan, C.R., 
1802 Shah, P.K., Rajavashisth, T.B., 2003. Calcification in atherosclerosis: bone biology and chronic 
1803 inflammation at the arterial crossroads. Proc Natl Acad Sci U S A 100, 11201-11206.
1804 76. Domalpally, A., Clemons, T.E., Danis, R.P., Sadda, S.R., Cukras, C.A., Toth, C.A., Friberg, T.R., Chew, 
1805 E.Y., 2017. Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-
1806 Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related 
60
1807 Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group. Ophthalmology 124, 
1808 479-487.
1809 77. Doyle, S.L., Campbell, M., Ozaki, E., Salomon, R.G., Mori, A., Kenna, P.F., Farrar, G.J., Kiang, A.S., 
1810 Humphries, M.M., Lavelle, E.C., O'Neill, L.A., Hollyfield, J.G., Humphries, P., 2012. NLRP3 has a 
1811 protective role in age-related macular degeneration through the induction of IL-18 by drusen 
1812 components. Nat Med 18, 791-798.
1813 78. Durocher, D., Jackson, S.P., 2002. The FHA domain. FEBS Lett 513, 58-66.
1814 79. Duvall, J., Tso, M.O., 1985. Cellular mechanisms of resolution of drusen after laser coagulation. An 
1815 experimental study. Arch Ophthalmol 103, 694-703.
1816 80. Duvall-Young, J., MacDonald, M.K., McKechnie, N.M., 1989. Fundus changes in (type II) 
1817 mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. The British 
1818 journal of ophthalmology 73, 297-302.
1819 81. Edwards, A.O., Malek, G., 2007. Molecular genetics of AMD and current animal models. 
1820 Angiogenesis 10, 119-132.
1821 82. Edwards, A.O., Ritter, R., 3rd, Abel, K.J., Manning, A., Panhuysen, C., Farrer, L.A., 2005. 
1822 Complement factor H polymorphism and age-related macular degeneration. Science 308, 421-424.
1823 83. Engel, A.G., 2018. Congenital Myasthenic Syndromes in 2018. Curr Neurol Neurosci Rep 18, 46.
1824 84. Essner, E., Gordon, S.R., 1983. Observations on the permeability of the choriocapillaris of the eye. 
1825 Cell Tissue Res 231, 571-577.
1826 85. Fain, G., Sampath, A.P., 2018. Rod and cone interactions in the retina. F1000Res 7.
1827 86. Fariss, R.N., Apte, S.S., Olsen, B.R., Iwata, K., Milam, A.H., 1997. Tissue inhibitor of 
1828 metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol 150, 323-328.
1829 87. Farkas, T.G., Sylvester, V., Archer, D., 1971a. The ultrastructure of drusen. Am J Ophthalmol 71, 
1830 1196-1205.
1831 88. Farkas, T.G., Sylvester, V., Archer, D., Altona, M., 1971b. The histochemistry of drusen. Am J 
1832 Ophthalmol 71, 1206-1215.
1833 89. Farrah, T., Deutsch, E.W., Omenn, G.S., Campbell, D.S., Sun, Z., Bletz, J.A., Mallick, P., Katz, J.E., 
1834 Malmstrom, J., Ossola, R., Watts, J.D., Lin, B., Zhang, H., Moritz, R.L., Aebersold, R., 2011. A high-
1835 confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. 
1836 Mol Cell Proteomics 10, M110.006353.
1837 90. Feeney-Burns, L., Gao, C.L., Berman, E.R., 1988. The fate of immunoreactive opsin following 
1838 phagocytosis by pigment epithelium in human and monkey retinas. Investigative ophthalmology & 
1839 visual science 29, 708-719.
1840 91. Fernandez-Godino, R., Pierce, E.A., Garland, D.L., 2016. Extracellular Matrix Alterations and 
1841 Deposit Formation in AMD. Adv Exp Med Biol 854, 53-58.
1842 92. Fine, B.S., 1981. Lipoidal degeneration of the retinal pigment epithelium. Am J Ophthalmol 91, 
1843 469-473.
1844 93. Flinn, J.M., Kakalec, P., Tappero, R., Jones, B., Lengyel, I., 2014. Correlations in distribution and 
1845 concentration of calcium, copper and iron with zinc in isolated extracellular deposits associated with 
1846 age-related macular degeneration. Metallomics 6, 1223-1228.
1847 94. Forrest, D., Swaroop, A., 2012. Minireview: the role of nuclear receptors in photoreceptor 
1848 differentiation and disease. Mol Endocrinol 26, 905-915.
1849 95. Fort, P.E., Lampi, K.J., 2011. New focus on alpha-crystallins in retinal neurodegenerative diseases. 
1850 Exp Eye Res 92, 98-103.
1851 96. Friedman, E., Smith, T.R., Kuwabara, T., 1963. Senile choroidal vascular patterns and drusen. Arch 
1852 Ophthalmol 69, 220-230.
1853 97. Fritsche, L.G., Igl, W., Bailey, J.N., Grassmann, F., Sengupta, S., Bragg-Gresham, J.L., Burdon, K.P., 
1854 Hebbring, S.J., Wen, C., Gorski, M., Kim, I.K., Cho, D., Zack, D., Souied, E., Scholl, H.P., Bala, E., Lee, 
1855 K.E., Hunter, D.J., Sardell, R.J., Mitchell, P., Merriam, J.E., Cipriani, V., Hoffman, J.D., Schick, T., 
1856 Lechanteur, Y.T., Guymer, R.H., Johnson, M.P., Jiang, Y., Stanton, C.M., Buitendijk, G.H., Zhan, X., 
1857 Kwong, A.M., Boleda, A., Brooks, M., Gieser, L., Ratnapriya, R., Branham, K.E., Foerster, J.R., 
1858 Heckenlively, J.R., Othman, M.I., Vote, B.J., Liang, H.H., Souzeau, E., McAllister, I.L., Isaacs, T., Hall, J., 
61
1859 Lake, S., Mackey, D.A., Constable, I.J., Craig, J.E., Kitchner, T.E., Yang, Z., Su, Z., Luo, H., Chen, D., 
1860 Ouyang, H., Flagg, K., Lin, D., Mao, G., Ferreyra, H., Stark, K., von Strachwitz, C.N., Wolf, A., Brandl, C., 
1861 Rudolph, G., Olden, M., Morrison, M.A., Morgan, D.J., Schu, M., Ahn, J., Silvestri, G., Tsironi, E.E., 
1862 Park, K.H., Farrer, L.A., Orlin, A., Brucker, A., Li, M., Curcio, C.A., Mohand-Said, S., Sahel, J.A., Audo, I., 
1863 Benchaboune, M., Cree, A.J., Rennie, C.A., Goverdhan, S.V., Grunin, M., Hagbi-Levi, S., Campochiaro, 
1864 P., Katsanis, N., Holz, F.G., Blond, F., Blanche, H., Deleuze, J.F., Igo, R.P., Jr., Truitt, B., Peachey, N.S., 
1865 Meuer, S.M., Myers, C.E., Moore, E.L., Klein, R., Hauser, M.A., Postel, E.A., Courtenay, M.D., 
1866 Schwartz, S.G., Kovach, J.L., Scott, W.K., Liew, G., Tan, A.G., Gopinath, B., Merriam, J.C., Smith, R.T., 
1867 Khan, J.C., Shahid, H., Moore, A.T., McGrath, J.A., Laux, R., Brantley, M.A., Jr., Agarwal, A., Ersoy, L., 
1868 Caramoy, A., Langmann, T., Saksens, N.T., de Jong, E.K., Hoyng, C.B., Cain, M.S., Richardson, A.J., 
1869 Martin, T.M., Blangero, J., Weeks, D.E., Dhillon, B., van Duijn, C.M., Doheny, K.F., Romm, J., Klaver, 
1870 C.C., Hayward, C., Gorin, M.B., Klein, M.L., Baird, P.N., den Hollander, A.I., Fauser, S., Yates, J.R., 
1871 Allikmets, R., Wang, J.J., Schaumberg, D.A., Klein, B.E., Hagstrom, S.A., Chowers, I., Lotery, A.J., 
1872 Leveillard, T., Zhang, K., Brilliant, M.H., Hewitt, A.W., Swaroop, A., Chew, E.Y., Pericak-Vance, M.A., 
1873 DeAngelis, M., Stambolian, D., Haines, J.L., Iyengar, S.K., Weber, B.H., Abecasis, G.R., Heid, I.M., 2016. 
1874 A large genome-wide association study of age-related macular degeneration highlights contributions 
1875 of rare and common variants. Nat Genet 48, 134-143.
1876 98. Garcia-Aranda, M., Serrano, A., Redondo, M., 2018. Regulation of Clusterin Gene Expression. Curr 
1877 Protein Pept Sci 19, 612-622.
1878 99. Gass, J.D., 1967. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 
1879 63, Suppl:1-139.
1880 100. Gehlbach, P., Li, T., Hatef, E., 2016. Statins for age-related macular degeneration. Cochrane 
1881 Database Syst Rev, Cd006927.
1882 101. George, A.K., Singh, M., Homme, R.P., Majumder, A., Sandhu, H.S., Tyagi, S.C., 2018. A 
1883 hypothesis for treating inflammation and oxidative stress with hydrogen sulfide during age-related 
1884 macular degeneration. Int J Ophthalmol 11, 881-887.
1885 102. German, O.L., Monaco, S., Agnolazza, D.L., Rotstein, N.P., Politi, L.E., 2013. Retinoid X receptor 
1886 activation is essential for docosahexaenoic acid protection of retina photoreceptors. J Lipid Res 54, 
1887 2236-2246.
1888 103. Geyer, P.E., Kulak, N.A., Pichler, G., Holdt, L.M., Teupser, D., Mann, M., 2016. Plasma Proteome 
1889 Profiling to Assess Human Health and Disease. Cell Syst 2, 185-195.
1890 104. Gonzalez, A., Valeiras, M., Sidransky, E., Tayebi, N., 2014. Lysosomal integral membrane protein-
1891 2: a new player in lysosome-related pathology. Mol Genet Metab 111, 84-91.
1892 105. Gonzalez-Fernandez, F., Kittredge, K.L., Rayborn, M.E., Hollyfield, J.G., Landers, R.A., Saha, M., 
1893 Grainger, R.M., 1993. Interphotoreceptor retinoid-binding protein (IRBP), a major 124 kDa 
1894 glycoprotein in the interphotoreceptor matrix of Xenopus laevis. Characterization, molecular cloning 
1895 and biosynthesis. J Cell Sci 105 ( Pt 1), 7-21.
1896 106. Gorgels, T.G., Teeling, P., Meeldijk, J.D., Nillesen, S.T., van der Wal, A.C., van Kuppevelt, T.H., 
1897 Bergen, A.A., 2012. Abcc6 deficiency in the mouse leads to calcification of collagen fibers in Bruch's 
1898 membrane. Exp Eye Res 104, 59-64.
1899 107. Grassmann, F., Kiel, C., Zimmermann, M.E., Gorski, M., Grassmann, V., Stark, K., Heid, I.M., 
1900 Weber, B.H., 2017. Genetic pleiotropy between age-related macular degeneration and 16 complex 
1901 diseases and traits. Genome Med 9, 29.
1902 108. Green, W.R., Enger, C., 1993. Age-related macular degeneration histopathologic studies. The 
1903 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100, 1519-1535.
1904 109. Green, W.R., Key, S.N., 3rd, 1977. Senile macular degeneration: a histopathologic study. . Retina 
1905 25, 180-250; discussion 250-184.
1906 110. Gross, S.R., Sin, C.G., Barraclough, R., Rudland, P.S., 2014. Joining S100 proteins and migration: 
1907 for better or for worse, in sickness and in health. Cell Mol Life Sci 71, 1551-1579.
1908 111. Guo, L., Hussain, A.A., Limb, G.A., Marshall, J., 1999. Age-dependent variation in 
1909 metalloproteinase activity of isolated human Bruch's membrane and choroid. Investigative 
1910 ophthalmology & visual science 40, 2676-2682.
62
1911 112. Guymer, R., Luthert, P., Bird, A., 1999. Changes in Bruch's membrane and related structures with 
1912 age. Prog Retin Eye Res 18, 59-90.
1913 113. Hageman, G.S., Anderson, D.H., Johnson, L.V., Hancox, L.S., Taiber, A.J., Hardisty, L.I., Hageman, 
1914 J.L., Stockman, H.A., Borchardt, J.D., Gehrs, K.M., Smith, R.J., Silvestri, G., Russell, S.R., Klaver, C.C., 
1915 Barbazetto, I., Chang, S., Yannuzzi, L.A., Barile, G.R., Merriam, J.C., Smith, R.T., Olsh, A.K., Bergeron, J., 
1916 Zernant, J., Merriam, J.E., Gold, B., Dean, M., Allikmets, R., 2005. A common haplotype in the 
1917 complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular 
1918 degeneration. Proc Natl Acad Sci U S A 102, 7227-7232.
1919 114. Hageman, G.S., Luthert, P.J., Victor Chong, N.H., Johnson, L.V., Anderson, D.H., Mullins, R.F., 
1920 2001. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes 
1921 at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin 
1922 Eye Res 20, 705-732.
1923 115. Hageman, G.S., Mullins, R.F., Russell, S.R., Johnson, L.V., Anderson, D.H., 1999. Vitronectin is a 
1924 constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented 
1925 epithelial cells. FASEB journal : official publication of the Federation of American Societies for 
1926 Experimental Biology 13, 477-484.
1927 116. Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., Spencer, K.L., Kwan, 
1928 S.Y., Noureddine, M., Gilbert, J.R., Schnetz-Boutaud, N., Agarwal, A., Postel, E.A., Pericak-Vance, 
1929 M.A., 2005. Complement factor H variant increases the risk of age-related macular degeneration. 
1930 Science 308, 419-421.
1931 117. Handa, J.T., Cano, M., Wang, L., Datta, S., Liu, T., 2017. Lipids, oxidized lipids, oxidation-specific 
1932 epitopes, and Age-related Macular Degeneration. Biochim Biophys Acta Mol Cell Biol Lipids 1862, 
1933 430-440.
1934 118. Hansson, G.K., Robertson, A.K., Soderberg-Naucler, C., 2006. Inflammation and atherosclerosis. 
1935 Annu Rev Pathol 1, 297-329.
1936 119. Happonen, K.E., Furst, C.M., Saxne, T., Heinegard, D., Blom, A.M., 2012. PRELP protein inhibits 
1937 the formation of the complement membrane attack complex. J Biol Chem 287, 8092-8100.
1938 120. Hiebl, V., Ladurner, A., Latkolik, S., Dirsch, V.M., 2018. Natural products as modulators of the 
1939 nuclear receptors and metabolic sensors LXR, FXR and RXR. Biotechnol Adv.
1940 121. Hogan, M.J., 1965. MACULAR DISEASES: PATHOGENESIS. ELECTRON MICROSCOPY OF BRUCH'S 
1941 MEMBRANE. Trans Am Acad Ophthalmol Otolaryngol 69, 683-690.
1942 122. Hogan, M.J., 1972. Role of the retinal pigment epithelium in macular disease. Trans Am Acad 
1943 Ophthalmol Otolaryngol 76, 64-80.
1944 123. Hoke, M., Speidl, W., Schillinger, M., Minar, E., Zehetmayer, S., Schonherr, M., Wagner, O., 
1945 Mannhalter, C., 2012. Polymorphism of the complement 5 gene and cardiovascular outcome in 
1946 patients with atherosclerosis. Eur J Clin Invest 42, 921-926.
1947 124. Hollyfield, J.G., Perez, V.L., Salomon, R.G., 2010. A hapten generated from an oxidation fragment 
1948 of docosahexaenoic acid is sufficient to initiate age-related macular degeneration. Mol Neurobiol 41, 
1949 290-298.
1950 125. Hollyfield, J.G., Salomon, R.G., Crabb, J.W., 2003. Proteomic approaches to understanding age-
1951 related macular degeneration. Adv Exp Med Biol 533, 83-89.
1952 126. Hopkins, P.N., 2013. Molecular biology of atherosclerosis. Physiol Rev 93, 1317-1542.
1953 127. Hoppe, G., Marmorstein, A.D., Pennock, E.A., Hoff, H.F., 2001. Oxidized low density lipoprotein-
1954 induced inhibition of processing of photoreceptor outer segments by RPE. Investigative 
1955 ophthalmology & visual science 42, 2714-2720.
1956 128. Hultgardh-Nilsson, A., Boren, J., Chakravarti, S., 2015. The small leucine-rich repeat 
1957 proteoglycans in tissue repair and atherosclerosis. J Intern Med 278, 447-461.
1958 129. Hussain, A.A., Lee, Y., Zhang, J.J., Marshall, J., 2011. Disturbed matrix metalloproteinase activity 
1959 of Bruch's membrane in age-related macular degeneration. Investigative ophthalmology & visual 
1960 science 52, 4459-4466.
63
1961 130. Hussain, A.A., Starita, C., Hodgetts, A., Marshall, J., 2010. Macromolecular diffusion 
1962 characteristics of ageing human Bruch's membrane: implications for age-related macular 
1963 degeneration (AMD). Exp Eye Res 90, 703-710.
1964 131. Hyman, L.G., Lilienfeld, A.M., Ferris, F.L., 3rd, Fine, S.L., 1983. Senile macular degeneration: a 
1965 case-control study. Am J Epidemiol 118, 213-227.
1966 132. Ida, H., Ishibashi, K., Reiser, K., Hjelmeland, L.M., Handa, J.T., 2004. Ultrastructural aging of the 
1967 RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse. Investigative 
1968 ophthalmology & visual science 45, 2348-2354.
1969 133. Ito, N., Ohashi, R., Nagata, M., 2017. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol 
1970 21, 541-551.
1971 134. Jang, H.L., Jin, K., Lee, J., Kim, Y., Nahm, S.H., Hong, K.S., Nam, K.T., 2014. Revisiting whitlockite, 
1972 the second most abundant biomineral in bone: nanocrystal synthesis in physiologically relevant 
1973 conditions and biocompatibility evaluation. ACS Nano 8, 634-641.
1974 135. Jansen, R.S., Kucukosmanoglu, A., de Haas, M., Sapthu, S., Otero, J.A., Hegman, I.E., Bergen, 
1975 A.A., Gorgels, T.G., Borst, P., van de Wetering, K., 2013. ABCC6 prevents ectopic mineralization seen 
1976 in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A 110, 
1977 20206-20211.
1978 136. Jobling, A.I., Guymer, R.H., Vessey, K.A., Greferath, U., Mills, S.A., Brassington, K.H., Luu, C.D., 
1979 Aung, K.Z., Trogrlic, L., Plunkett, M., Fletcher, E.L., 2015. Nanosecond laser therapy reverses 
1980 pathologic and molecular changes in age-related macular degeneration without retinal damage. 
1981 FASEB journal : official publication of the Federation of American Societies for Experimental Biology 
1982 29, 696-710.
1983 137. Johnson, L.V., Forest, D.L., Banna, C.D., Radeke, C.M., Maloney, M.A., Hu, J., Spencer, C.N., 
1984 Walker, A.M., Tsie, M.S., Bok, D., Radeke, M.J., Anderson, D.H., 2011. Cell culture model that mimics 
1985 drusen formation and triggers complement activation associated with age-related macular 
1986 degeneration. Proc Natl Acad Sci U S A 108, 18277-18282.
1987 138. Johnson, L.V., Ozaki, S., Staples, M.K., Erickson, P.A., Anderson, D.H., 2000. A potential role for 
1988 immune complex pathogenesis in drusen formation. Exp Eye Res 70, 441-449.
1989 139. Johnson, P.T., Lewis, G.P., Talaga, K.C., Brown, M.N., Kappel, P.J., Fisher, S.K., Anderson, D.H., 
1990 Johnson, L.V., 2003. Drusen-associated degeneration in the retina. Investigative ophthalmology & 
1991 visual science 44, 4481-4488.
1992 140. Jones, S.E., Jomary, C., Grist, J., Makwana, J., Neal, M.J., 1999. Retinal expression of gamma-
1993 crystallins in the mouse. Investigative ophthalmology & visual science 40, 3017-3020.
1994 141. Kalbitz, M., Grailer, J.J., Fattahi, F., Jajou, L., Herron, T.J., Campbell, K.F., Zetoune, F.S., Bosmann, 
1995 M., Sarma, J.V., Huber-Lang, M., Gebhard, F., Loaiza, R., Valdivia, H.H., Jalife, J., Russell, M.W., Ward, 
1996 P.A., 2015. Role of extracellular histones in the cardiomyopathy of sepsis. FASEB journal : official 
1997 publication of the Federation of American Societies for Experimental Biology 29, 2185-2193.
1998 142. Kamaraj, B., Purohit, R., 2014. Mutational analysis of oculocutaneous albinism: a compact 
1999 review. Biomed Res Int 2014, 905472.
2000 143. Kamei, M., Hollyfield, J.G., 1999. TIMP-3 in Bruch's membrane: changes during aging and in age-
2001 related macular degeneration. Investigative ophthalmology & visual science 40, 2367-2375.
2002 144. Kani, T., Kani, M., Moriwaki, Y., Doi, Y., 1983. Microbeam x-ray diffraction analysis of dental 
2003 calculus. J Dent Res 62, 92-95.
2004 145. Kannan, R., Sreekumar, P.G., Hinton, D.R., 2016. Alpha crystallins in the retinal pigment 
2005 epithelium and implications for the pathogenesis and treatment of age-related macular 
2006 degeneration. Biochim Biophys Acta 1860, 258-268.
2007 146. Kauppinen, A., Paterno, J.J., Blasiak, J., Salminen, A., Kaarniranta, K., 2016. Inflammation and its 
2008 role in age-related macular degeneration. Cell Mol Life Sci 73, 1765-1786.
2009 147. Keelan, P.C., Bielak, L.F., Ashai, K., Jamjoum, L.S., Denktas, A.E., Rumberger, J.A., Sheedy, I.P., 
2010 Peyser, P.A., Schwartz, R.S., 2001. Long-term prognostic value of coronary calcification detected by 
2011 electron-beam computed tomography in patients undergoing coronary angiography. Circulation 104, 
2012 412-417.
64
2013 148. Keenan, T.D., Clark, S.J., Unwin, R.D., Ridge, L.A., Day, A.J., Bishop, P.N., 2012. Mapping the 
2014 differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera. 
2015 Investigative ophthalmology & visual science 53, 7528-7538.
2016 149. Kestenbaum, B.R., Adeney, K.L., de Boer, I.H., Ix, J.H., Shlipak, M.G., Siscovick, D.S., 2009. 
2017 Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study 
2018 of Atherosclerosis. Kidney Int 76, 991-998.
2019 150. Khan, K.N., Mahroo, O.A., Khan, R.S., Mohamed, M.D., McKibbin, M., Bird, A., Michaelides, M., 
2020 Tufail, A., Moore, A.T., 2016. Differentiating drusen: Drusen and drusen-like appearances associated 
2021 with ageing, age-related macular degeneration, inherited eye disease and other pathological 
2022 processes. Prog Retin Eye Res 53, 70-106.
2023 151. Kiel, C., Vogt, A., Campagna, A., Chatr-aryamontri, A., Swiatek-de Lange, M., Beer, M., Bolz, S., 
2024 Mack, A.F., Kinkl, N., Cesareni, G., Serrano, L., Ueffing, M., 2011. Structural and functional protein 
2025 network analyses predict novel signaling functions for rhodopsin. Mol Syst Biol 7, 551.
2026 152. Kim, Y.H., He, S., Kase, S., Kitamura, M., Ryan, S.J., Hinton, D.R., 2009. Regulated secretion of 
2027 complement factor H by RPE and its role in RPE migration. Graefes Arch Clin Exp Ophthalmol 247, 
2028 651-659.
2029 153. Kinnunen, K., Petrovski, G., Moe, M.C., Berta, A., Kaarniranta, K., 2012. Molecular mechanisms 
2030 of retinal pigment epithelium damage and development of age-related macular degeneration. Acta 
2031 Ophthalmol 90, 299-309.
2032 154. Klaver, C.C., Kliffen, M., van Duijn, C.M., Hofman, A., Cruts, M., Grobbee, D.E., van Broeckhoven, 
2033 C., de Jong, P.T., 1998. Genetic association of apolipoprotein E with age-related macular 
2034 degeneration. Am J Hum Genet 63, 200-206.
2035 155. Klein, R., Klein, B.E., Franke, T., 1993. The relationship of cardiovascular disease and its risk 
2036 factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 100, 406-414.
2037 156. Klein, R.J., Zeiss, C., Chew, E.Y., Tsai, J.Y., Sackler, R.S., Haynes, C., Henning, A.K., SanGiovanni, 
2038 J.P., Mane, S.M., Mayne, S.T., Bracken, M.B., Ferris, F.L., Ott, J., Barnstable, C., Hoh, J., 2005. 
2039 Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389.
2040 157. Kobayashi, H., Okamoto, H., Murakami, A., Iwata, T., 2014. Plasma proteome analysis on 
2041 cynomolgus monkey (Macaca fascicularis) pedigrees with early onset drusen formation. Exp Anim 63, 
2042 305-310.
2043 158. Kornzweig, A.L., 1977. Changes in the choriocapillaris associated with senile macular 
2044 degeneration. Ann Ophthalmol 9, 753-756, 759-762.
2045 159. Kruijt, C.C., de Wit, G.C., Bergen, A.A., Florijn, R.J., Schalij-Delfos, N.E., van Genderen, M.M., 
2046 2018. The Phenotypic Spectrum of Albinism. Ophthalmology.
2047 160. Kunchithapautham, K., Atkinson, C., Rohrer, B., 2014. Smoke exposure causes endoplasmic 
2048 reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and 
2049 complement activation. J Biol Chem 289, 14534-14546.
2050 161. Lai, X., Wichers, H.J., Soler-Lopez, M., Dijkstra, B.W., 2018. Structure and Function of Human 
2051 Tyrosinase and Tyrosinase-Related Proteins. Chemistry 24, 47-55.
2052 162. Lee, J.S., Morrisett, J.D., Tung, C.H., 2012. Detection of hydroxyapatite in calcified cardiovascular 
2053 tissues. Atherosclerosis 224, 340-347.
2054 163. Lee, Y., Hussain, A.A., Seok, J.H., Kim, S.H., Marshall, J., 2015. Modulating the Transport 
2055 Characteristics of Bruch's Membrane With Steroidal Glycosides and its Relevance to Age-Related 
2056 Macular Degeneration (AMD). Investigative ophthalmology & visual science 56, 8403-8418.
2057 164. Lengyel, I., Csutak, A., Florea, D., Leung, I., Bird, A.C., Jonasson, F., Peto, T., 2015. A Population-
2058 Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like 
2059 Lesions at the Peripheral Retina. Ophthalmology 122, 1340-1347.
2060 165. Lengyel, I., Flinn, J.M., Peto, T., Linkous, D.H., Cano, K., Bird, A.C., Lanzirotti, A., Frederickson, 
2061 C.J., van Kuijk, F.J., 2007. High concentration of zinc in sub-retinal pigment epithelial deposits. Exp 
2062 Eye Res 84, 772-780.
65
2063 166. Lengyel, I., Tufail, A., Hosaini, H.A., Luthert, P., Bird, A.C., Jeffery, G., 2004. Association of drusen 
2064 deposition with choroidal intercapillary pillars in the aging human eye. Investigative ophthalmology & 
2065 visual science 45, 2886-2892.
2066 167. Li, C.M., Chung, B.H., Presley, J.B., Malek, G., Zhang, X., Dashti, N., Li, L., Chen, J., Bradley, K., 
2067 Kruth, H.S., Curcio, C.A., 2005a. Lipoprotein-like particles and cholesteryl esters in human Bruch's 
2068 membrane: initial characterization. Investigative ophthalmology & visual science 46, 2576-2586.
2069 168. Li, C.M., Presley, J.B., Zhang, X., Dashti, N., Chung, B.H., Medeiros, N.E., Guidry, C., Curcio, C.A., 
2070 2005b. Retina expresses microsomal triglyceride transfer protein: implications for age-related 
2071 maculopathy. J Lipid Res 46, 628-640.
2072 169. Li, M., Dolz-Marco, R., Messinger, J.D., Wang, L., Feist, R.M., Girkin, C.A., Gattoussi, S., Ferrara, 
2073 D., Curcio, C.A., Freund, K.B., 2018. Clinicopathologic Correlation of Anti-Vascular Endothelial Growth 
2074 Factor-Treated Type 3 Neovascularization in Age-Related Macular Degeneration. Ophthalmology 125, 
2075 276-287.
2076 170. Li, M., Jia, C., Kazmierkiewicz, K.L., Bowman, A.S., Tian, L., Liu, Y., Gupta, N.A., Gudiseva, H.V., 
2077 Yee, S.S., Kim, M., Dentchev, T., Kimble, J.A., Parker, J.S., Messinger, J.D., Hakonarson, H., Curcio, 
2078 C.A., Stambolian, D., 2014. Comprehensive analysis of gene expression in human retina and 
2079 supporting tissues. Human molecular genetics 23, 4001-4014.
2080 171. Loeffler, K.U., Lee, W.R., 1998. Terminology of sub-RPE deposits: do we all speak the same 
2081 language? The British journal of ophthalmology 82, 1104-1105.
2082 172. Lutty, G.A., Hasegawa, T., Baba, T., Grebe, R., Bhutto, I., McLeod, D.S., 2010. Development of the 
2083 human choriocapillaris. Eye (Lond) 24, 408-415.
2084 173. Machalinska, A., Safranow, K., Dziedziejko, V., Mozolewska-Piotrowska, K., Paczkowska, E., Klos, 
2085 P., Pius, E., Grymula, K., Wiszniewska, B., Karczewicz, D., Machalinski, B., 2011. Different populations 
2086 of circulating endothelial cells in patients with age-related macular degeneration: a novel insight into 
2087 pathogenesis. Investigative ophthalmology & visual science 52, 93-100.
2088 174. Mahley, R.W., 2016. Apolipoprotein E: from cardiovascular disease to neurodegenerative 
2089 disorders. J Mol Med (Berl) 94, 739-746.
2090 175. Malek, G., Li, C.M., Guidry, C., Medeiros, N.E., Curcio, C.A., 2003. Apolipoprotein B in 
2091 cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J 
2092 Pathol 162, 413-425.
2093 176. Maltzman, B.A., Mulvihill, M.N., Greenbaum, A., 1979. Senile macular degeneration and risk 
2094 factors: a case-control study. Ann Ophthalmol 11, 1197-1201.
2095 177. Mancini, M.A., Frank, R.N., Keirn, R.J., Kennedy, A., Khoury, J.K., 1986. Does the retinal pigment 
2096 epithelium polarize the choriocapillaris? Investigative ophthalmology & visual science 27, 336-345.
2097 178. Marshall, G.E., Konstas, A.G., Reid, G.G., Edwards, J.G., Lee, W.R., 1992. Type IV collagen and 
2098 laminin in Bruch's membrane and basal linear deposit in the human macula. The British journal of 
2099 ophthalmology 76, 607-614.
2100 179. McLeod, D.S., Grebe, R., Bhutto, I., Merges, C., Baba, T., Lutty, G.A., 2009. Relationship between 
2101 RPE and choriocapillaris in age-related macular degeneration. Investigative ophthalmology & visual 
2102 science 50, 4982-4991.
2103 180. Miteva, K., Madonna, R., De Caterina, R., Van Linthout, S., 2018. Innate and adaptive immunity 
2104 in atherosclerosis. Vascul Pharmacol.
2105 181. Molins, B., Romero-Vazquez, S., Fuentes-Prior, P., Adan, A., Dick, A.D., 2018. C-Reactive Protein 
2106 as a Therapeutic Target in Age-Related Macular Degeneration. Front Immunol 9, 808.
2107 182. Moore, D.J., Clover, G.M., 2001. The effect of age on the macromolecular permeability of 
2108 human Bruch's membrane. Investigative ophthalmology & visual science 42, 2970-2975.
2109 183. Moore, D.J., Hussain, A.A., Marshall, J., 1995. Age-related variation in the hydraulic conductivity 
2110 of Bruch's membrane. Investigative ophthalmology & visual science 36, 1290-1297.
2111 184. Moreira-Neto, C.A., Moult, E.M., Fujimoto, J.G., Waheed, N.K., Ferrara, D., 2018. Choriocapillaris 
2112 Loss in Advanced Age-Related Macular Degeneration. J Ophthalmol 2018, 8125267.
66
2113 185. Mullins, R.F., Johnson, M.N., Faidley, E.A., Skeie, J.M., Huang, J., 2011. Choriocapillaris vascular 
2114 dropout related to density of drusen in human eyes with early age-related macular degeneration. 
2115 Investigative ophthalmology & visual science 52, 1606-1612.
2116 186. Mullins, R.F., Russell, S.R., Anderson, D.H., Hageman, G.S., 2000. Drusen associated with aging 
2117 and age-related macular degeneration contain proteins common to extracellular deposits associated 
2118 with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB journal : official 
2119 publication of the Federation of American Societies for Experimental Biology 14, 835-846.
2120 187. Mullins, R.F., Schoo, D.P., Sohn, E.H., Flamme-Wiese, M.J., Workamelahu, G., Johnston, R.M., 
2121 Wang, K., Tucker, B.A., Stone, E.M., 2014. The membrane attack complex in aging human 
2122 choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol 184, 3142-
2123 3153.
2124 188. Mungrue, I.N., Zhao, P., Yao, Y., Meng, H., Rau, C., Havel, J.V., Gorgels, T.G., Bergen, A.A., 
2125 MacLellan, W.R., Drake, T.A., Bostrom, K.I., Lusis, A.J., 2011. Abcc6 deficiency causes increased infarct 
2126 size and apoptosis in a mouse cardiac ischemia-reperfusion model. Arterioscler Thromb Vasc Biol 31, 
2127 2806-2812.
2128 189. Musser, J.M., Arendt, D., 2017. Loss and gain of cone types in vertebrate ciliary photoreceptor 
2129 evolution. Dev Biol 431, 26-35.
2130 190. Nakanishi, M., Grebe, R., Bhutto, I.A., Edwards, M., McLeod, D.S., Lutty, G.A., 2016. Albumen 
2131 Transport to Bruch's Membrane and RPE by Choriocapillaris Caveolae. Investigative ophthalmology & 
2132 visual science 57, 2213-2224.
2133 191. Nakata, K., Crabb, J.W., Hollyfield, J.G., 2005. Crystallin distribution in Bruch's membrane-
2134 choroid complex from AMD and age-matched donor eyes. Exp Eye Res 80, 821-826.
2135 192. Nan, R., Farabella, I., Schumacher, F.F., Miller, A., Gor, J., Martin, A.C., Jones, D.T., Lengyel, I., 
2136 Perkins, S.J., 2011. Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible 
2137 implications for age-related macular degeneration. J Mol Biol 408, 714-735.
2138 193. Nan, R., Gor, J., Lengyel, I., Perkins, S.J., 2008. Uncontrolled zinc- and copper-induced 
2139 oligomerisation of the human complement regulator factor H and its possible implications for 
2140 function and disease. J Mol Biol 384, 1341-1352.
2141 194. Nan, R., Tetchner, S., Rodriguez, E., Pao, P.J., Gor, J., Lengyel, I., Perkins, S.J., 2013. Zinc-induced 
2142 self-association of complement C3b and Factor H: implications for inflammation and age-related 
2143 macular degeneration. J Biol Chem 288, 19197-19210.
2144 195. Narumi, K., Miyakawa, R., Ueda, R., Hashimoto, H., Yamamoto, Y., Yoshida, T., Aoki, K., 2015. 
2145 Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE. J Immunol 
2146 194, 5539-5548.
2147 196. Newsome, D.A., Hewitt, A.T., Huh, W., Robey, P.G., Hassell, J.R., 1987. Detection of specific 
2148 extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body. Am J Ophthalmol 104, 
2149 373-381.
2150 197. Nijholt, D.A., Ijsselstijn, L., van der Weiden, M.M., Zheng, P.P., Sillevis Smitt, P.A., Koudstaal, P.J., 
2151 Luider, T.M., Kros, J.M., 2015. Pregnancy Zone Protein is Increased in the Alzheimer's Disease Brain 
2152 and Associates with Senile Plaques. J Alzheimers Dis 46, 227-238.
2153 198. Nordgaard, C.L., Berg, K.M., Kapphahn, R.J., Reilly, C., Feng, X., Olsen, T.W., Ferrington, D.A., 
2154 2006. Proteomics of the retinal pigment epithelium reveals altered protein expression at progressive 
2155 stages of age-related macular degeneration. Investigative ophthalmology & visual science 47, 815-
2156 822.
2157 199. Novais, E.A., Badaro, E., Regatieri, C.V., Duker, J., de Oliveira Bonomo, P.P., 2015. Regression of 
2158 drusen after combined treatment using photodynamic therapy with verteporfin and ranibizumab. 
2159 Ophthalmic Surg Lasers Imaging Retina 46, 275-278.
2160 200. Okuno, S., Ishimura, E., Kitatani, K., Fujino, Y., Kohno, K., Maeno, Y., Maekawa, K., Yamakawa, T., 
2161 Imanishi, Y., Inaba, M., Nishizawa, Y., 2007. Presence of abdominal aortic calcification is significantly 
2162 associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J 
2163 Kidney Dis 49, 417-425.
67
2164 201. Oshikawa, M., Tsutsui, C., Ikegami, T., Fuchida, Y., Matsubara, M., Toyama, S., Usami, R., 
2165 Ohtoko, K., Kato, S., 2011. Full-length transcriptome analysis of human retina-derived cell lines ARPE-
2166 19 and Y79 using the vector-capping method. Investigative ophthalmology & visual science 52, 6662-
2167 6670.
2168 202. Pao, P.J., Emri, E., Abdirahman, S.B., Soorma, T., Zeng, H.H., Hauck, S.M., Thompson, R.B., 
2169 Lengyel, I., 2018. The effects of zinc supplementation on primary human retinal pigment epithelium. 
2170 J Trace Elem Med Biol 49, 184-191.
2171 203. Pauleikhoff, D., Chen, J.C., Chisholm, I.H., Bird, A.C., 1990. Choroidal perfusion abnormality with 
2172 age-related Bruch's membrane change. Am J Ophthalmol 109, 211-217.
2173 204. Pelisek, J., Wendorff, H., Wendorff, C., Kuehnl, A., Eckstein, H.H., 2016. Age-associated changes 
2174 in human carotid atherosclerotic plaques. Ann Med 48, 541-551.
2175 205. Penfold, P.L., Madigan, M.C., Gillies, M.C., Provis, J.M., 2001. Immunological and aetiological 
2176 aspects of macular degeneration. Prog Retin Eye Res 20, 385-414.
2177 206. Pikuleva, I.A., Curcio, C.A., 2014. Cholesterol in the retina: the best is yet to come. Prog Retin 
2178 Eye Res 41, 64-89.
2179 207. Pilgrim, M.G., Lengyel, I., Lanzirotti, A., Newville, M., Fearn, S., Emri, E., Knowles, J.C., Messinger, 
2180 J.D., Read, R.W., Guidry, C., Curcio, C.A., 2017. Subretinal Pigment Epithelial Deposition of Drusen 
2181 Components Including Hydroxyapatite in a Primary Cell Culture Model. Investigative ophthalmology 
2182 & visual science 58, 708-719.
2183 208. Pino, R.M., 1985. Restriction to endogenous plasma proteins by a fenestrated capillary 
2184 endothelium: an ultrastructural immunocytochemical study of the choriocapillary endothelium. Am J 
2185 Anat 172, 279-289.
2186 209. Pino, R.M., Essner, E., 1981. Permeability of rat choriocapillaris to hemeproteins. Restriction of 
2187 tracers by a fenestrated endothelium. J Histochem Cytochem 29, 281-290.
2188 210. Pinto, E., 2007. Blood pressure and ageing. Postgrad Med J 83, 109-114.
2189 211. Radu, R.A., Hu, J., Jiang, Z., Bok, D., 2014. Bisretinoid-mediated complement activation on retinal 
2190 pigment epithelial cells is dependent on complement factor H haplotype. J Biol Chem 289, 9113-
2191 9120.
2192 212. Rakoczy, P.E., Sarks, S.H., Daw, N., Constable, I.J., 1999. Distribution of cathepsin D in human 
2193 eyes with or without age-related maculopathy. Exp Eye Res 69, 367-374.
2194 213. Ramrattan, R.S., van der Schaft, T.L., Mooy, C.M., de Bruijn, W.C., Mulder, P.G., de Jong, P.T., 
2195 1994. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. 
2196 Investigative ophthalmology & visual science 35, 2857-2864.
2197 214. Rayborn, M.E., Sakaguchi, H., Shadrach, K.G., Crabb, J.W., Hollyfield, J.G., 2006. Annexins in 
2198 Bruch's membrane and drusen. Adv Exp Med Biol 572, 75-78.
2199 215. Ronchetti, I., Boraldi, F., Annovi, G., Cianciulli, P., Quaglino, D., 2013. Fibroblast involvement in 
2200 soft connective tissue calcification. Front Genet 4, 22.
2201 216. Ruiz, A., Brett, P., Bok, D., 1996. TIMP-3 is expressed in the human retinal pigment epithelium. 
2202 Biochemical and biophysical research communications 226, 467-474.
2203 217. Sakaguchi, H., Miyagi, M., Shadrach, K.G., Rayborn, M.E., Crabb, J.W., Hollyfield, J.G., 2002. 
2204 Clusterin is present in drusen in age-related macular degeneration. Exp Eye Res 74, 547-549.
2205 218. Sallo, F.B., Rechtman, E., Peto, T., Stanescu-Segall, D., Vogt, G., Bird, A.C., Fitzke, F.W., 2009. 
2206 Functional aspects of drusen regression in age-related macular degeneration. The British journal of 
2207 ophthalmology 93, 1345-1350.
2208 219. Sarks, J.P., Sarks, S.H., Killingsworth, M.C., 1988. Evolution of geographic atrophy of the retinal 
2209 pigment epithelium. Eye (Lond) 2 ( Pt 5), 552-577.
2210 220. Sarks, J.P., Sarks, S.H., Killingsworth, M.C., 1994. Evolution of soft drusen in age-related macular 
2211 degeneration. Eye (Lond) 8 ( Pt 3), 269-283.
2212 221. Sarks, S.H., 1976. Ageing and degeneration in the macular region: a clinico-pathological study. 
2213 The British journal of ophthalmology 60, 324-341.
68
2214 222. Sarks, S.H., Arnold, J.J., Killingsworth, M.C., Sarks, J.P., 1999. Early drusen formation in the 
2215 normal and aging eye and their relation to age related maculopathy: a clinicopathological study. The 
2216 British journal of ophthalmology 83, 358-368.
2217 223. Sarks, S.H., Van Driel, D., Maxwell, L., Killingsworth, M., 1980. Softening of drusen and subretinal 
2218 neovascularization. Trans Ophthalmol Soc U K 100, 414-422.
2219 224. Schaumberg, D.A., Christen, W.G., Buring, J.E., Glynn, R.J., Rifai, N., Ridker, P.M., 2007. High-
2220 sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular 
2221 degeneration in women. Arch Ophthalmol 125, 300-305.
2222 225. Schlanitz, F., Baumann, B., Sacu, S., Baumann, L., Pircher, M., Hitzenberger, C.K., Schmidt-
2223 Erfurth, U.M., 2018. Impact of drusen and drusenoid retinal pigment epithelium elevation size and 
2224 structure on the integrity of the retinal pigment epithelium layer. The British journal of 
2225 ophthalmology.
2226 226. Schlieper, G., Aretz, A., Verberckmoes, S.C., Kruger, T., Behets, G.J., Ghadimi, R., Weirich, T.E., 
2227 Rohrmann, D., Langer, S., Tordoir, J.H., Amann, K., Westenfeld, R., Brandenburg, V.M., D'Haese, P.C., 
2228 Mayer, J., Ketteler, M., McKee, M.D., Floege, J., 2010. Ultrastructural analysis of vascular 
2229 calcifications in uremia. J Am Soc Nephrol 21, 689-696.
2230 227. Schunkert, H., von Scheidt, M., Kessler, T., Stiller, B., Zeng, L., Vilne, B., 2018. Genetics of 
2231 coronary artery disease in the light of genome-wide association studies. Clin Res Cardiol 107, 2-9.
2232 228. Serban, C., Dragan, S., 2014. The relationship between inflammatory and oxidative stress 
2233 biomarkers, atherosclerosis and rheumatic diseases. Curr Pharm Des 20, 585-600.
2234 229. Serhan, C.N., Dalli, J., Colas, R.A., Winkler, J.W., Chiang, N., 2015. Protectins and maresins: New 
2235 pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. 
2236 Biochim Biophys Acta 1851, 397-413.
2237 230. Shah, F.A., Lee, B.E.J., Tedesco, J., Larsson Wexell, C., Persson, C., Thomsen, P., Grandfield, K., 
2238 Palmquist, A., 2017. Micrometer-Sized Magnesium Whitlockite Crystals in Micropetrosis of 
2239 Bisphosphonate-Exposed Human Alveolar Bone. Nano Lett 17, 6210-6216.
2240 231. Simmons, R.D., Kumar, S., Thabet, S.R., Sur, S., Jo, H., 2016. Omics-based approaches to 
2241 understand mechanosensitive endothelial biology and atherosclerosis. Wiley Interdiscip Rev Syst Biol 
2242 Med 8, 378-401.
2243 232. Sivaprasad, S., Bailey, T.A., Chong, V.N., 2005. Bruch's membrane and the vascular intima: is 
2244 there a common basis for age-related changes and disease? Clin Exp Ophthalmol 33, 518-523.
2245 233. Skeie, J.M., Mahajan, V.B., 2014. Proteomic landscape of the human choroid-retinal pigment 
2246 epithelial complex. JAMA Ophthalmol 132, 1271-1281.
2247 234. Smith, S.S., Pino, R.M., Thouron, C.L., 1989. Binding and transport of transthyretin-gold by the 
2248 endothelium of the rat choriocapillaris. J Histochem Cytochem 37, 1497-1502.
2249 235. Snow, K.K., Seddon, J.M., 1999. Do age-related macular degeneration and cardiovascular disease 
2250 share common antecedents? Ophthalmic Epidemiol 6, 125-143.
2251 236. Sohn, E.H., Wang, K., Thompson, S., Riker, M.J., Hoffmann, J.M., Stone, E.M., Mullins, R.F., 2015. 
2252 Comparison of drusen and modifying genes in autosomal dominant radial drusen and age-related 
2253 macular degeneration. Retina 35, 48-57.
2254 237. Song, Y., Stampfer, M.J., Liu, S., 2004. Meta-analysis: apolipoprotein E genotypes and risk for 
2255 coronary heart disease. Ann Intern Med 141, 137-147.
2256 238. Spaide, R.F., Ooto, S., Curcio, C.A., 2018. Subretinal Drusenoid Deposits AKA Pseudodrusen. Surv 
2257 Ophthalmol.
2258 239. Spraul, C.W., Lang, G.E., Grossniklaus, H.E., Lang, G.K., 1999. Histologic and morphometric 
2259 analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with 
2260 age-related macular degeneration and histologic examination of surgically excised choroidal 
2261 neovascular membranes. Surv Ophthalmol 44 Suppl 1, S10-32.
2262 240. Starita, C., Hussain, A.A., Patmore, A., Marshall, J., 1997. Localization of the site of major 
2263 resistance to fluid transport in Bruch's membrane. Investigative ophthalmology & visual science 38, 
2264 762-767.
69
2265 241. Stefansson, E., Geirsdottir, A., Sigurdsson, H., 2011. Metabolic physiology in age related macular 
2266 degeneration. Prog Retin Eye Res 30, 72-80.
2267 242. Strauss, O., 2005. The retinal pigment epithelium in visual function. Physiol Rev 85, 845-881.
2268 243. Strunnikova, N.V., Maminishkis, A., Barb, J.J., Wang, F., Zhi, C., Sergeev, Y., Chen, W., Edwards, 
2269 A.O., Stambolian, D., Abecasis, G., Swaroop, A., Munson, P.J., Miller, S.S., 2010. Transcriptome 
2270 analysis and molecular signature of human retinal pigment epithelium. Human molecular genetics 
2271 19, 2468-2486.
2272 244. Suzuki, M., Curcio, C.A., Mullins, R.F., Spaide, R.F., 2015. REFRACTILE DRUSEN: Clinical Imaging 
2273 and Candidate Histology. Retina 35, 859-865.
2274 245. Tabas, I., Williams, K.J., Boren, J., 2007. Subendothelial lipoprotein retention as the initiating 
2275 process in atherosclerosis: update and therapeutic implications. Circulation 116, 1832-1844.
2276 246. Tas, A.C., 2000. Synthesis of biomimetic Ca-hydroxyapatite powders at 37 degrees C in synthetic 
2277 body fluids. Biomaterials 21, 1429-1438.
2278 247. Tate, D.J., Jr., Oliver, P.D., Miceli, M.V., Stern, R., Shuster, S., Newsome, D.A., 1993. Age-
2279 dependent change in the hyaluronic acid content of the human chorioretinal complex. Arch 
2280 Ophthalmol 111, 963-967.
2281 248. Templeton, J.P., Wang, X., Freeman, N.E., Ma, Z., Lu, A., Hejtmancik, F., Geisert, E.E., 2013. A 
2282 crystallin gene network in the mouse retina. Exp Eye Res 116, 129-140.
2283 249. Tessarz, P., Kouzarides, T., 2014. Histone core modifications regulating nucleosome structure 
2284 and dynamics. Nat Rev Mol Cell Biol 15, 703-708.
2285 250. Thanos, S., Bohm, M.R., Meyer zu Horste, M., Prokosch-Willing, V., Hennig, M., Bauer, D., 
2286 Heiligenhaus, A., 2014. Role of crystallins in ocular neuroprotection and axonal regeneration. Prog 
2287 Retin Eye Res 42, 145-161.
2288 251. The Eye Disease Case-Control Study, C., 1992. Risk factors for neovascular age-related macular 
2289 degeneration. Arch Ophthalmol 110, 1701-1708.
2290 252. Thompson, R.B., Reffatto, V., Bundy, J.G., Kortvely, E., Flinn, J.M., Lanzirotti, A., Jones, E.A., 
2291 McPhail, D.S., Fearn, S., Boldt, K., Ueffing, M., Ratu, S.G., Pauleikhoff, L., Bird, A.C., Lengyel, I., 2015. 
2292 Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial 
2293 deposit formation in the aging eye. Proc Natl Acad Sci U S A 112, 1565-1570.
2294 253. Tian, L., Kazmierkiewicz, K.L., Bowman, A.S., Li, M., Curcio, C.A., Stambolian, D.E., 2015. 
2295 Transcriptome of the human retina, retinal pigmented epithelium and choroid. Genomics 105, 253-
2296 264.
2297 254. Tikellis, G., Sun, C., Gorin, M.B., Klein, R., Klein, B.E., Larsen, E.K., Siscovick, D.S., Hubbard, L.D., 
2298 Wong, T.Y., 2007. Apolipoprotein e gene and age-related maculopathy in older individuals: the 
2299 cardiovascular health study. Arch Ophthalmol 125, 68-73.
2300 255. Tohyama, J., Nakashima, M., Nabatame, S., Gaik-Siew, C., Miyata, R., Rener-Primec, Z., Kato, M., 
2301 Matsumoto, N., Saitsu, H., 2015. SPTAN1 encephalopathy: distinct phenotypes and genotypes. J Hum 
2302 Genet 60, 167-173.
2303 256. Toomey, C.B., Johnson, L.V., Bowes Rickman, C., 2018. Complement factor H in AMD: Bridging 
2304 genetic associations and pathobiology. Prog Retin Eye Res 62, 38-57.
2305 257. Toops, K.A., Tan, L.X., Lakkaraju, A., 2016. Apolipoprotein E Isoforms and AMD. Adv Exp Med 
2306 Biol 854, 3-9.
2307 258. Toy, B.C., Krishnadev, N., Indaram, M., Cunningham, D., Cukras, C.A., Chew, E.Y., Wong, W.T., 
2308 2013. Drusen regression is associated with local changes in fundus autofluorescence in intermediate 
2309 age-related macular degeneration. Am J Ophthalmol 156, 532-542.e531.
2310 259. Tu, H., Okamoto, A.Y., Shan, B., 2000. FXR, a bile acid receptor and biological sensor. Trends 
2311 Cardiovasc Med 10, 30-35.
2312 260. Ulshafer, R.J., Allen, C.B., Nicolaissen, B., Jr., Rubin, M.L., 1987. Scanning electron microscopy of 
2313 human drusen. Investigative ophthalmology & visual science 28, 683-689.
2314 261. van der Schaft, T.L., de Bruijn, W.C., Mooy, C.M., Ketelaars, D.A., de Jong, P.T., 1992. Element 
2315 analysis of the early stages of age-related macular degeneration. Arch Ophthalmol 110, 389-394.
70
2316 262. van der Schaft, T.L., Mooy, C.M., de Bruijn, W.C., de Jong, P.T., 1993. Early stages of age-related 
2317 macular degeneration: an immunofluorescence and electron microscopy study. The British journal of 
2318 ophthalmology 77, 657-661.
2319 263. van Leeuwen, E.M., Emri, E., Merle, B.M.J., Colijn, J.M., Kersten, E., Cougnard-Gregoire, A., 
2320 Dammeier, S., Meester-Smoor, M., Pool, F.M., de Jong, E.K., Delcourt, C., Rodrigez-Bocanegra, E., 
2321 Biarnes, M., Luthert, P.J., Ueffing, M., Klaver, C.C.W., Nogoceke, E., den Hollander, A.I., Lengyel, I., 
2322 2018. A new perspective on lipid research in age-related macular degeneration. Prog Retin Eye Res.
2323 264. Verhoeff, F.H., Grossman, H.P., 1937. The Pathogenesis of Disciform Degeneration of the 
2324 Macula. Trans Am Ophthalmol Soc 35, 262-294.
2325 265. Vidaurri, J.S., Pe'er, J., Halfon, S.T., Halperin, G., Zauberman, H., 1984. Association between 
2326 drusen and some of the risk factors for coronary artery disease. Ophthalmologica 188, 243-247.
2327 266. Vingerling, J.R., Dielemans, I., Bots, M.L., Hofman, A., Grobbee, D.E., de Jong, P.T., 1995. Age-
2328 related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J 
2329 Epidemiol 142, 404-409.
2330 267. Wakatsuki, Y., Shinojima, A., Kawamura, A., Yuzawa, M., 2015. Correlation of Aging and 
2331 Segmental Choroidal Thickness Measurement using Swept Source Optical Coherence Tomography in 
2332 Healthy Eyes. PLoS One 10, e0144156.
2333 268. Wang, J., Gu, B.J., Masters, C.L., Wang, Y.J., 2017. A systemic view of Alzheimer disease - insights 
2334 from amyloid-beta metabolism beyond the brain. Nat Rev Neurol 13, 612-623.
2335 269. Wang, L., Clark, M.E., Crossman, D.K., Kojima, K., Messinger, J.D., Mobley, J.A., Curcio, C.A., 
2336 2010. Abundant lipid and protein components of drusen. PLoS One 5, e10329.
2337 270. Warwick, A., Khandhadia, S., Ennis, S., Lotery, A., 2014. Age-Related Macular Degeneration: A 
2338 Disease of Systemic or Local Complement Dysregulation? J Clin Med 3, 1234-1257.
2339 271. Wasmuth, S., Lueck, K., Baehler, H., Lommatzsch, A., Pauleikhoff, D., 2009. Increased vitronectin 
2340 production by complement-stimulated human retinal pigment epithelial cells. Investigative 
2341 ophthalmology & visual science 50, 5304-5309.
2342 272. Weber, B.H., Vogt, G., Pruett, R.C., Stohr, H., Felbor, U., 1994. Mutations in the tissue inhibitor 
2343 of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nature genetics 8, 352-
2344 356.
2345 273. Whitmore, S.S., Wagner, A.H., DeLuca, A.P., Drack, A.V., Stone, E.M., Tucker, B.A., Zeng, S., 
2346 Braun, T.A., Mullins, R.F., Scheetz, T.E., 2014. Transcriptomic analysis across nasal, temporal, and 
2347 macular regions of human neural retina and RPE/choroid by RNA-Seq. Exp Eye Res 129, 93-106.
2348 274. Williams, K.J., Tabas, I., 1995. The response-to-retention hypothesis of early atherogenesis. 
2349 Arterioscler Thromb Vasc Biol 15, 551-561.
2350 275. Wilson, C.J., Das, M., Jayaraman, S., Gursky, O., Engen, J.R., 2018. Effects of Disease-Causing 
2351 Mutations on the Conformation of Human Apolipoprotein A-I in Model Lipoproteins. Biochemistry.
2352 276. Wilson, M.R., Zoubeidi, A., 2017. Clusterin as a therapeutic target. Expert Opin Ther Targets 21, 
2353 201-213.
2354 277. Woodell, A., Rohrer, B., 2014. A mechanistic review of cigarette smoke and age-related macular 
2355 degeneration. Adv Exp Med Biol 801, 301-307.
2356 278. Xu, H., Chen, M., Forrester, J.V., 2009. Para-inflammation in the aging retina. Prog Retin Eye Res 
2357 28, 348-368.
2358 279. Xu, Q., Cao, S., Rajapakse, S., Matsubara, J.A., 2018. Understanding AMD by analogy: systematic 
2359 review of lipid-related common pathogenic mechanisms in AMD, AD, AS and GN. Lipids Health Dis 17, 
2360 3.
2361 280. Yang, J., Xu, Z., Sui, M., Han, J., Sun, L., Jia, X., Zhang, H., Han, C., Jin, X., Gao, F., Liu, Y., Li, Y., 
2362 Cao, J., Ling, H., Zhang, F., Ren, H., 2015. Co-Positivity for Anti-dsDNA, -Nucleosome and -Histone 
2363 Antibodies in Lupus Nephritis Is Indicative of High Serum Levels and Severe Nephropathy. PLoS One 
2364 10, e0140441.
2365 281. Yehoshua, Z., Wang, F., Rosenfeld, P.J., Penha, F.M., Feuer, W.J., Gregori, G., 2011. Natural 
2366 history of drusen morphology in age-related macular degeneration using spectral domain optical 
2367 coherence tomography. Ophthalmology 118, 2434-2441.
71
2368 282. Young, R.W., 1987. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 31, 
2369 291-306.
2370 283. Yuan, X., Gu, X., Crabb, J.S., Yue, X., Shadrach, K., Hollyfield, J.G., Crabb, J.W., 2010. Quantitative 
2371 proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular 
2372 degeneration and normal eyes. Mol Cell Proteomics 9, 1031-1046.
2373 284. Zamiri, P., Masli, S., Streilein, J.W., Taylor, A.W., 2006. Pigment epithelial growth factor 
2374 suppresses inflammation by modulating macrophage activation. Investigative ophthalmology & visual 
2375 science 47, 3912-3918.
2376 285. Zhang, J.J., Sun, Y., Hussain, A.A., Marshall, J., 2012. Laser-mediated activation of human retinal 
2377 pigment epithelial cells and concomitant release of matrix metalloproteinases. Investigative 
2378 ophthalmology & visual science 53, 2928-2937.
2379 286. Zhang, P., Dufresne, C., Turner, R., Ferri, S., Venkatraman, V., Karani, R., Lutty, G.A., Van Eyk, J.E., 
2380 Semba, R.D., 2015a. The proteome of human retina. Proteomics 15, 836-840.
2381 287. Zhang, P., Kirby, D., Dufresne, C., Chen, Y., Turner, R., Ferri, S., Edward, D.P., Van Eyk, J.E., 
2382 Semba, R.D., 2016. Defining the proteome of human iris, ciliary body, retinal pigment epithelium, and 
2383 choroid. Proteomics 16, 1146-1153.
2384 288. Zhang, Y., Wen, Z., Guan, L., Jiang, P., Gu, T., Zhao, J., Lv, X., Wen, T., 2015b. Extracellular 
2385 histones play an inflammatory role in acid aspiration-induced acute respiratory distress syndrome. 
2386 Anesthesiology 122, 127-139.
2387 289. Zhang, Z., Chen, X.Y., Baum, L., Ng, H.K., Mok, V., Wong, K.S., 2018. Association Between the 
2388 Apolipoprotein E Gene Polymorphism and Atherosclerotic Middle Cerebral Artery Stenosis. 
2389 Neurologist 23, 47-50.
2390 290. Zheng, W., Mast, N., Saadane, A., Pikuleva, I.A., 2015. Pathways of cholesterol homeostasis in 
2391 mouse retina responsive to dietary and pharmacologic treatments. J Lipid Res 56, 81-97.
2392 291. Zweifel, S.A., Spaide, R.F., Curcio, C.A., Malek, G., Imamura, Y., 2010. Reticular pseudodrusen are 
2393 subretinal drusenoid deposits. Ophthalmology 117, 303-312.e301.
2394
72
2395 Legends to Figures and (S)Tables.
2396 Figure legends:
2397
2398 Figure 1. Heterogeneity of drusen. Imaging of drusen and drusen content with various 
2399 clinical and laboratory methods. On color fundus images, the yellow spots identify 
2400 drusen (A). On OCT image the elongated RPE is reflective. Drusen appear as 
2401 homogeneous and hyper-reflective sub-RPE-BL space focal entities. (B); scale bar: 500 
2402 µm. On hematoxylin-eosin staining, drusen appears between the brown pigments of the 
2403 RPE and the Bruch’s membrane (C); scale bar: 10 µm. Note the inclusions without 
2404 staining. Drusen contain numerous von Kossa positive spherule structures identifying 
2405 hydroxyapatite spherules (D); scale bar: 10 µm. Auto-fluorescence of the more or less 
2406 circular drusen is indicative of the protein and lipid accumulation. Auto-fluorescence of 
2407 the RPE is more intense and yellowish. Auto-fluorescence of the BrM adjacent to the RPE 
2408 is greenish (E); scale bar: 10 µm.
2409
2410 Figure 2 a-d. Functional molecular network analysis (4 networks). For all four networks: 
2411 Molecular network analysis of physical or functional interactions between 89 drusen 
2412 genes/proteins using Ingenuity. The knowledge database generated four most likely 
2413 functional networks from the given input (drusen proteins). The functionalities in the 
2414 figures are generated based on a combination of available molecular and cellular 
2415 experimental data in human, mouse, rat, and in vitro data. In each network the circles, 
2416 squares and other symbols represent proteins from a homologue from either human, rat 
2417 or mouse. The systematic name of the gene/protein is printed on each symbol. Double 
2418 circles in a single symbol denotes a group or /family of entries with a specific function 
2419 and are sometimes introduced by the knowledge database to make networks possible or 
2420 to simplify them. Solid lines represent strong physical or functional interaction between 
2421 the entries, taken from published peer reviewed literature and/or transcriptomics and 
2422 proteomics databases. Dotted lines represent weaker, associated relationships between 
2423 the genes/proteins based on published peer reviewed experimental data (for example 
2424 co-upregulation of expression in an in vitro experiment). The lines represent thus 
2425 functionalities found in either, both, or all experiments on human, rat or mice (tissues) 
2426 and in vitro findings. For example, the functional relationship between molecules A, B, C, 
2427 could possibly be defined as follows A-functional mouse finding-B-functional human 
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2428 finding-C. The underlying hypothesis is that the functionalities in human, mouse and rat 
2429 are very similar. One can also generate networks of human (or rat or mice) functional 
2430 data separately, but they are frequently quite similar, but less extensive.
2431 In the first network (Figure 2a), clearly three functional clusters of closely related 
2432 entries can be recognized: The complement cluster, the collagen cluster and the 
2433 crystallin cluster.  The second network (Figure 2b) is much more complicated and 
2434 heterogeneous and is a network of genes and proteins related to development and 
2435 genetic or ophthalmic disorders. The common theme of the third network (Figure 2c) is 
2436 the immune response. Finally, the fourth and last network (Figure 2d) presents 
2437 functional and structural relationships between entries involved in cell-cell interactions 
2438 and systemic involvement.
2439
2440 Figure 3. Schematic overview of various strategies used for dataset curation.  This figure 
2441 shows several ways to curate (pre-existing) transcriptomics or proteomics datasets to 
2442 form an improved, thorough or more specific dataset. For example, in (A) several 
2443 datasets are merged into a cumulative new one by simply combining the datasets. The 
2444 possible overlap is counted only once in the new merged database. One dataset was 
2445 deleted, because it did not adhere to quality standard or had a different signature as the 
2446 other ones. Strategy (B) has been published before (Booij et al., 2010b). In this case the 
2447 original enriched RPE database contains 10% of the highest expressed genes in the cell. 
2448 Some of the expressed genes in the RPE10% dataset overlap with the genes expressed in 
2449 the adjacent tissues (photoreceptors and/or choroid). These “overlapping expressed 
2450 genes” are therefore not specific of the RPE. Thus, to obtain a more specific (smaller) 
2451 dataset, we discard of all the “overlapping expressed genes” in the RPE dataset, to obtain 
2452 a highly enriched RPE dataset. Curation strategy C shows the breakdown of two datasets 
2453 into desired subfamilies: The overlap between datasets X and Z is Y.  Dataset Y can be 
2454 used if overlap between X and Z is desired. Dataset X minus Y can be used to obtain 
2455 unique entries from X (compared to set Z).
2456
2457 Figure 4. Scheme of the relationships between the respective transcriptomic and 
2458 proteomic datasets used for quantitative studies. The curated drusen protein dataset 
2459 represents 89 proteins known to be present in drusen/sub-RPE-BL space deposits 
2460 (black box in the middle). These were compared with the entries present or produced 
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2461 uniquely from the neural side of drusen (photoreceptor/RPE neural source), and with 
2462 entries uniquely from the systemic side of drusen (blood /choroid basal source).
2463 The “neural source” and “systemic source” merged data-sets each consist of non-curated 
2464 datasets and curated datasets.  The non-curated (pure) dataset contain, by virtue of their 
2465 nature or previous curation in the literature) only entries from, respectively, the neural 
2466 (RPE-ST; RPE-IVS) and systemic side (BL-SP1; BL-SP2) of drusen. The curated datasets 
2467 (cPRos; cPR-ET and cChor-ET)) contained, before curation, a number of entries 
2468 expressed/present in both the neural and systemic side (see PRos; PR-ET and Chor-ET). 
2469 Thus, we removed all overlapping expressed genes between the PRos; PR-ET and Chor-
2470 ET datasets, to obtain unique datasets from both sides of drusen.
2471
2472 Figure 5. Potential contribution of neural and systemically expressed/present proteins 
2473 to drusen formation. Venn diagram showing overlap between (A) neural RPE and 
2474 photoreceptor-derived proteins, (B) systemically derived choroid and blood proteins 
2475 and (C) drusen-associated proteins. 
2476
2477 Figure 6. Hydroxyapatite spherules can retain proteins originating from blood in the 
2478 sub-RPE-BL space. (A) Immunocytochemical labelling of histidine-rich glycoprotein 
2479 (HRG) using a specific anti-HRG primary antibody (green) on the surface of a HAP 
2480 spherule labelled by LiCor680 (magenta); scale bar: 10 µm. (B) Binding of purified 
2481 human HRG to HAP-coated magnetic beads. Binding assays were performed using 0.3 
2482 mg beads per sample. HAP-beads were washed with 50 mM Tris, 140 mM NaCl, pH 7.4 
2483 and incubated with 400 µl of 0-1µM human HRG for an hour at room temperature. The 
2484 protein-bound beads were washed with the same buffer twice followed by blocking with 
2485 1% BSA for an hour. Rabbit anti-human HRG antibody (1:1000 dilution) and HRP-
2486 conjugated anti-rabbit antibody (1:10000 dilution) were respectively used as primary 
2487 and secondary antibodies. Detection was done at 492 nm using o-phenylenediamine 
2488 dihydrochloride (OPD, Sigma Aldrich) substrate.
2489
2490 Figure 7. A model for drusen formation. Top row (A-E) is adopted from the schematic 
2491 diagram proposed for sub-RPE-BL space deposit formation by Thompson and colleagues 
2492 (Thompson et al., 2015). (A) Healthy eyes show no sub-RPE-BL space deposit formation. 
2493 (B) At Stage 1 lipid droplets are retained in the sub-RPE-BL space (black dot). (C) At 
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2494 Stage 2 mineralization occurs surrounding the lipid droplets (magenta ring). (D) At 
2495 Stage 3 proteins bind to the HAP surfaces (blue ring). (E) At Stage 4 proteins and lipids 
2496 start accumulating around the “seed” (yellow material). The bottom row (A’-E’) shows 
2497 morphological evidence for the prediction in the top row. (A’) Retinal pigment 
2498 epithelium forms a monolayer along the inner collagenous layer of the Bruch’s 
2499 membrane in healthy eyes (scanning electron microscopic image); scale bar: 10 µm. (B’) 
2500 Transmission electron micrograph of lipid droplets that accumulate in the sub-RPE-BL 
2501 space; reproduced with permission from Curcio and Millican (Curcio and Millican, 
2502 1999); scale bar: 2 µm.  (C’) Scanning electron microscopic identification of a single 
2503 spherule located between the RPE basement membrane and the inner collagenous layer 
2504 of Bruch’s membrane; scale bar: 2 µm. (D’) Immunofluorescent labelling of HRG (green) 
2505 on the surface of a HAP spherule (magenta); scale bar: 2 µm. (E’) An immunofluorescent 
2506 labelling of complement factor H on a spherule surrounded by the autofluorescence of 
2507 drusen (green) and RPE cells (yellow) (blue is DAPI staining the cell nuclei); scale bar: 
2508 10 µm.
2509
2510 Figure 8. Schematic showing factors that are identified to contribute to mineralization of 
2511 soft tissues and may contribute to HAP deposition in the sub-RPE-BL space. 
2512 Abbreviations: ABCC6, ATP binding cassette subfamily C member 6; ANKH, ankylosis 
2513 protein homolog; ATP, adenosine triphosphate; BrMP2, bone morphogenetic protein-2; 
2514 BrMP2R, bone morphogenetic protein-2 receptor; BSP, bone sialoprotein; Ca, calcium; 
2515 Cbfa-1, core-binding factor alpha-1; ENPP1, ectonucleotide 
2516 pyrophosphatase/phosphodiesterase; Glu- and Gla-MGP, uncarboxylated- and 
2517 carboxylated-matrix Gla protein; OPG, osteoprotegerin; OPN, osteopontin; Pi, inorganic 
2518 phosphate; Pit-1, phosphate transporter-1; PPi, pyrophosphate; RANKL, receptor 
2519 activator of nuclear factor kappa-B ligand; TNAP, tissue non-specific alkaline 
2520 phosphatase. Figure adapted from (Ronchetti et al., 2013).
2521
2522 Figure 9. Proteins present in atherosclerotic plaques and drusen. A. Venn diagram 
2523 showing 64 out of 89 drusen proteins overlap with the atherosclerotic plaque proteome, 
2524 while 25 entries are unique to drusen in this comparison.  B. Venn diagram showing 50 
2525 out of 60 proteins (from the 89 drusen proteins) that come from blood (as unique 
2526 source or shared with the PR/RPE) are actually present in atherosclerotic plaques. C. 
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2527 Venn diagram displaying the uniqueness and overlap of proteins between drusen (C.A), 
2528 Alzheimer plaque proteins (C.B.)  and atherosclerotic plaque proteins (C.C). The 
2529 corresponding STable 11 and STable 11a present the corresponding entries in detail.
2530
2531 Table Legends:
2532
2533 Table 1. List of proteins present in the curated drusen dataset. We assembled a list of 89 
2534 drusen proteins, mostly derived from the macular area, from the literature. For each 
2535 entry the Gene symbol, Entrez gene name, location and type, human 
2536 immunohistochemistry source and literature references are provided based on 
2537 information found via the Ingenuity knowledge database (Qiagen, all rights reserved), 
2538 relevant literature (PubMed searches) and other public databases, such as Genecard 
2539 (www.genecard.org) and DAVID (https://david.ncifcrf.gov/)
2540 Crabb 2002 (Crabb et al., 2002); Wang 2002 (Wang et al., 2010); Entries with *: although 
2541 assigned to drusen by proteomics, IHC studies suggest a more likely protein location 
2542 around or directly external from drusen. Further detailed investigation is warranted for 
2543 these entries. **First detected in cynomolgus monkeys, afterwards in human drusen.
2544
2545 Table 2. Summary of Ingenuity knowledge database core analysis of 89 proteins present 
2546 in the curated drusen protein dataset. Summary of enriched motifs present in the 
2547 dataset presented as top disease and biological functions, canonical pathways and 
2548 discrete molecular networks. Note that these functional annotations types relate to 
2549 either cellular (LRX/RXR/FXR activation; macrophages) or systemic (acute phase, 
2550 atherosclerosis) entities. In the top disease and biological functions, we see that the 
2551 dataset is enriched for hereditary disorders, ophthalmic disease, injury, metabolic 
2552 diseases and developmental disorders. Finally, in the top functional or structural 
2553 molecular networks, we find combinations of very basic functions (cancer and cellular) 
2554 to more specific pathobiological ones (ophthalmic and neurological disease etc.
2555
2556 Table 3. Summary of datasets used in this study and their respective functional clusters. 
2557 Table displaying various datasets used in this study, along with their characteristics. In 
2558 the first column, the result of the Ingenuity network analysis of drusen proteins is given 
2559 in 4 significant molecular networks (N=1-4) corresponding to the networks shown in 
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2560 Figure 2a-2d. Within these networks, six functional molecule clusters can be observed. 
2561 For example, Network 1 (N1) contains 3 functional clusters: the complement (Network 
2562 1. cluster 1), the collagen (1.2) and the crystallines (heatshock) (1.3). Network 2 consist 
2563 of 1 large cluster (2.4) being genetic and developmental ophthalmic disorders. Network 
2564 3 can be viewed as a cluster (# 5) of injury and inflammatory response and 
2565 dermatological disease. Network 4 (N4) contains a cluster (4.6) of cell-to cell-signaling 
2566 and systemic involvement. Column B gives the actual gene/protein names in these 
2567 clusters. Column C states the overall functional annotation of these clusters. The first 
2568 row of the Table from column D onward states the compartment of the datasets to be 
2569 compared with drusen proteins in the functional clusters (within brackets, the number 
2570 of entire in each dataset are given). In row 2 (acronym) from column D onward, the 
2571 short and systematic acronym of each dataset is given. Row 3 (reference) contains from 
2572 column D onward, the reference where the dataset can be found. Row 4 (methodology), 
2573 from column D onward, contains the method by which the data were generated 
2574 (transcriptomics, proteomics). Row five (source), from column D onward, contains the 
2575 primary author who submitted the data or who can be contacted to obtain further 
2576 information. The remaining boxes contains information which entries of the functional 
2577 cluster are present both in drusen as well as in the transcriptomics or proteomics 
2578 dataset(s).  Combined analysis of the clusters in different datasets gives a qualitative 
2579 idea from which cell type(s) drusen protein are derived. 
2580
2581 Table 4. Summary of Ingenuity knowledge database core analysis of the curated 
2582 photoreceptor gene expression (cPR-ET) dataset. Functional annotation of the curated 
2583 and highly enriched photoreceptor cPR-ET database using the ingenuity knowledge 
2584 database. The data driven top canonical pathways are highly relevant for photoreceptor 
2585 function:  Phototransduction pathway, glutamate receptor signaling, cholesterol 
2586 biosynthesis and Wnt/Ca2+ signaling.  The only surprise in our data-driven analysis 
2587 could be the Huntinton disease signaling pathway. However, it has recently become 
2588 clear that in Huntington’s disease (HD), an inherited neurodegenerative disorder 
2589 resulting in motor disturbances, cognitive and behavioral changes, deficits in retinal and 
2590 visual processing function are significantly present (Coppen et al., 2018). Although we 
2591 curated the PR database quite extensively, and thus selected for specific photoreceptor 
2592 molecular signature and function, it is interesting to see that these motifs occur also in a 
78
2593 number of other (top) diseases and functions, such as cancer, organismal injury, 
2594 gastrointestinal disease, Hepatic disease and reproductive system disease. This may 
2595 reflect the accumulating evidence that a substantial number of genetic or metabolic 
2596 disease are also affect photoreceptor function. Similar to the canonical pathways and the 
2597 biological motifs, the functional annotation of the photoreceptor selected molecular 
2598 machinery apparently reflects a broad spectrum of biological and disease processes.
2599
2600 Table 5. Summary of Ingenuity knowledge database core analysis of the curated choroid, 
2601 cChor-ET datasets. In this Table, we present the summary of the functional annotation of 
2602 the choroid. Of course, the choroid is not a single tissue, but contains multiple cell types 
2603 (endothelial cells, fibroblasts, macrophages, etc.) and the sample is inevitably 
2604 contaminated with the blood. Within these limitations, data driven analysis of this 
2605 specifically curated data set yielded a number of interesting enriched motifs, which 
2606 indeed can be contributed to the choroid or blood: The canonical pathways indicate 
2607 enriched immunological themes, such as the complement system, acute phase response 
2608 signaling, and antigen-presenting cells, which is confirmed by several biological motifs 
2609 (inflammatory disease and response, injury). Further, the canonical pathways generated, 
2610 suggest an overlap between the molecular machinery of the choroid and atherosclerosis 
2611 signaling. Indeed, in this manuscript, we devoted a whole section (8) to the 
2612 pathobiological and molecular similarities                                                                                                                                                                               
2613 between drusen and atherosclerotic plaques, and their –in time-associated diseases: 
2614 AMD and atherosclerosis. Finally, a homology between hepatic function and choroid was 
2615 observed. Indeed, there are a number of reports in the literature of cross-talk between 
2616 liver and choroidal function, but that potential relationship remains to be elucidated. 
2617 The final biological motifs are cancer and connective tissue disorders. Cancer, is of 
2618 course very broad and frequently relates to blood vessel metabolism or (abnormal) cell 
2619 division, while the connective tissue motif may relate to the action of local fibroblasts. 
2620 The choroidal networks, show, again a very broad spectrum of molecular interactions, 
2621 but this spectrum is quite distinct from the functional annotation of the photoreceptor 
2622 networks presented in Table 5.
2623
2624 Table 6. Drusen proteins expressed or present in the PR/RPE and their characteristics. 
2625 Overview and characteristics of ten drusen proteins, which most likely originate from 
79
2626 the neural side of drusen (namely PR and Chor). In the first column (A), general used 
2627 abbreviations (according Gen bank) for gene/protein names are given. In column B, C, D 
2628 respectively systematic Entrez number, cellular location and protein type corresponding 
2629 to these proteins are presented. Column E and F contain the amino acid (aa) size and 
2630 Molecular weight (Mw) of the proteins. Further the isoelectric point (pI; column G), the 
2631 number of negative and positive charged aa residues (column H), the protein instability 
2632 Index number (column I); the Alipathic index for solubility (J), and the GRAVY 
2633 (hydrophobicity and hydrophilicity index). These are all standard characteristic of 
2634 proteins which can be found in the Ingenuity database (Qiagen all right reserved) and 
2635 public databases such as DAVID, (https://david.ncifcrf.gov), SWISS-prot 
2636 (https://www.ebi.ac.uk/uniprot), Genecards (www.genecard.org) and/or the data 
2637 shows that these entries apparently do not have specific characteristics, except perhaps 
2638 for their ability to interact with one another, that could explain why they would get 
2639 stuck in BrM as a drusen protein.  We conclude that, if it is not the proteins that explain 
2640 this, it must be the structure of BrM.
2641
2642 Supplementary Table Legends:
2643
2644 Table S1. List of 276 proteins present in the RPE-IVS dataset. For each entry the gene 
2645 symbol, Entrez gene name, location and type are provided based on information found 
2646 in the Ingenuity knowledge database.
2647
2648 Table S2. List of 170 proteins present in the RPE-ST dataset. For each entry the gene 
2649 symbol, Entrez gene name, location and type are provided based on information found 
2650 in the Ingenuity knowledge database.
2651
2652 Table S3. List of 412 proteins present in the Pros-EP dataset. For each entry the gene 
2653 symbol, Entrez gene name, location and type are provided based on information found 
2654 in the Ingenuity knowledge database.
2655
2656 Table S4. List of 995 proteins present in the BLP-SP1 dataset. For each entry the gene 
2657 symbol, Entrez gene name, location and type are provided based on information found 
2658 in the Ingenuity knowledge database.
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2659
2660 Table S5. List of 262 HAP binding proteins in the BL-PHP blood proteome dataset.  For 
2661 each entry the gene symbol, Entrez gene name, location and type are provided based on 
2662 information found in the Ingenuity knowledge database.
2663
2664 Table S6. List of 754 expressed genes present in the cPR-ET dataset. For each entry the 
2665 gene symbol, Entrez gene IDs for human and mouse are provided.
2666
2667 Table S7. List of 848 expressed genes present in the cChor-ET dataset. For each entry the 
2668 gene symbol, Entrez gene IDs for human and mouse are provided.
2669
2670 Table S8. Annotation of 37 drusen proteins (out of 89) that may uniquely originate from 
2671 the blood. For each entry, the gene symbol. Entrez gene IDs for human and mouse are 
2672 presented.
2673
2674 Table S8a Functional annotation of 37 drusen proteins that may originate from the 
2675 blood. Combinations of genes/proteins in this group makes up specific functional 
2676 categories associated with biological function or disease.
2677
2678 Table S9. Annotation of 23 drusen proteins that may originate either from the neural or 
2679 from the systemic side, using Ingenuity. For each entry its functional category, specific 
2680 associated disease or function, p-value, gene names of associated proteins and number 
2681 of proteins in each category are provided. 
2682
2683 Table S9a Functional annotation of 23 drusen proteins that may originate from either 
2684 the neural or the systemic side of drusen using Ingenuity. Combinations of 
2685 genes/proteins in this group makes up specific functional categories associated with 
2686 biological function or disease.
2687
2688 Table S10 Annotation of 19 drusen proteins of unclear origin. Entrez gene IDs for human 
2689 and mouse are presented.
2690
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2691 Table S10a Functional annotation of 19 drusen proteins of unclear origin using 
2692 Ingenuity. For each entry its functional category, specific associated disease or function, 
2693 p-value, gene names of associated proteins and number of proteins in each category are 
2694 provided.
2695
2696 Table S11 List of 64 proteins common to both drusen and atherosclerotic plaques. For 
2697 each entry, the gene symbol and Entrez Gene IDs for human and mouse and are 
2698 provided.
2699
2700 Table S11a Functional annotation of 64 proteins common to both drusen and 
2701 atherosclerotic plaques. For each entry its functional category, specific associated 
2702 disease or function, p-value, gene names of associated proteins and number of proteins 
2703 in each category are provided.
2704
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2706
2707
2708
2709
2710
2711
2712
2713
2714
2715
2716
2717
2718
2719
2720
2721
2722
2723 Next page : Table 1: 89 drusen proteins used in this study.
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ID/Symbol Entrez Gene Name Location Type(s) Source Human IHC refACTB Actin beta Cytoplasm other (Crabb et al., 2002)  ACTN1 Actinin alpha 1 Cytoplasm transcription regulator (Crabb et al., 2002)  ALB Albumin Extracellular Space transporter (Crabb et al., 2002) (Hollyfield et al., 2003)ALDH1A1 Aldehyde dehydrogenase 1 family, A1 Cytoplasm enzyme (Crabb et al., 2002)  AMBP Alpha-1-microglobulin/bikufinbulin 5 drusennin precursor Extracellular Space transporter (Crabb et al., 2002)  ANXA1 Annexin A1 Plasma Membrane enzyme (Crabb et al., 2002) (Rayborn et al., 2006)ANXA2 Annexin A2* Plasma Membrane other (Crabb et al., 2002) (Crabb et al., 2002)*ANXA5 Annexin A5 Plasma Membrane transporter (Crabb et al., 2002)  ANXA6 Annexin A6 Plasma Membrane ion channel (Crabb et al., 2002) (Crabb et al., 2002); (Rayborn et al., 2006)APCS Amyloid P component, serum Extracellular Space other (Crabb et al., 2002) (Mullins et al., 2000)APOA1 Apolipoprotein A1 Extracellular Space transporter (Crabb et al., 2002) (Mullins et al., 2000)APOA4 Apolipoprotein A4 Extracellular Space transporter (Crabb et al., 2002)  APOE Apolipoprotein E Extracellular Space transporter (Crabb et al., 2002) (Mullins et al., 2000)ATP5A1 ATP synth., H+ transp., mitochondr. F1 compl., alpha sub. 1, cardiac muscle Cytoplasm transporter (Crabb et al., 2002)  ATP5B ATP synth., H+ transp., mitochondr. F1 compl., beta pp Cytoplasm transporter (Wang et al., 2010)  BFSP1 Beaded filament structural protein 1 Cytoplasm enzyme (Crabb et al., 2002)  BFSP2 Beaded filament structural protein 2 Cytoplasm other (Crabb et al., 2002)  BGN Biglycan Extracellular Space other (Crabb et al., 2002)  
83
C7 Complement C7 Extracellular Space other (Crabb et al., 2002)  C8A Complement C8 alpha chain Extracellular Space other (Crabb et al., 2002) (Wang et al., 2010)C8B Complement C8 beta chain Extracellular Space other (Crabb et al., 2002) (Wang et al., 2010)C8G Complement C8 gamma chain Extracellular Space transporter (Crabb et al., 2002) (Wang et al., 2010)CFH Complement factor H Extracellular Space other (Wang et al., 2010) (Arya et al., 2018)CKB Creatine kinase B Cytoplasm kinase (Crabb et al., 2002)  CLU Clusterin Cytoplasm other (Crabb et al., 2002) (Sakaguchi et al., 2002)COL1A2 Collagen type I alpha 2 chain Extracellular Space other (Crabb et al., 2002) (Newsome et al., 1987)COL6A1 Collagen type VI alpha 1 chain Extracellular Space other (Crabb et al., 2002)  COL6A2 Collagen type VI alpha 2 chain Extracellular Space other (Crabb et al., 2002)  COL8A1 Collagen type VIII alpha 1 chain Extracellular Space other (Crabb et al., 2002)  CRYAB Crystallin alpha B* Nucleus other (Crabb et al., 2002) (De et al., 2007)*CRYBA1 Crystallin beta A1 Other other (Crabb et al., 2002)  CRYBA4 Crystallin beta A4 Other other (Crabb et al., 2002)  CRYBB1 Crystallin beta B1 Other other (Crabb et al., 2002)  CRYBB2 Crystallin beta B2 Other other (Crabb et al., 2002)  CRYGB Crystallin gamma B Nucleus other (Crabb et al., 2002)  CRYGC Crystallin gamma C Cytoplasm other (Crabb et al., 2002)  CRYGD Crystallin gamma D Cytoplasm other (Crabb et al., 2002)  CRYGS Crystallin gamma S Other other (Crabb et al., 2002)  CTSD Cathepsin D* Cytoplasm peptidase (Crabb et al., 2002) (Rakoczy et al., 1999)*
84
DIP2C Disco interacting protein 2 homolog C Other other (Crabb et al., 2002)  EFEMP1 EGF containing fibulin like ECM protein 1 Extracellular Space enzyme (Crabb et al., 2002)  ELN Elastin* Extracellular Space other (Crabb et al., 2002)*ENO2 Enolase 2 Cytoplasm enzyme (Wang et al., 2010)  FBLN5 Fibulin 5 Extracellular Space other (Crabb et al., 2002) (Mullins et al., 2000)FGG Fbrinogen gamma chain Extracellular Space other (Crabb et al., 2002) (Mullins et al., 2000)FHAD1 Forkhead ass.phosphopept.bind. dom. 1 Other other (Wang et al., 2010)  FN1 Fibronectin 1 Extracellular Space enzyme (Crabb et al., 2002) (Newsome et al., 1987)FRZB Frizzled-related protein Extracellular Space other (Crabb et al., 2002)  GAPDH Glyceraldehyde-3-phosphate dehydrogenase Cytoplasm enzyme (Crabb et al., 2002)  GPNMB Glycoprotein nmb Plasma Membrane enzyme (Crabb et al., 2002)  HIST1H1E Histone cluster 1 H1 family member e Nucleus other (Crabb et al., 2002)  HIST1H2BJ Histone cluster 1 H2B family member j Nucleus other (Crabb et al., 2002)  HIST1H2BL Histone cluster 1 H2B family member l Nucleus other (Crabb et al., 2002)  HIST2H2BE Histone cluster 2 H2B family member e Nucleus other (Crabb et al., 2002)  HLA-DRA Major histocompatibility complex, class II, DR alpha Plasma Membrane transmembrane receptor (Wang et al., 2010)  HRG Histidine rich glycoprotein Extracellular Space other (Kobayashi et al., 2014)** Figure 6 and 7 (this study)LAMB2 Laminin subunit beta 2 Extracellular Space enzyme (Crabb et al., 2002) (Newsome et al., 1987)
85
LTF Lactotransferrin Extracellular Space peptidase (Crabb et al., 2002)  LUM Lumican Extracellular Space other (Crabb et al., 2002)  MFAP4 Microfibril associated protein 4 Extracellular Space other (Crabb et al., 2002)  MYH9 Myosin heavy chain 9 Cytoplasm enzyme (Crabb et al., 2002)  OGN Osteoglycin Extracellular Space growth factor (Crabb et al., 2002)  ORM1 Orosomucoid 1 Extracellular Space other (Crabb et al., 2002)  PLG Plasminogen Extracellular Space peptidase (Crabb et al., 2002)  PRDX1 peroxiredoxin 1 Cytoplasm enzyme (Crabb et al., 2002)  PRELP Pro, Arg rich end Leu rich repeat protein Extracellular Space other (Crabb et al., 2002)  PSMB5 Proteasome subunit beta 5 Cytoplasm peptidase (Crabb et al., 2002)  RBP3 Retinol binding protein 3 Extracellular Space transporter (Crabb et al., 2002)  RDH5 Retinol dehydrogenase 5 Cytoplasm enzyme (Wang et al., 2010)  RGR Retinal G protein coupled receptor Plasma Membrane G-protein coupled recept. (Crabb et al., 2002)  RNASE4 Ribonuclease A family member 4 Extracellular Space enzyme (Crabb et al., 2002)  S100A7 S100 calcium binding proteA7 Cytoplasm other (Crabb et al., 2002) (Crabb et al., 2002)S100A8 S100 calcium binding protein A8 Cytoplasm other (Crabb et al., 2002) (Crabb et al., 2002)S100A9 S100 calcium binding protein A9 Cytoplasm other (Crabb et al., 2002) (Crabb et al., 2002)SAA1 Serum amyloid A1 Extracellular Space transporter (Crabb et al., 2002)  SCARB2 Scavenger receptor class B member 2 Plasma Membrane other (Wang et al., 2010)  
86
SEMA3B Semaphorin 3B Extracellular Space other (Crabb et al., 2002)  SERPINA1 Serpin family A member 1 Extracellular Space other (Crabb et al., 2002)  SERPINA3 Serpin family A member 3 Extracellular Space other (Crabb et al., 2002)  SERPINF1 Serpin family F member 1 Extracellular Space other (Crabb et al., 2002)  SPP2 Secreted phosphoprotein 2 Extracellular Space other (Crabb et al., 2002)  SPTAN1 Spectrin alpha, non-erythrocytic 1 Plasma Membrane other (Crabb et al., 2002)  THBS4 Thrombospondin 4 Extracellular Space other (Crabb et al., 2002)  TIMP3 TIMP metallopeptidase inhibitor 3* Extracellular Space other (Crabb et al., 2002) (Kamei and Hollyfield, 1999)* TNC Tenascin C Extracellular Space other (Crabb et al., 2002)  TUBA1C Tubulin alpha 1c Cytoplasm other (Crabb et al., 2002)  TUBB3 Tubulin beta 3 class III Cytoplasm other (Crabb et al., 2002)  TYRP1 Tyrosinase related protein 1 Cytoplasm enzyme (Crabb et al., 2002)  VIM Vimentin* Cytoplasm other (Crabb et al., 2002) (Johnson et al., 2003)*
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Ingenuity Pathway Analysis (IPA). Table 2.
Analysis Name: Table 2 Functional annotation 89 drusen proteins 
Bergen et al.09:05 AM Analysis Creation Date: 2018-05-02
Build version: 470319M
Content version: 43605602 (Release Date: 2018-03-28)
Top Canonical Pathways
Name p-value Overlap
Acute Phase Response Signaling 7,51E-15 8,2 % 14/170
LXR/RXR Activation 2,29E-12 9,1 % 11/121
FXR/RXR Activation 9,39E-11 7,9 % 10/126
Atherosclerosis Signaling 2,35E-09 7,1 % 9/127
IL-12 Signaling and Production in Macrophages 1,42E-07 5,5 % 8/146
Top Diseases and Bio Functions
Diseases and Disorders
Name
Hereditary Disorder
p-value 
1,04E-04 - 3,14E-19
#Molecules 
51
Ophthalmic Disease 1,04E-04 - 3,14E-19 37
Organismal Injury and Abnormalities 1,19E-04 - 3,14E-19 88
Metabolic Disease 9,39E-05 - 4,75E-14 47
Developmental Disorder 1,04E-04 - 9,87E-14 34
Molecular and Cellular Functions
Name
Cellular Movement
p-value 
1,18E-04 - 2,86E-16
#Molecules 
44
(c) 2000-2018 QIAGEN. All rights reserved. 2
 Summary of Analysis - Table 2 Final annotation 89 drusen proteins 2018 - 2018-05-02 09:05 AM 
Cell-To-Cell Signaling and Interaction 1,18E-04 - 1,74E-12 43
Lipid Metabolism 9,71E-05 - 1,02E-10 27
Molecular Transport 1,09E-04 - 1,02E-10 33
Small Molecule Biochemistry 9,71E-05 - 1,02E-10 27
Physiological System Development and Function
Name
Embryonic Development
p-value 
1,04E-04 - 3,33E-17
#Molecules 
30
Nervous System Development and Function 1,04E-04 - 3,33E-17 31
Organ Development 1,04E-04 - 3,33E-17 25
Organismal Development 1,04E-04 - 3,33E-17 53
Tissue Development 1,08E-04 - 3,33E-17 52
  Top Networks
ID Associated Network Functions Score
1.Cancer, Connective Tissue Disorders, Organismal Injury and Abnormalities 44
2.Developmental Disorder, Ophthalmic Disease, Organismal Injury and Abnormalities 30
3.Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Lipid Metabolism 27
4.Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Neurological Disease 25
5. Neurological Disease, Infectious Diseases, Respiratory Disease 22
(c) 2000-2018 QIAGEN. All rights reserved. 1
Ingenuity Pathway Analysis (IPA). Table 4.
Analysis Name:Table 4 Summary photoreceptor core annotation analysis (745); Bergen et al. 
2018-05-07 10:07 PM Analysis Creation Date: 2018-05-07
Build version: 470319M
Content version: 43605602 (Release Date: 2018-03-28)
Top Canonical Pathways
Name p-value Overlap
Phototransduction Pathway 7,98E-11 28,3 % 15/53
Huntington's Disease Signaling 2,04E-04 8,0 % 20/250
Glutamate Receptor Signaling 4,79E-04 14,0 % 8/57
Superpathway of Cholesterol Biosynthesis 1,87E-03 17,9 % 5/28
Wnt/Ca+ pathway 4,20E-03 11,1 % 7/63
Top Diseases and Bio Functions
Diseases and Disorders
Name 
Cancer
p-value 
1,31E-02 - 6,87E-28
#Molecules 
680
Organismal Injury and Abnormalities 1,33E-02 - 6,87E-28 685
Gastrointestinal Disease 1,21E-02 - 4,26E-22 629
Hepatic System Disease 2,47E-03 - 8,92E-15 474
Reproductive System Disease 1,27E-02 - 3,21E-08 420
Molecular and Cellular Functions
Name
Cellular Assembly and Organization
p-value 
1,28E-02 - 1,06E-08
#Molecules 
165
(c) 2000-2018 QIAGEN. All rights reserved. 2
 Summary of Analysis - photoreceptor core annotation analysis; Bergen et al. (745) - 2018-05-07 
Cellular Function and Maintenance 1,31E-02 - 1,06E-08 185
Cell Death and Survival 1,32E-02 - 3,71E-06 240
Cell Morphology 1,31E-02 - 5,38E-06 149
Cell-To-Cell Signaling and Interaction 1,16E-02 - 8,21E-06 61
Physiological System Development and Function
Name
Organ Development
p-value 
1,25E-02 - 3,12E-06
#Molecules 
88
Tissue Development 1,28E-02 - 3,12E-06 129
Visual System Development and Function 1,16E-02 - 3,12E-06 30
Nervous System Development and Function 1,28E-02 - 8,07E-06 161
Tissue Morphology 1,28E-02 - 9,43E-06 92
Top Networks
ID Associated Network Functions Score
1.Cellular Assembly and Organization, Cellular Function and Maintenance, Molecular Transport 50
2.Molecular Transport, RNA Trafficking, Behavior 47
3.Developmental Disorder, Neurological Disease, Cellular Assembly and Organization 47
4.Molecular Transport, RNA Trafficking, Connective Tissue Development and Function 42
5.Developmental Disorder, Hereditary Disorder, Organismal Injury and Abnormalities 42
(c) 2000-2018 QIAGEN. All rights reserved. 1
Diseases and Disorders
Ingenuity Pathway Analysis (IPA). Table 5.
Analysis Name: Table 5 Summary Functional Annotation Choroid- Bergen et al 
Analysis Creation Date: 2018-05-07
Build version: 470319M
Content version: 43605602 (Release Date: 2018-03-28)
Top Canonical Pathways
Name p-value Overlap
Antigen Presentation Pathway 7,58E-12 36,8 % 14/38
Atherosclerosis Signaling 3,26E-11 18,0 % 23/128
Hepatic Fibrosis / Hepatic Stellate Cell Activation 3,88E-11 14,7 % 28/191
Acute Phase Response Signaling 5,19E-10 14,5 % 25/172
Complement System 1,90E-09 31,6 % 12/38
Top Diseases and Bio Functions
Diseases and Disorders
Name 
Cancer
p-value 
1,44E-06 - 4,74E-32
#Molecules 
730
Organismal Injury and Abnormalities 1,48E-06 - 4,74E-32 746
Inflammatory Response 1,09E-06 - 1,87E-21 263
Connective Tissue Disorders 1,48E-06 - 1,46E-17 192
Inflammatory Disease 4,57E-08 - 1,46E-17 174
Molecular and Cellular Functions
Name
Cellular Movement
p-value
1,26E-06 - 1,81E-32
#Molecules
257
(c) 2000-2018 QIAGEN. All rights reserved. 2
 Summary of Analysis - 
Cell Death and Survival 1,47E-06 - 4,17E-21 323
Cell-To-Cell Signaling and Interaction 1,50E-06 - 9,12E-15 218
Cellular Development 1,49E-06 - 1,14E-14 326
Cellular Function and Maintenance 8,75E-07 - 3,23E-12 274
Physiological System Development and Function
Name
Cardiovascular System Development and Function
p-value 
9,30E-07 - 1,46E-28
#Molecules 
192
Organismal Development 1,47E-06 - 1,38E-24 325
Immune Cell Trafficking 1,29E-06 - 1,10E-23 158
Hematological System Development and Function 1,29E-06 - 3,90E-23 236
Organismal Survival 5,54E-08 - 1,79E-22 244
Top Networks
ID Associated Network Functions Score
1.Organ Morphology, Organismal Injury and Abnormalities, Renal Atrophy 49
2.Organismal Injury and Abnormalities, Skeletal and Muscular Disorders, Developmental Disorder 41
3.Molecular Transport, Nucleic Acid Metabolism, Small Molecule Biochemistry 38
4.Tissue Development, Cellular Movement, Hair and Skin Development and Function 37
5.Cell Cycle, Gene Expression, Cellular Growth and Proliferation 36
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